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SUMMARY
Adenylate cyclase toxin (CyaA) was produced and purified in the toxic 
CyaC-modified form and the unmodified non-toxic form from both B. pertussis 
and recombinant E, coli strains in sufficient quantity to allow large scale 
experimentation. Immunoblot analysis of crude and purified CyaA preparations 
revealed that the toxins were prepared as full length 200 kDa proteins with a 
small amount of degradation products of lower molecular weight protein in both 
toxic and non-toxic forms. The in vivo CyaC-modified CyaA toxin produced 
from recombinant E. coli showed comparable levels of cytotoxic and invasive 
activity to that produced from B, pertussis but its haemolytic activity was weaker.
In addition, the leukotoxin (LktA) from Pasteurella haemolytica was also 
produced by expression from recombinant plasmids in E. coli, in both the LktC- 
modified toxic form and unmodified non-toxic form. The A and C proteins of 
both toxins were produced separately in E. coli and each could be co-expressed 
on compatible plasmids. This allowed heterologous activation of CyaA by LktC 
and LktA by CyaC. The LktC- or CyaC-modified LktA of 105 kDa protein was 
produced and partially purified from recombinant E, coli strains, but the yield of 
LktA production was low compared to that of CyaA in the same T7 expression 
system. The LktC-modified CyaA toxin was also produced but showed no 
cytotoxic or haemolytic activity. Heterologous activation of LktA by CyaC was 
successful and the toxin was almost as active against bovine lymphoma (BL3) 
cells as the LktC-modified toxin. However, the heterologous activation by CyaC 
did not change its specificity for ruminant cells, because no cytotoxic activity 
against mouse J774.2 cells or haemolytic activity against horse red blood cells 
was detected. The CyaC-modified LktA showed a greater haemolytic to cytotoxic 
ratio than LktC-modified LktA. Thus, LktA modified by CyaC was more
XX
haemolytic than the LktC-modified form, but nevertheless retained the specificity 
for ruminant cells which is a feature of the native toxin.
Two hybrid toxins derived from CyaA and LktA were also produced and 
purified. Hybl contained the N-terminal enzymic domain and the pore forming 
domain from CyaA (amino acids [aa] 1-687), with the remainder of the protein 
derived from the C-terminal end of LktA (aa 379-953). Hyb2 was created from 
H ybl by replacement of the LktA C-terminal domain of H ybl with the C- 
terminal domain of CyaA (aa 919-1706 ). Part of the region concerned with C- 
modification site of CyaA (aa 688-918) was therefore replaced with the 
equivalent region from LktA. The Hybl toxin of 150 kDa protein had normal AC 
enzymic activity, but showed no toxic activity when modified in vivo by CyaC 
or LktC. In contrast to CyaA, the 200 kDa Hyb2 protein was activated more 
efficiently by LktC than by CyaC, although the cytotoxic and haemolytic activity 
of Hyb2 modified with LktC or CyaC was lower compared to recombinant active 
CyaA modified by CyaC. However, LktC-modified Hyb2 showed more toxic 
activity against ruminant than against murine nucleated cells, whereas CyaC- 
activated Hyb2 displayed a similar, but lower, activity against both cell types, 
indicating that LktC and the region with which it interacted had an influence on 
the target cell specificity of the activated toxin.
An in vitro activation system was developed to investigate the nature of the 
modification of the protoxins (CyaA, LktA and Hyb2) by CyaC or LktC. 
ProCyaA, proLktA and proHyb2 and the activator proteins CyaC or LktC were 
overproduced separately in recombinant E. coli strains using an efficient T7 RNA 
polymerase expression system and then partially purified. Active CyaA, LktA or 
Hyb2 toxin were produced in vitro when the protoxins were mixed with C- 
proteins together with a cytosolic extract (CAF) derived from E. coli. However, 
although LktC was able to activate LktA or Hyb2 in vitro, it was unable to
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activate proCyaA as found when the two proteins were expressed in vivo in E. 
coli. Hyb2 in vitro-activated by LktC was more active than Hyb2 in vitro- 
activated by CyaC. Thus, these results were similar to those found in vivo. 
Activation was assumed to occur by an acylation reaction which by analogy with 
previous data from E. coli haemolysin activation, was assumed to require acyl 
carrier protein (ACT) as a cofactor. The cytosolic activator factor for toxin 
activation was lost if the E. coli S I00 extract was dialysed before use and the 
cytosolic factor could be replaced in the in vitro reaction by ACP charged 
separately in vitro with palmitic acid. A range of commercially available fatty 
acids was used to charge ACP, among which palmitic acid and to a lesser extent, 
myristic acid-charged ACP were able to activate CyaA, LktA or Hyb2 protoxins 
in vitro in the presence of CyaC or LktC.
The role of CyaA toxin as a protective antigen against bacterial colonization, 
in the intranasal mouse protection test was studied. Active CyaA or Hyb2 toxins 
were shown to have no obvious toxicity as measured by mouse weight gain. 
Active CyaA from B. pertussis or from recombinant E. coli strains and LktC- 
modified Hyb2 were protective against bacterial colonization, whereas non-toxic 
CyaA and non-modified Hyb2 toxin were not protective in mice.
The adjuvanticity of CyaA toxin on the antibody response to itself and to 
another protein antigen (ovalbumin) was also investigated. The antibody response 
to ovalbumin was enhanced when active CyaA toxin was co-administered with 
ovalbumin, whereas the inactive toxin did not enhance the antibody response. The 
antibody response to active CyaA alone was higher than that to inactive CyaA 
alone. Preliminary studies on the cytokine responses of spleen cells isolated from 
mice immunised with active CyaA indicated a predominantly Th2-type response.
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OBJECT OF RESEARCH
The overall objectives of the research were to;
1. Purify CyaA in an active and inactive form from both B. pertussis and 
recombinant E. coli and to compare the enzymic, toxic and immunological 
properties of the toxins.
2  Express CyaA , LktA , CyaC and LktC on separate plasmids in E. coli 
and to assess the capacity of CyaC and LktC to trans-activate LktA and CyaA 
respectively.
3. Examine the properties of a hybrid derivative of CyaA where the region 
involved in activation had been replaced by that of LktA,
4  Develop an in vitro system for activation of CyaA and LktA to establish 
the nature of the activation process for these toxins, to investigate whether the 
protoxins could be charged with different fatty acids and to examine the 
biological properties of the toxins activated in vitro. In particular to assess if 
different acyl groups had an effect on toxicity and target cell specificity.
5. Compare the protective capacity of the activated and non-activated 
forms of CyaA and the CyaA hybrid in the mouse intranasal model of infection 
and to assess the toxicity of the active toxins.
6. Assess the adjuvant properties of active and inactive CyaA and CyaA 
hybrid by co-administration of these proteins with another antigen.
INTRODUCTION
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1.1 TU E GENUS BORDETELLA
There are six recognised species in the genus Bordetella which are 
responsible for respiratory infections of humans and animals. B. pertussis is 
responsible for a severe disease of child-hood called whooping cough or 
pertussis, mainly in unvaccinated communities. Pertussis is characterised by 
paroxysmal coughing, whooping and vomiting (reviewed by Parton, 1997). 
B. parapertussis causes a milder form of whooping cough in humans 
(Heininger et a i ,  1994; Wirsing von Konig and Finger, 1994). The main 
difference between B. pertussis and B. parapertussis is due to pertussis toxin 
which is produced only by B. pertussis. B. bronchiseptica is an important 
respiratory pathogen in wild and domesticated animals but rarely in humans 
(Pittman and W ardlaw, 1981). It is implicated in atrophic rhinitis and 
bronchopneumonia in pigs (Rutter, 1985; Woolfrey and Moody, 1991) and 
kennel cough in dogs (Goodnow, 1980; Bemis, 1992). B. avium is a causative 
agent of the respiratory disease, turkey coryza or turkey rhinotracheitis in 
turkey poults or other birds (Kersters et a l,  1984). B. hinzii is found mainly in 
the respiratory tracts of chickens and turkeys where it is thought to be a non- 
pathogenic agent (Vandamme et al., 1995) and has also been isolated from 
human sputum and the blood of an AIDS patient (Cookson et al., 1994). 
Reeently, the species B. holmesii has been isolated from blood cultures of 
human patients, especially in immunocompromised cases (Weyant et a l ,
1995).
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1.2 THE SPECIES BORDETELLA PERTUSSIS
1.2.1 Historical perspective
Bordetella pertussis was first isolated in 1906 by Bordet and Gengou on a 
blood-based potato glycerol agar without peptone. It was initially named 
Haemophilus pertussis, and later shown to be the causative agent of whooping 
cough. The growth of the organism in this liquid medium in the absence of X 
and V factors in blood (which is cntical for growth of the genus Haemophilus) 
led to the conclusion that the organism had to be classified in another genus 
rather than Haemophilus (Hornibrook, 1940). However, Bordetella pertussis 
remained in the genus Haemophilus until Moreno-Lopez (1952) created the 
new genus Bordetella for the causative bacterium of pertussis and named it in 
honour of the initial work of Jules Bordet.
1.2.2 Characteristics
B. pertussis is a small gram negative coccobacillus, non-motile, strictly 
aerobic, nutritionally fastidious bacterium that is probably encapsulated and 
does not produce a spore. On BG agar plates containing 15-20% horse blood at 
37 °C in a humid atmosphere, B. pertussis gives rise to tiny (0.5 mm diameter), 
smooth, convex, pearl-like colonies with entire edges and surrounded by a 
narrow zone of haemolysis (Pittman, 1974). A liquid defined medium was 
introduced by Stainer and Scholte (1971) and contained glutamic acid, proline, 
L-cysteine, ascorbic acid, nicotinic acid, glutathione, salts and Tris buffer. 
When supplemented with heptakis (2,6-0-dim ethyl) p-cyclodextrin and
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casamino acids, this not only improved the growth of B. pertussis but also 
increased the yield of major components such as PT, FHA and CyaA in culture 
supernatants (Imaizumi et aL, 1983). B. pertussis is a human pathogen that 
attaches and multiplies in the ciliated respiratory mucosa of the upper 
respiratory tract to cause pertussis infection (Bromberg, 1989; Sandros and 
Tuomanen, 1993), although it may invade the pulmonary macrophages and has 
been found inside cells (Bromberg etaL, 1991; Khelef etaL , 1994).
1.2.3 Genome organisation
A physical map of the B. pertussis chromosome was constructed by Stibitz 
and Galetts (1992) to demonstrate the location of the virulence-associated 
genes (jha, ptx, etc.) and other genes. The genome size of B. pertussis was 
about 3,750 kb which is approximately 80% of the genome size of E. co ll 
Bordetella virulence genes are scattered over the bacterial chromosome and 
some of them, such as the genes encoding pertussis toxin {ptx genes) and genes 
involved in secretion of pertussis toxin {ptl genes) are arranged in opérons. 
There was no significant linkage between the virulence genes except for jha, 
bvg and some genes involved in fimbrial synthesis which were located close to 
each other. Insertion sequence (IS) elements and related repeated DNA 
sequences have been found in the genome of the B, pertussis but these 
elements are not thought to be involved in rearrangements of the genome or 
expression of virulence factors. IS481 is one of the specified insertion sequence 
elements which is scattered in 80 copies around the genome of B. pertussis and 
constitutes about 2% of the DNA (Stibitz and Galetts, 1992; Weiss, 1992).
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1.3 PERTUSSIS, THE DISEASE
Whooping cough was first reported as an unusual type of coughing disease 
in Moulton's "The mirror of health" in 1540 (Lapin, 1943). Pertussis, a disease 
with world wide endemicity, is an acute respiratory disease of young children 
with most death in infants under one year old. Although maternal antibody 
does pass to the foetus, protection is incomplete so that infections occur in 
early infancy (Preston, 1987). However, pertussis affects persons of all ages 
and adults with mild cases of whooping cough are the major reservoir of 
infection for children in an immunized population (Muller et al., 1986). 
Whooping cough is transmitted from patients (usually children, sometimes 
adults) to non-immune healthy persons or non-immune child contacts at school 
by means of the secretions in the mouth and nose, to some extent through 
towels, hand kerchiefs, hand to hand contact, but to a large extent by droplet 
infection (Long et a l ,  1990). M ortality from whooping cough has been 
dramatically reduced over the past half century in developed countries with a 
combination of widespread effective vaccination, improved socio-economic 
conditions, intensive care in hospitals, and antibiotic therapy. The disease still 
occurs in epidemic waves at about 3 to 4  year intervals, presumably due to new 
susceptibles being exposed to the organism (Preston, 1987; Cherry et a i,
1989).
1.3.1 Steps in pertussis infection
Following inhalation of droplets, in the first step of infection the organisms 
attach to the ciliated epithelial cells of the bronchial tree. In the second step, the
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bacteria proliferate on the surface of ciliated cells and colonize the mucosa of 
the respiratory tract between the entrance of the air way and the beginning of 
the lung. As a result of bacterial colonization and the production of toxic 
components by the bacteria, the ciliated cells will ultimately be damaged. In 
some uncommon cases of pertussis the bacteria move from the upper 
respiratory tract into the lungs and produce a form of pneumonia which can be 
complicated by the systemic effects of the disease (Wilson eta l., 1991).
1.3.2 Stages of pertussis disease
Typical clinical pertussis is divided for descriptive purpose into three 
separate stages, although the clinical features of illness may differ with age, 
general health and immune system status (Cherry et aL, 1988; Walker, 1988). 
The first stage, called catarrhal or prodromal, almost always begins within 7-14 
days after exposure to pertussis infection (Lapin, 1943). The catarrhal stage 
lasts from 1-2 weeks (Olson, 1975), presumably allowing active multiplication 
of bacteria in the respiratory epithelium. During this period of time, the patient 
exhibits only mild symptoms of an uncomplicated upper respiratory infection 
including sneezing, a watery nasal discharge, frequent cough, low grade fever 
and occasionally conjunctivitis . The second stage, called paroxysmal, usually 
lasts from 1-4 weeks and is characterized by progression to a paroxysmal 
cough that is a hallmark of the disease (Cherry et aL, 1988, Walker, 1988). A 
paroxysmal cough is characterized by uncontrollable coughing, up to 5 to 20 
forcible hacking coughs in 15 to 20 seconds with no time for breathing 
between coughs (Preston, 1988). If prolonged, it may induce anoxia and 
cyanosis and often terminates with production of mucus or vomiting, followed
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by a whoop which is a characteristic sound produced by an inspiratory breath 
through the narrowed glottis (Pittman, 1970). This symptom (whoop) gives the 
disease its name. Respiratory complications and central nervous system 
damage (irreversible neurological damage) can arise due to pressure effects and 
anoxia, both resulting from paroxysmal coughing (Cherry et aL, 1988). The 
third and final stage named convalescent stage, lasts several months and is 
characterized by a gradually decreasing number and frequency of paroxysmal 
coughing, and the disappearance of viable B. pertussis organisms from the 
respiratory tract until they are rarely found after the fourth week (Fine and 
Clarkson, 1982). The reason for persistence of the paroxsysmal cough long 
after the bacteria are no longer detectable in the respiratory tract is 
unexplained, but may possibly be due to some form of tissue sensitivity 
resulting from increasing histamine as observed in the infected mouse model 
(Pittman a/., 1980).
1.3.3 Diagnosis
Unfortunately, the early stage (catarrhal) of the disease resembles a 
common cold and the true diagnosis of the disease may not be possible until 
the paroxysmal stage. Thus B. pertussis infection has to be diagnosed at the 
catarrhal stage paraclinically by recovery of the bacteria by culturing from a 
nasopharyngeal aspirate or cough plate or from nasal or oropharyngeal 
swabs (Onorato et a i ,  1987). However, recovery of B. pertussis from 
previously immunised persons or patients treated with antibiotic is much more 
difficult than from un treated or un-immunized persons (Baraff et aL, 1978). 
Because B. pertussis is very sensitive to drying, the specimen from the patient
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must be either directly cultured on freshly prepared BG agar and incubated at 
37 °C in a moist atmosphere for 7 days or the specimen placed in a suitable 
transport medium (Field and Parker, 1979). The biochemical reactions of 
B. pertussis, including positive oxidase, negative urease, negative motility or 
no growth on MacConkey agar can then be used for differentiation from other 
species of the genus Bordetella. In addition to the culture and biochemical 
reactions, serological identification tests of B. pertussis are available including 
fluorescent antibody, agglutination, complem ent fixation, ELISA and 
measurement of anti-pertussis toxin IgA that will confirm the isolation 
(reviewed by Friedman, 1988).
Measurement of cAMP produced from incubation of the clinical specimens 
with medium containing ATP and calmodulin has been used (Confer et aL,
1990). B. pertussis can also be identified in nasopharyngeal swabs by PCR 
amplification of suitable sequences in the genome (reviewed by Meade and 
Bollen, 1994).
1.3.4 Treatment
Treatment for pertussis is primarily with supportive care or nursing 
supervision of high risk people (children under one year of age) during the 
second stage when the disease is usually diagnosed. This might involve careful 
suction to remove the tenacious mucus secretion from the respiratory tract, 
oxygen therapy with increased humidity, hydration, nutrition and restoration of 
electrolyte balance (Altmeier and Ayoub, 1977). Antibiotic therapy has little 
clinical effect when the pertussis infection is well established and diagnosis 
occurs at the paroxysmal stage, although the bacterium is susceptible to
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erythromycin and to a lesser extent to chloramphenicol or tetracycline. There is 
some evidence that if erythromycin is given early during the catarrhal stage, 
before the paroxysmal cough develops, and for at least 14 days, it may reduce 
and shorten the severity of whooping cough, presumably by elimination of 
bacteria from the nasopharynx. Antibiotic therapy also reduces the possibility 
of secondary infection such as bronchitis or pneumonia. Erythromycin may 
also be given to non-vaccinated infants or other high risk persons including 
hospital personnel who may be exposed to the pertussis patients or are in close 
contact with active cases, to reduce infectivity and to control or prevent the 
spread of infection (prophylaxis) (Bass, 1985). The efficacy of treatment with 
human pertussis hyper immune serum has not been established, possibly 
because the serum was not checked for the presence of all three agglutinins 
(Preston, 1987).
1.3.5 Control and prevention
Neither antibiotics nor immunoglobulins are very effective for the 
prevention or control of pertussis in the population, even if given during the 
incubation period or the catarrhal stage. Control of the disease by quarantine is 
also unrealistic because patients typically distribute the organism for many 
weeks or months and children are infectious even before the most characteristic 
symptoms develop (Muller et aL, 1986). The best way for the prevention of 
whooping cough is by active immunization (vaccination).
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1.4 PERTUSSIS VACCINES
1.4.1 Whole cell pertussis vaccine
An effective whole cell pertussis vaccine (WCV) was first developed in the 
1940s (reviewed by Rappuoli et aL, 1991). There have been three generations 
of vaccines for induction of active protection against pertussis. The first 
generation was prepared from whole bacterial cells, whereas the second and 
third generations were prepared from purified protective components or 
toxoided virulence factors of B. pertussis and named acellular vaccines. The 
currently available WCV is usually given in a combined preparation 
(commonly called DPT vaccine) which contains diphtheria and tetanus toxoids 
and a suspension of whole B. pertussis cells, killed by formalin, heated at 56 °C 
for 30 min and absorbed on aluminium hydroxide as an adjuvant to enhance 
the immunogenicity and efficacy of the vaccine. This vaccine is still in 
widespread use except in Japan (Rappuoli et aL, 1991). In countries with a 
well-developed medical service, DPT vaccination is routinely begun at about 
two months of age unless pertussis is prevalent in the community in which case 
vaccination should be started earlier. DPT vaccine in three equal doses 
(4 protective units per dose) is given at 4-8 week intervals, with a booster 
vaccination at 12 to 18 months after first vaccination or prior to school. This 
schedule should give more than 90% protection (Preston, 1987),
Although the efficacy of pertussis vaccine is generally high, it may cause a 
local and occasionally systemic reaction in infants such as skin redness, pain, 
induration, fever, prolonged crying, convulsions and collapse. More serious 
systemic toxic reactions, including permanent brain damage and death may
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occur at an estimated rate of 1 in 100,000 vaccinations. The concern about 
these reactogenic effects, especially the neurological damage, due to DPT 
vaccination led to a decrease in the acceptance of the vaccine in many western 
countries. For example in the U.K., vaccination fell from 90% to 30% of the 
population in the 1970s and as a consequence there was an increasing 
incidence of whooping cough. Because the risks associated with the disease are 
now recognised as greater than those associated with the side effects of 
vaccination, acceptance of vaccination in the U.K. has returned to the previous 
level of >80% (Parton, 1991). Flowever, serious doubts about the safety of 
WCV have largely passed, and the World Health Organization recommends 
that vaccination with WCV has to be continued while at the same time the 
research is being focused on the development of new acellular vaccines with 
minimal side effects.
1.4.2 Acellular vaccine
The best solution to avoid the side effects arising from pertussis WCV is to 
produce a less toxic vaccine. A first step towards this goal is to analyse the 
composition of WCV and to identify the components that are immunogenic 
and important in the virulence of B. pertussis. As shown by Weiss et aL (1984), 
by construction of mutant B. pertussis defective in the expression of individual 
virulence factors, pertussis toxin (PT) is a major virulence factor and is also 
protective against challenge in the mouse model of infection (Rappuoli et at., 
1991). The first acellular vaccine was developed by Sato and contained 
formaldehyde toxoided PT and filamentous hemagglutinin (FHA) rather than 
intact bacteria, and this or similar vaccines have been used in Japan since 1981
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(Sato et a i, 1984). Because the Japanese do not vaccinate children until they 
are 2 years old, the incidence of pertussis in Japan is still high in children up to 
2 years of age. In Sweden two acellular vaccines, one containing only formalin 
toxoided PT and the other vaccine containing formalin toxoided PT with FHA 
were used in field trials in 1986. Although both vaccines had lower protection 
efficacy (about 80%) than WCV and low reactogenicity, they still had some 
side-effects. There has been speculation that this reactogenicity was due to 
cross reactivity of anti-FHA with brain blood vessels or to incomplete chemical 
detoxification of PT (Kimura and Hikino, 1985; Ad Hoc group, 1988; 
Tuomanen et a i ,  1993). On the basis of these observations, a number of other 
acellular vaccines have undergone field trials. All include chemically toxoided 
PT, alone or with one or more pertussis antigens such as FHA, pertactin (PRN) 
and agglutinogens (fimbrial antigens) (Storsaeter et al., 1990). In order to 
achieve maximum safety and avoid the risk of side effects, a third generation of 
vaccines based on the construction of genetically detoxified pertussis toxin has 
been developed (Podda et aL, 1993; Rappuoii, 1993), because chemical 
detoxification of PT can not guarantee the absolute absence of active PT in 
acellular vaccine preparations. By substitution of two amino acids in the S 1 
subunit (Glul29 was replaced by Gly, Arg-9 with Lys) a non-toxic PT protein 
was produced which contains the immunodominant epitopes both for B- and T- 
lymphocytes and was highly immunogenic. Two candidate vaccines containing 
the double mutant PT-9K/129G molecule alone or associated with FHA and 
PRN were clinically tested in 250 infants. Preliminary results of these clinical 
trials showed that both vaccines were safe and more immunogenic than 
vaccines containing formalin toxoided PT (Rappuoii, 1996).
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1.5 IMMUNITY IN PERTUSSIS
Recovery from whooping cough is accompanied by development of an 
immunity which lasts for many years. Second attacks occur only infrequently 
in children and then they are very mild but in older people second attacks are 
more severe. However, immunity acquired after infection with B. pertussis 
does not protect against the other Bordetella species. The antibody response 
following pertussis infection results in circulating antibody against B, pertussis 
antigens such as PT, FHA, PRN, AGGs and adenylate cyclase toxin (CyaA). 
These play a role in preventing bacterial attachment to the respiratory tract 
(Ashworth et aL, 1982). The basis of immunity in pertussis is however 
incompletely understood. Because the titres of specific humoral antibodies may 
decrease over a period of years, effective immunity to whooping cough may 
not necessarily depend on the presence of circulating antibody.
Cell mediated immunity may be a crucial component of long-term 
immunity against B. pertussis. It has been reported that B. pertussis is not only 
an extracellar pathogen but also can invade and survive within eukaryotic cells, 
including macrophages, in which case cell mediated immunity would be 
necessary to prevent intracellular persistence of B. pertussis (Bromberg et aL,
1991). The cellular immune response to pertussis infection induces specific 
CD4+ T-cell clone proliferation in humans and mice (Gearing et al., 1989). 
Adults who have had pertussis in childhood show T-cell responses to PT, FHA 
and PRN, but PT may not be a major target for T-cell responses in adults 
previously infected or vaccinated with DPT vaccine (De Magistris et at, 1988). 
B. pertussis-specific CD4+ T-cell clones from previously infected humans 
release IL-2 and INFy, but little or no IL-4 which is characteristic of the T hl
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response involved in cytotoxic functions for bacterial clearance from lungs 
(Peppoloni et a l ,  1991). Redhead et a l  (1993) showed that mice vaccinated 
with pertussis WCV produced a very good T h l response and moderate 
antibody titre, whereas mice vaccinated with an acellular vaccine produced a 
strong ThZ-antibody response (a characteristic of true helper T-cells for 
stimulating antibody response) and a low T hl response. However, the antibody 
stimulated by Th2 cells in mice vaccinated with acellular vaccine did play a 
role in elimination of bacteria from the lungs in the early stages of infection 
which is compatible with involvement of the Thl response in bacterial 
clearance.
Whatever the precise mechanism, recent studies in immunity to pertussis 
have concluded that while antibody responses do play a role in preventing 
bacterial colonization in the early stages of host defence against pertussis, a 
cell mediated response is required for complete bacterial elimination in the 
later stages of disease, presumably via stimulation of mechanisms for killing 
intracellular B. pertussis in infected macrophages (Redhead etal., 1993).
1.6 VIRULENCE FACTORS
B. pertussis produces several potential virulence factors that may play a 
role in the pathogenesis of pertussis. These include adhesin factors that mediate 
attachment to cultured mammalian cells such as PT, FHA, PRN and fimbrial 
agglutinogens. In addition, toxins such as tracheal cytotoxin (TCT), heat labile 
toxin (HLT), endotoxin lipopolysaccharide (LPS) and adenylate cyclase toxin 
(CyaA) are produced as aggressins to combat the host's immune system (Weiss
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and Hewlett, 1986; Friedman, 1988). The biological properties of these 
components are discussed in detail below,
1.6.1 Tracheal cytotoxin (TCT)
Tracheal cytotoxin is released extracellularly into the culture medium as a 
result of bacterial lysis or during the logarithmic growth phase of at least four 
species of Bordetella. This unusual toxin is a peptidoglycan fragment (1,6 
anhydromuramic acid-N-acetyl-glucosam ine tetra-peptide) with a low 
molecular weight (921 daltons) (Goldman, 1988). A recent study using human 
nasal biopsy specimens showed that TCT may play a role in pertussis infection, 
possibly by causing ciliostasis (destruction of ciliated cells) followed by 
ciliated cell extrusion from the epithelium of the respiratory tract (Heiss et al., 
1994). The ciliostatic effect of TCT was initially discovered by Goldman and 
Baseman (1980), in hamster tracheal organ cultures and inhibition of DNA 
synthesis in the hamster trachea epithelial (non-ciliated ) cell cultures was also 
noted. TCT may cause these cytotoxic effects on ciliated and non-ciliated 
epithelial cells by causing synthesis of nitric oxide in response to stimulation of 
IL-1 secretion by T h l cells (Heiss etal., 1994). Such effects could well explain 
the cause of some of the pathological events in pertussis infection such as 
coughing, stimulation of excessive mucus production in the air ways, the 
persistence of respiratory tract abnormality in pertussis long after bacterial 
elimination from the lung and predisposition to secondary bacterial infections 
(Wardlaw and Parton, 1988). The immunogenicity of tracheal cytotoxin in 
pertussis is not known.
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1.6.2 Heat-labile toxin (HLT)
on & g
Heat labile toxin or dermonecrotising toxin was^he first toxin^described in 
the genus Bordetella (Livey et al., 1978). HLT is present mainly in the 
cytoplasm of Bordetella but may be partially located on the surface of the 
bacterial cells (Livey and Wardlaw, 1984; Walker and Weiss, 1994). Because 
of its instability, the purification of HLT in toxic form has proved very difficult 
(Nakase and Endoh, 1988). HLT is a 102 kDa protein reportedly consisting of 
two 24- and two 30-kDa subunits (Endoh et al., 1986) which causes a 
dermonecrotic reaction (skin necrosis), loss of normal weight gain and spleen 
atrophy when injected subcutanously at low doses in mice or is responsible for 
mouse lethal toxicity when injected at high doses (Endoh et aL, 1990). The 
skin lesions resulting in mice after HLT injection could be due to a specific 
constrictive effect on vascular smooth muscle and such effects on the vascular 
smooth muscle tissues of the respiratory tract may cause a local inflammatory 
reaction and may be responsible for some of the pathological effects in 
pertussis infection (Nakase and Endoh, 1988). HLT has no role in protection 
induced by WCV because in the process of WCV preparation, HLT is 
inactivated by heating at 56°C for 10 min (Manclark and Cowell, 1984). A 
mutant strain deficient in HLT production was not impaired in its ability to 
cause a lethal infection in mice, indicating that HLT has no significant role in 
the disease process, at least in mice (Weiss etal., 1989).
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1.6.3 Lipopolysaccharide (LPS)
Endotoxin or LPS produced by all species of Bordetella comprises about 
2% of the dry weight of bacterial cells. B. pertussis produces two distinct LPS 
molecules, LPS type I has a standard lipid A portion like the LPS of E. coli, 
whereas LPS type II has a distinctive lipid portion named lipid-X (2,3- 
diacyl glucosamine 1-phosphate). The two types of LPS also have different 
polysaccharide portions. In LPS type I, the polysaccharide portion has an 
oligosaccharide core with 2-keto-3-octulosonic acid (non-phosphorylated 
KDO), and LPS type II contains an oligosaccharide core with phosphorylated 
KDO. Both LPS I and II lack the long chain polysaccharide O antigen as found 
in E. coli or other enterobacterial LPS (Brodeur et a l,  1993). Thus both types 
of B. pertussis LPS are generally referred to as a lipo-oligosaccharide (LOS), 
although they have the same kind of activities as classical LPS types such as 
that of E. coli, including toxicity, pyrogenicity and adjuvanticity as well as 
some unusual functions such as activation of the alternative complement 
pathway, stimulation of cytokine release, specific antiviral activity, B-cell 
m itogenicity, polyclonal B-cell and mononuclear phagocyte activation 
(Haeffner-Cavaillon et a i ,  1984; Winters et aL, 1985; Chaby and Caroff, 
1988). However, the role of LPS in the pathogenesis of pertussis is not 
established, although it may be responsible for the mild fever in the early 
stages of pertussis and may cause much of the reactogenic symptoms of the 
commercial WCV. One of the main aims of developing an acellular vaccine 
was to eliminate this toxin and reduce significantly its reactogenic side effects 
(Cherry et a i ,  1988). Although, LPS in WCV is not generally considered to be 
a protective antigen, it may have some role in immunity to pertussis infection
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because boiled WCV still has heat stable LPS antigens and protects mice 
against intranasal challenge with B. pertussis (Standfast, 1958; Pittman, 1984). 
In addition, high titre of anti-LPS antibody have been reported in 
tracheobronchial washings from mice but not in serum (Wardlaw and 
Stevenson, 1984).
B. pertussis LPS was found to be a good immunological adjuvant for 
diphtheria toxoid in the guinea pig. It has the ability to stimulate antibody 
responses, and Lipid A was the most efficient adjuvant fragment (Munoz and 
Bergman, 1979; Ayme e ta l ,  1980).
1 .6.4 Filamentous haemagglutinin (FHA)
FHA was initially observed as a component of the B. pertussis cell that 
agglutinated red blood cells, a feature that explained the name fimbrial 
haemagglutinin (Keogh et al., 1947). Later work established that FHA is 
synthesised as a large precursor protein of 360 kDa which is exported to the 
bacterial surface where it is cleaved proteolytically to release the N-terminal 
220 kDa mature protein that forms a rod shaped highly hydrophobic fine 
filamentous structure 2 nm in diameter and 40-100 nm in length on the surface 
of the cell (Arai and Sato, 1976; Domenighini et al., 1990). The C-terminal 
portion remains in the outer membrane of the cell. The filamentous structures 
do not have the ordered structure characteristic of pill as previously thought, 
and thus seem to be a non-fimbrial surface protein (Ashworth etal., 1982).
FHA acts as an adhesin, having binding activities which allow B. pertussis 
to adhere to ciliated cells or macrophages (Tuomanen and Weiss, 1985). The 
secondary infections in childhood pertussis may be explained by a piracy
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phenomenon, whereby FHA in soluble form, and possibly in conjunction with 
PT, adheres either to B. pertussis itself or to unrelated bacteria such as 
Haemophilus influenzae or Streptococcus pneumoniae, which results in sticky 
bacterial cells that can attach to the cilia of respiratory ciliated cells 
(Tuomanen, 1988). The FHA binds to galactose residues of sulfated glycolipid 
in the membrane of ciliated cells as well as binding to a glycoprotein receptor 
(CR3) on polymorphonuclear neutrophils (PMN) or mononuclear cells 
(macrophage) by its Arg-Gly-Asp (RGD) domains. Such FHA-mediated 
binding of B. pertussis to ciliated cells or macrophages leads to entry of the 
organism into the lungs or enhances phagocytosis without triggering an 
oxidative burst which may be critical in the development of lethal pneumonia 
or intracellular survival of B. pertussis in macrophages respectively (Locht 
et al., 1993; Mooi, 1994). Infection experiments in mice with a B. pertussis 
mutant unable to produce FHA have shown that the colonization in the lung 
and the persistence in the upper respiratory tract of mice were significantly 
reduced (Weiss and Goodwin , 1989).
In mice, immunization with FHA followed by intranasal challenge with 
B. pertussis showed protective activity of FHA antigen by a reduction of lung 
colonization (Kimura et al., 1990). Passive immunization with antibodies to 
FHA have indicated that the adherence of B. pertussis to mammalian cells was 
inhibited (Sato et al., 1981). FHA is one of the prime candidate antigens in the 
acellular pertussis vaccine (see section 1.4.2), because of its lack of toxicity 
and its protective activity in mice and induction of humoral and cellular 
immune responses in humans during natural disease.
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1.6.5 Agglutinogens ( AGGs)
Eidering et al. (1957) initially reported 14 agglutinogens as surface 
antigens which can induce production of bacterial cell agglutinating antibodies 
(agglutinins). The serotype of isolates in the genus Bordetella  can be 
determined based on agglutination and agglutinin adsorption characteristics of 
agglutinogens (Preston et aL, 1982). B. pertussis strains produce three major 
agglutinogens, of which AGO 1 is species specific and AGG 2 and AGG 3 are 
strain specific fimbrial proteins (Irons etal., 1985), and 5 minor agglutinogens 
(AGG 4-7 and 13) of which AGG 4-6 are strain specific, and AGG 7 and AGG 
13 are shared with B. parapertussis or with B. bronchiseptica respectively 
(Preston et al., 1982). AGG2 and AGG3 fimbrial proteins in B. pertussis 
serotypes are mainly composed of protein subunits of 22.5 and 22 kDa 
respectively and both types also contain a minor component of 40 kDa (FimD). 
There are three serotypes such as 1,2,3; 1,2 and 1,3 (possessing at least two 
AGGs) which are recognized in B. pertussis infection in man (Preston, 1988). 
B. pertussis cells without fimbriae adhered well to human ciliated cells 
(Tuomanen and Weiss, 1985), but there is some evidence that AGGs may have 
a role as adhesins for establishment of pertussis infection by the initial 
adherence of B. pertussis to ciliated epithelial cells of the human respiratory 
tract (Gorringe et al., 1985; Tuomanen, 1988). The fimbrial protein FimD may 
be located at the tip of the fimbrial structure and capable of binding 
B. pertussis to the VLA-5 cell surface integrin of human monocytes and thus 
may serve to facilitate phagocytosis (Mooi, 1994). Purified fimbrial proteins 
have been shown to protect mice against respiratory infection with different 
serotypes of B. pertussis (Robinson et al., 1989). There is a suggestion that
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WCV should contain AGGs 1,2  and 3, in order to protect efficiently against all 
the serotypes of B. pertussis (Preston, 1988) and that fimbrial agglutinogens 
should be included in acellular vaccines as candidate antigens for induction of 
serospecific protection in children (reviewed by Cherry, 1993).
1.6.6 Pertactin  (PRN)
Pertactin was first reported by Brennan et al. (1988) as a non- fimbrial 
AGG outer membrane protein (OMP). It is a surface associated protein and is 
produced by B. pertussis, B. parapertussis and B. bronchiseptica as a protein of 
MW 69, 70 and 68 kDa respectively as determined by SDS-PAGE analysis 
(Kobisch and Novotny, 1990). PRN from B. pertussis is first synthesized as a 
precursor polypeptide molecule of 93.5 kDa, which is then proteolytically 
cleaved to remove a 3 kDa N-terminal signal sequence and a 30 kDa C-terminal 
portion to produce a mature protein of 60 kDa. The descriptor P69 relates to the 
anomalous migration of the protein in SDS-PAGE with an apparent MW of 69 
kDa. The cleaved C-terminal polypeptide remains as a protein (P30) in the outer 
membrane (Charles et a l ,  1994). Both FHA and PRN have arginine-glycine- 
aspartic acid (RGD) integrin binding domains thus suggesting a role for both 
proteins in binding of B. pertussis to mammalian cells (Leininger et a l ,  1991; 
Charles et a l ,  1994). However PRN can mediate adhesion of B. pertussis to 
eukaryotic cells even in the absence of a functional RGD motif (Everest et al.,
1996). Pertactin has two proline-rich regions (PRRs) in its helix structure 
(Emsley et a l ,  1996). One of the PRRs is a (GGXXP)5 sequence which is 
located directly after the RGD sequence and may be associated with binding 
activity of pertactin to epithelial cells. The other C-terminal PRR contains the
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motif (PQP)5, and is known to contain the immunoprotective epitope. In fact 
PRN in association with FHA may operate more efficiently than either alone in 
cell binding. In experimental B. pertussis infection, purified PRN (P69) alone or 
in association with FHA was protective in mice against aerosol challenge, PRN 
is now a candidate antigen in acellular vaccines to increase the potency of the 
vaccines in association with other protective antigens.
1.6.7 Other B. pertussis outer membrane proteins (OMPs)
Recently two other virulence-associated OMPs of B. pertussis, BrkA 
{Bordetella resistance to killing) and TCF (tracheal colonization factor), have 
been reported that have structural homology with PRN. The BrkA protein, like 
P69, is synthesised as a large precursor polypeptide molecule of 103 kDa, and 
proteolytically cleaved into two fragments, the N-terminal 73 kDa BrkA and a 
30 kDa C-terminal fragment localized in the outer membrane. BrkA has two 
RGD domains and may potentiate the virulence of B. pertussis in respiratory 
tract infection by conferring adhesive properties and by resistance to 
complement dependent serum killing (Fernandez and Weiss, 1994). TCF is 
produced in the culture supemate of B. pertussis during growth. TCF protein of 
68 kDa contains a RGD sequence and a proteolytic cleavage site which 
releases a 30 kDa C-terminal fragment. TCF probably has a role in colonisation 
of B. pertussis in mouse trachea (Finn and Stevens, 1995).
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1.6.8 Pertussis toxin (PT)
Pertussis toxin was initially called histamine-sensitizing factor or mouse- 
protective antigen or heat labile adjuvant according to its activities (Levine and 
Pieroni, 1966) and also it was named leukocytosis and lymphocytosis 
promoting factor or islet activating protein (Yajima et a i ,  1978). The term 
pertussigen was used for this toxin by Munoz and Bergman (1979) until it was 
named pertussis toxin with universal acceptance by Pittman (1979). 
B. parapertussis and B. bronchiseptica have transcriptionally silent genes for 
PT and only B. pertussis can produce it (Marchitto etaL, 1987).
PT is a complex protein exotoxin of 105 kDa, secreted during in vivo and 
in vitro bacterial growth and it consists of five different subunits called SI, 82, 
S3, S4 and S5. PT is a hexamer toxin molecule (5 binding subunits and 1 
enzymatic subunit) because it contains two S4 subunits. PT is an A-B toxin 
like cholera toxin, except that the binding subunit of PT is more complex. The 
A subunit is a single polypeptide, with a disulfide bond, that carries the 
biological activity and the B oligomer subunit consists of two dimers, (S2-S4 
and S3-S4) linked by S5, that binds the complex to the cell membrane of 
different cell types including T lymphocytes before transfer of the A subunit 
into the cytoplasm (Tamura e ta l., 1982; Katada e /a /., 1983). The SI subunit 
acts as an ADP-ribosyl transferase and also as a NAD-glycohydrolase. After 
passage of the A subunit (SI unit) into the cytoplasm by conformational 
changes of the binding B subunit, the disulfide bridge of the SI subunit is 
reduced inside the cytoplasm to release the active form of the enzyme. This 
then catalyses the ADP-ribosylation of the Gi protein of the host cell which
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promotes increased adenylate cyclase activity and ultimately increases the 
cAMP level in the host cell (Hildebrandt etaL, 1983 ; Ui, 1988).
Although many toxic activities of PT depend on the A subunit enzymatic 
activity, other activities, such as the T-cell mitogenic and haemagglutinating 
activities are due to the B subunit binding to cell surfaces, PT operates as an 
adhesin via its B subunit for binding of B. pertussis to ciliated cells and 
macrophages (Sandros and Tuomanen, 1993).
PT has been proposed to play a central role in the pathogenesis of pertussis 
(Pittman, 1984) but its actual role in disease progression in vivo is not known. 
PT could be responsible for increasing respiratory secretions and mucus 
production in pertussis, or in association with FHA, facilitate binding to human 
ciliated cells or promote B. pertussis uptake by macrophages. It may allow 
other bacteria such as H. influenzae to bind to human ciliated cells and thus 
may be responsible for the secondary infections associated with pertussis. PT 
probably is not responsible for paroxysmal coughing of pertussis, because 
B. parapertussis does not produce PT but causes the same type of cough 
(Tuomanen, 1988). PT is required for B. pertussis respiratory infection in the 
mouse model and this is probably due to the effect of PT on normal functions 
of circulating immune cells such as macrophages and lymphocytes (Weiss and 
Goodwin, 1989). Active immunization with formaldehyde-treated PTd or 
recombinant immunogenic detoxified PTd protects mice against intracerebral 
or intranasal B. pertussis infection.
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1.6.9 Adenylate cylase toxin (CyaA)
T his toxin  is produced by B. pertussis, B. parapertussis and
B. bronchiseptica (Hewlett and Gordon, 1988) and is considered to be an
important virulence factor. The CyaA of B.pertussis was first shown to be
associated with toxic activity by its ability to attenuate neutrophil superoxideoproduction and bactericidal capability. Subsequently, CyaA was shown to 
penetrate and intoxicate a wide range of cell types (Hewlett and Gordon, 1988). 
Immune effector cells such as neutrophils, monocytes, macrophages and 
natural killer cells are thought to be the primary targets, where those functions 
necessary for combating infection are inhibited. CyaA is dealt with in more 
detail in section 1.8.
1.7 Regulation o f virulence factors
B. pertussis virulence genes can be regulated by both phenotypic (antigenic 
modulation) and genotypic (phase variation) changes. Antigenic modulation 
was first described by Lacey (1960) as a freely-reversible phenotypic change in 
response to enviromental changes like concentration of certain salts, organic 
acids and temperature. In the laboratory, expression of virulence genes is 
highest when B. pertussis is grown in medium containing NaCl at 37 °C, 
whereas at lower temperature (25 °C) or in the presence of magnesium sulphate 
or nicotinic acid, the expression of virulence genes is suppressed. Weiss et aL 
(1984) first identified by a single Tn5 insertion in the B. pertussis chi'omosome 
a virulence regulatory locus named bvg that activates the expression of 
B. pertussis virulence genes. The bvg locus contains two genes, bvg A  and
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bvg S, which constitute an operon and encode members of a two-component 
regulatory system (BvgA and BvgS) (Arico e taL , 1989; Scarlato e ta l ,  1991; 
Stibitz and Yang, 1991). BvgS is a histidine kinase with apparent molecular 
weight of 135 kDa that first senses environmental signals (temperature, Mg^+ 
and nicotinic acid) and autophosphorylates and then transfers the phosphoryl 
group to the transcriptional activator BvgA (23 kDa protein) which modulates 
responses to environmental signals via gene transcription (Steffen et aL, 1996; 
Zu et a l ,  1996; Karimova et aL, 1996). Phosphorylated BvgA (BvgA-p) 
activates the expression of important B. pertussis virulence activated genes 
(vag) to produce virulence factors such as FHA, PRN, PT, AGGs and CyaA. 
Initially BvgA-p activates the bvg locus itself and the jha  gene, the activation 
of the ptx and cyaA genes require higher levels of BvgA-p and it is thought 
that early transcription of genes for adherence, such as those encoding FHA 
and AGGs, allow initial colonisation of the host. This is followed later by 
transcription of genes for toxins which combat the host immune response to the 
initial infection (Scarlato et al., 1991; Prugnola e ta l., 1995). BvgA'-p acts to 
repress other, virulence repressed genes (vrg). These genes may play a role in 
later stages of an adaptive process (for example bacterial survival once bacteria 
enter the phagocytic cells) as one vrg locus (vrg-6) contributes to colonization 
and survival in mice (Beattie et al., 1992). A B. pertussis DNA fragment 
carrying the bvg locus together with the fha  locus, when cloned in E. coli, 
expressed FHA antigen, but when a plasmid carrying the jha  locus alone was 
cloned into E. coli, no FHA was expressed. This finding confirmed that trans­
acting bvg locus gene products are important for the expression of the ftia gene 
(Stibitz et a l ,  1988; Domenighini et a l ,  1990). The bvg locus of B. 
brochiseptica has also been characterised and genetic analysis has shown that
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the loci of B. pertussis and B. brochiseptica are functionally interchangeable 
(Tejada etal., 1996).
Phase variation from the virulent (Vir+) to the non-virulent phenotype 
(Vir~) or vice versa occurs at a frequency of about 10~^ and for some strains 
has been shown to be caused by a frame shift mutation or irreversible deletion 
in the bvg locus (Stibitz and Miller, 1994).
1.8 ADENYLATE CYCLASE TOXIN (CyaA)
1.8.1 Historical perspective
Adenylate cyclase from B. pertussis was initially described in the 
supernate of a commercial whole-cell pertussis vaccine extracted by sodium 
chloride (Wolff and Cook, 1973). Subsequently, AC enzyme was purified from 
culture supemates of B. pertussis and whole-cell extracts (Hewlett and Wolff, 
1976). Although B.pertussis CyaA was found in the culture supemate during 
log phase of bacterial growth, it was mainly cell-associated protein and 
localized on the external side of the cell membrane (Cowell etal., 1979).
Hewlett et al. (1979 a) found that the enzyme was activated by a protein 
component present in commercial preparations of certain proteins such as 
haemoglobin and later identified as calmodulin (CaM) (Berkowitz etal., 1980). 
Goldhammer and W olff (1982) noted that the activation of enzymic activity 
was dependent on calmodulin concentration. Greenlee et al. (1982) observed 
that Ca^+ was not required for the majority of the enzymic CyaA activation by 
calmodulin. It stimulated activity at nanomolar levels of calmodulin but not 
when the calmodulin concentration was increased. W olff and Cook (1982)
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reported that phospholipids and some detergents activated CyaA enzyme 
activity and also increased calmodulin activation.
Utsumi et al. (1978) noticed that a urea extract of B. pertussis inhibited 
neutrophil functions such as chemotaxis and oxygen consumption. Confer and 
Eaton (1982) first demonstrated that this toxic activity was due to CyaA. 
Preparations of CyaA with a high specific activity generated a high level of 
intracellular cAMP from endogenous ATP in a time and dose dependent 
manner in human neutrophils and alveolar macrophages and impaired their 
abilities for chemotaxis, superoxide generation, phagocytosis and microbial 
killing. Leppla (1982) reported that Bacillus anthracis, the causative agent of 
anthrax also produced a calmodulin-dependent adenylate cyclase toxin or 
edema factor which could penetrate into target cells after binding to a cell 
surface receptor. In contrast to the Bacillus anthracis toxin, B. pertussis CyaA 
penetrates target cells without binding to a specific receptor (Gordon et al., 
1989; Mock and Ullmann, 1993).
1.8.2 Structure
The native CyaA of B. pertussis has been isolated in multiple forms with 
different molecular masses ranging from 43 to 630 kDa. The non-toxic smaller 
forms of the calmodulin activable CyaA (45-50 kDa) were probably formed by 
proteolytic cleavage of the high molecular weight toxic form of the enzyme 
(which has an apparent mass of 200-216 kDa in SDS-PAGE), and the larger 
forms (>200 kDa) were probably formed by aggregation of the catalytic 
products, because polyclonal antiserum raised against the smaller form of
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CyaA cross-reacted with the larger form (Ladant, 1988; Rogeî et aL, 1988; 
Bellalou eta l., 1990 a).
The toxic form of B. pertussis CyaA has an apparent molecular mass of 
200 kDa, and is the form capable of penetrating eukaryotic cells and catalysing 
the formation of intracellular cAMP (Hanski, 1989). Masure and Storm (1989) 
have reported that the 45 kDa form of B. pertussis CyaA is also capable by 
itself or in the combination with other polypeptides of invading target cells. 
The 45 kDa protein is the major form of the enzyme which appears in the 
bacterial culture medium. It is possible that the toxic 200 kDa form of the 
enzyme is released into the medium but rapidly degraded and therefore its 
quantity is very small and barely detectable in the culture medium (Masure 
et al., 1990). The extensive purification of the CyaA of 45 kDa from culture 
supemate yielded a CaM sensitive CyaA, which always lacked toxic activity 
(Bellalou et al., 1990 b). In the presence of proteolytic inhibitors, only the toxic 
form of 200 kDa CyaA could be detected in the culture medium (Bellalou 
et al., 1990 a). However, more than 90% of the toxic form of CyaA is cell 
surface associated protein and localized on the outer surface of the bacterial 
cell membrane (Cowell eta l., 1979 ).
The first 450 amino acids at the N-terminal end of CyaA constitute the 
calmodulin-activated catalytic portion of the enzyme. Tryptic fragments of the 
N-terminal domain have established that the catalytic domain is located 
between amino acid residues 1-235/237 in which the ATP-binding site was 
located between amino acids 54-70. It contained lysine residues at positions 58 
and 65 which were shown to be essential for the catalytic activity. The CaM 
activation domain was located between amino acids 235/237-399 in which the 
CaM binding site was between amino acids 235 and 254 around trp 242, a
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region displaying an a  helical structure (Glaser et al,. 1989; Ladant et al., 
1989). Further cleavage of the calmodulin-stimulated catalytic domain into two 
fragments produced a 28 kDa fragment corresponding to the N-terminal end 
which was shown to possess ATP-binding capacity, and a 19 kDa fragment 
which was reported to have the CaM-binding site (Munier et al., 1991), The 
remaining 1250 carboxy terminal amino acids act as a haemolytic domain and 
share homology with a family of Ca2+-dependent pore-foraiing cytolytic 
toxins (RTX toxins, see section 1.8.4). This portion consists of four structurally 
distinct regions that seem to be responsible for specific functions of the toxin: 
(1) Four hydrophobic potentially membrane-spanning regions, located between 
amino acids residues 500-700, and which are probably involved in insertion of 
the toxin into target cell membranes, in pore formation and translocation of the 
catalytic domain into target cells; (2) A CyaC-dependent activation region 
located between amino acids 710-1000; (3) A highly periodical structure 
consisting of glycine- and aspartate-rich repeats units located between residues 
1000-1600 which represent the main Ca^+ binding sites of the protein; (4) The 
non-processed carboxy terminal secretion signal within the last 270 residues of 
CyaA which interacts with the membrane-located CyaB, CyaD and CyaE 
proteins (Sebo et al., 1991; Gross et al., 1992; Coote, 1992; Hewlett and 
Maloney , 1994). A simplified model for CyaA structure is given in Fig. 1 and 
for RTX toxins in general in Fig. 2B.
1.8.3 Genetic organization
The structural gene for the Bordetella pertussis adenylate cyclase toxin 
(cyaA) has been cloned (Brownlie et al., 1988; Glaser et a l ,  1988 a) and
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F ig .l
Schematic representation of the structural organization and functional 
domains within the CyaA toxin.
The adenylate cyclase enzymic domain is contained within the N-terminal 400 
amino acid residue. The catalytic domain is located between amino acid 
residues 1-235/237, ATP binding site between amino acid residues 54-70 and 
the calmodulin activation site is located between amino acid residues 235-399. 
The C-terminal 1306 amino acids of CyaA contains hydrophobic membrane 
spanning regions between amino acid residues 500-700 (responsible for 
insertion, pore formation and translocation), CyaC-dependent activation region 
between amino acid residues 710-1000, glycine- and aspartate-rich repeat 
region located between amino acid residues 1000-1600 (responsible for Ca^+ 
binding sites) and secretion signal located within the last 270 amino acid 
residues.
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sequenced (Glaser et a l ,  1988 a). The cyaA gene has an open reading frame of 
1706 codons. Three additional genes downstream from the cyaA gene, cyaB, 
cyaD and cyaE have also been described, the gene products of which are 
required for secretion and transport of CyaA to the surface of the bacterial cell 
or to the culture medium (Glaser et at., 1988 b; Coote, 1992). The cyaC gene 
whose product CyaC protein activates the CyaA protoxin, is located upstream 
of cyaA (Barry et al., 1991).These genes exhibit extensive homology with 
similar opérons encoding other RTX toxins (see section 1.8.4). For example, 
the E. coli a-haemolysin operon consists of four genes; hlyA, encoding a -  
haemolysin; hlyC required for the activation of HlyA; and hlyB and hlyD 
required for secretion of HlyA (Mackman et al ., 1988). These genes are 
expressed as a single operon which is activated by a cis-acting element hly R 
(Koronakis e ta l., 1989). Similarly, the genes encoding the leukotoxin (LktA) 
of P. haemolytica are transcribed as a single operon (Strathdee and Lo, 1989). 
Highlander et a/.,(1989) identified a region upstream of IktC which forms a 
DNA bend by virtue of four CAG (C/T) A repeats occurring at 10-base 
intervals. This may act as a regulatory sequence controlling the expression of 
the Ikt operon. Analysis of the transcriptional organization of the B. pertussis 
cya locus has shown that cyaA, B, D  and E are organized in a single operon and 
transcribed from the cyaA promoter adjacent to the cyaA gene (Laoide and 
Ullmann , 1990), and that the cyaC gene is transcribed in the opposite direction 
( Barry et al., 1991 ). The cyaC  gene is transcribed at a low level in a bvg- 
independent m anner (Goyard and Ullmann 1991). In B. pertussis, the 
regulation of the expression of the other cya genes is achieved by the central 
regulatory bvg locus as described for regulation of virulence factors (section
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1.7). A schematic model of gene arrangement and the direction of gene 
transcription of the RTX cytotoxin determinants is shown in Fig, 2A.
1.8.4 Homology among RTX toxins
A number of Gram negative bacterial pathogens produce Ca^+ -dependent 
cytolytic toxins. These include CyaA of B. pertussis, LktA of P. haemolytica 
HlyA of E. coli, haemolysin (ApxA) of Actinobacillus pleuropneumoniae and 
leukotoxin (AktA) of Actinobacillus actinomycetemcomitans. These form the 
RTX family (repeats in toxin) because of a common series of glycine-rich 
nonapeptide repeats (L-X-G-G-X-G-N-D-X), located close to the C-terminal 
end of each toxin (Strathdee and Lo, 1987; Welch, 1991; Coote, 1992). The 
gene clusters of the hly, Ikt, cya, akt and apx determinants (Fig. 2A) share 
remarkable sequence homology. LktB and HlyB differ in length by only one 
amino acid residue and share 573 identical amino acids and have 81% identity, 
whereas LktD and HlyD are the same length and share 287 identical residues 
and have 60% identity (Strathdee and Lo, 1987). Similar degrees of homology 
have been reported between the hly gene products and those of the akt, apx and 
cya determinants, and thus it is likely that the toxins have marked similarities 
in their structure, the manner of secretion and pore forming activity on target 
cells (Lally eta l., 1989; Kraig eta l., 1990; Coote, 1992).
In spite of remarkable similarities between the products of the RTX 
opérons, the target cell specifities of the toxins vary. LktA is toxic for ruminant 
leukocytes or platelets (Shewen and Wilkie, 1982; Clinkenbeard and Upton, 
1991), whereas AktA is only toxic for human or primate leukocytes (Taichman 
et al., 1987). CyaA and HlyA have little target cell specif!ty (Hanski and
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Fig. 2
A. Gene arrangements of the RTX cytotoxin determinants
Four genes constitute the RTX determinants for the RTX cytotoxins. The A 
gene is the toxin structural gene, the C gene is requried for toxin activation and 
the B and D gene products are required for toxin secretion. For the CyaA toxin 
an additional gene, cyaE, is also required for toxin secretion. Vertical bars 
represent the regions encoding the repeat units and the arrows indicate the 
direction of transcrition. The figure is adopted from Coote (1992).
1 Bordetella pertussis adenylate cyclase (Cya A)
2 Escherichia coli haemolysin (HlyA)
3 Pasmrella haemolytica leukotoxin (LktA)
4 Actinobacillus actinomycetemcomitans leukotoxin (AktA)
5 Actinobacillus pleuropneumoniae haemolysin (ApxA)
B. Schematic representation of the RTX toxin structure
Four functional domains have been recognized in the structure of all RTX 
toxins. The hydrophobic domains are responsible for pore formation. The 
acylation site and adjacent repeat region are assumed to be resposible for 
conformational changes of the toxins necessary for interaction of the toxins 
with target cell membranes. The extreme C-teminal region functions as a 
secretion signal. The figure is adopted from Coote (1996).
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Farfel, 1985; Coote, 1992) and will attack a wide variety of mammalian cells 
from different species. What influences target cell specificity is not known but 
it may be related to the folding of the toxin which influences its interaction 
with target cells and its ability to create pores in the cell membrane of different 
compositions (Coote, 1992). Specific receptors for RTX toxins have not been 
identified and binding may be non-specific. Variation in acylation by the 
attachment of different fatty acyl groups to each toxin may have an influence 
on the interaction of the proteins with membrane and their cell specificity 
(Szabo etaL , 1994) and this aspect was investigated in the work reported here.
1,8.5 Interaction of CyaA with target cells
Bordetella pertussis adenylate cyclase toxin binds to the target cells 
through a Ca^+ dependent process and directly penetrates the host cell plasma 
membrane. Two distinct steps for penetration of CyaA into target cells have 
been identified, namely insertion and translocation (Hanski, 1994). The Gly- 
Asp rich repeats of CyaA toxin are the target of Ca^+ binding which is 
involved primarily in the interaction of the toxin with the target cell membrane 
and the process of insertion and translocation. Acylation of the toxin by CyaC 
also favours interaction of the toxin with the target cell membrane. Ca^+ 
binding causes a conformational change of the CyaA toxin, corresponding to a 
transition from a globular stmcture to an elongated form (Hewlett etaL, 1991). 
It is proposed that the toxin first inserts into the plasma membrane in the 
presence of low concentrations of exogenous Ca^"^ (pM) at a temperature 
ranging from 4 to 37 °C, through its hydrophobic domain, which is located 
between amino acids 500-700, and then in the second step, the N-terminal 45
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kDa catalytically active fragment of the toxin in the presence of a high 
concentration of exogenous Ca2+ (mM) and above 20°C, is partially unfolded 
and translocated through a channel created by the hydrophobic domain of the 
toxin (Rogel and Hanski, 1992 a). The cleavage of the N-terminal fragment is 
not required for the translocation step or cAMP generation within the target 
cell stimulated by endogenous CaM, but it does take place in sheep 
erythrocytes (Friedman et al., 1987 a; Hanski, 1994). A model for the 
interaction of CyaA toxin with target cells is given in Fig. 3. A  and B.
1.8,6 Haemolytic activity
The toxic form of 200 kDa CyaA also possesses haemolytic activity. The 
pore-forming capacity of the CyaA molecule is responsible for haemolytic 
activity against sheep erythrocytes and is entirely independent of the presence 
and activities of the catalytic domain (Bellalou et at., 1990 b; Rogel et at., 
1991; Szabo et al., 1994). However, the main function of the haemolytic 
domain is probably not to lyse erythrocytes but to form channels for 
translocation of the N-terminal catalytic domain through the target cell 
membrane, and thus the pore forming capacity of CyaA is required for both 
haemolytic and toxic activities of CyaA (Bellalou e ta l ,  1990 b).
However, cAMP generation induced by CyaA toxin in sheep erythrocytes 
is immediate whereas the haemolysis of erythrocytes is delayed by about 1 
hour and requires a higher level of adenylate cyclase toxin activity (Rogel and 
Hanski, 1992). Addition of exogenous calmodulin to sheep erythrocytes 
enhanced the haemolytic activity of the toxin, but blocked cAMP generation. 
Exogenous CaM appeared to inhibit the translocation of the catalytic domain
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Fig. 3
A Simplified model for the binding, insertion and translocation of
CyaA toxin in the target cell membrane
The interaction of the acylation site and the repeat region of the toxin may 
create a conformational change in the toxin which allows it to bind to the 
receptor of the target cell membrane and insert the toxin into the plamsa 
membrane through its hydrophobic domain. The amino terminal portion of the 
toxin is assumed to be translocated into the target cells through a channel 
created by the hydrophobic domain of the toxin in the presence of Ca ^+. 
Abbreviations: R, receptor; Ac, acyl group; M, cell membrane; N, N-terminal 
and C, C-terminal end of the toxin. The figure adopted from Coote (1992).
B A simplified model for invasion of a target cell by pertussis 
CyaA toxin
B. pertussis CyaA penetrates the host cell plasma membrane with its 
hydrophobic domain, exposing the catalytic and CaM binding sites to the 
cytosol. The enzyme is activated upon interaction with CaM and converts 
intracellular ATP to cAMP. The enzyme within the cell is degraded and 
inactivated by a protease. The figure is derived from the model proposed by 
Rogel and Hanski (1989).
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into erythrocytes but pore formation still took place and caused haemolysis 
(Rogel et al., 1991). These data suggest that the toxic and haemolytic functions 
of B. pertussis CyaA toxin are separable and probably mediated by different 
domains on the CyaA toxin polypeptide (Sebo et al., 1991; Rogel et al., 1991). 
Szabo et al. (1994) demonstrated that CyaA toxin produces ion-permeable, 
cation-selective pores in phospholipid bilayers. However, the resulting 
membrane conductance was absolutely calcium dependent, as were the 
intoxication and haemolytic activities, and it was strongly affected by the 
polarity and magnitude of the membrane potential and enhanced by the 
presence of negatively charged phospholipid. The inactive CyaA toxin 
produced little or no change in conductance. Evaluation of the current-voltage 
relationships and the concentration dependence of pore form ation or 
haemolysis suggested that a multimer of CyaA toxin, probably consisting of 
three or more holotoxin m olecules, is involved in pore formation and 
haemolysis.
1.8.7 In vivo activation
In vivo activation of CyaA takes place intracellularly by transfer of a fatty 
acyl group to the protoxin from acyl carrier protein in the presence of CyaC. 
Two well-known types of protein acylation are palymitoylation through an oxy 
or thioester linkage to serine, threonine or cysteine residues and myristoylation 
through an amide linkage to an N-terminal glycine (Schlesinger et a l ,  1993). 
Hackett et a l  (1994) reported that proCyaA was modified in vivo by amide- 
linked palmitoylation of the 6-amino group of lysine 983, because the toxic 
effect of CyaA was resistant to hydroxylamine treatment and therefore no
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ester-linked modification was implicated. Palmitoylated Lys-983 is not present 
in inactive AC toxin produced by a mutant strain BP DE386 in which the 
accessory gene, cyaC has been disrupted. The palmitoyl-Lys-983 in CyaA lies 
between the hydrophobic domain and the calcium-binding domain (Fig. 3). A 
lysine residue at the equivalent position is conserved among some of the other 
RTX toxins.
Two kinds of peptides, composing the Lys-983 residue, were synthesized 
with and without the palmitoyl group and tested for their effects on toxin and 
haemolytic activities of CyaA. The non-palm itoylated peptide had no 
inhibitory effect on CyaA toxic activity. In contrast, the palmitoylated peptide 
reduced cAMP accumulation in a concentration dependent manner. These data 
suggest that palmitoylation at this site represents the modification that is 
required for the toxicity and haemolytic activity of CyaA toxin (Hackett et a l, 
1994). Palmitoylation has been reported to mediate both protein-protein and 
protein-lipid interaction (Wedegaertner et a i ,  1993). The work of Szabo et al. 
(1994), which indicated that the ability of CyaA toxin to create a 
transmembrane pore in an artificial lipid bilayer system was dependent on 
oligomerization of the toxin, suggested that the palmitoyl groups may be 
involved in protein-protein interactions to facilitate oligomerization. This 
thought is supported by the results from experiments in which the addition of 
palmitoyated peptide to CyaA toxin before addition of the mixture to the target 
cells was much more inhibitory for toxic effects than if the peptide was added 
to target cells before addition of the toxin (Hackett eta l., 1994).
For HlyA, the internal residues Lys 564 and Lys-690 are the modification 
sites in vivo (Ludwig et al., 1996). Lys-690 of HlyA corresponds in location to 
Lys-983 of CyaA. Interestingly, when CyaA was isolated from recombinant E.
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coli expressing CyaA and CyaC, it was found to be palmitoylated at Lys-860 as 
well as Lys-983 (Hackett et a l ,  1995). Lys-860 corresponds to Lys-564 of 
HlyA. The proximal Lys residue is strongly conserved in all RTX toxins, but 
the distal site is not. For example, the equivalent of Lys-690 in HlyA or Lys- 
983 in CyaA is absent from LktA of P, haemolytica (Stanley etal., 1994).
1.8.8 In vitro activation
Hardie et al. (1991) have demonstrated that in vitro post-translational 
activation of E. coli proHlyA was possible in a defined in vitro reaction 
containing purified proHlyA, HlyC and cytosolic activating factor (CAF). 
ProHlyA and HlyC proteins were produced separately by expression of 
recombinant plasmids in E. coli and CAF was found in the cytosol of 
enterobacteria such as E. coli, Proteus vulgaris, Proteus mirabilis and 
Salmonella typhimurium, but not in Bacteroides fragilis or Enterococcus 
faecalis or eukaryotic cells. CAF behaved as a 10 kDa polypeptide which was 
protease-sensitive and found to be identical to the acyl carrier protein. Protoxin 
was modified to mature protein by transfer of a fatty acyl group from acyl 
carrier protein to proHlyA and required HlyC to act as an acyl transferase. 
Only acyl carrier protein could promote HlyC-directed proHlyA acylation, but 
a range of acyl groups were effective (Issartel eta l., 1991). Acylation of one or 
more amino groups in proHlyA would explain the increased negative charge of 
the activated HlyA compared with proHlyA (Nicaud et a i ,  1985). In vitro 
activation of proHlyA is calcium-independent and effective over a pH range of 
6 to 9 and at temperatures from 4 °C to 42 °C. The HlyC of 20 kDa was present 
physiologically in a multimeric form (20-40 kDa) (Hardie etal., 1991).
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Although acyl transferase activity must presumably reside in HlyC, 
comparison of the HlyC sequence with known acyl transferases produced no 
identity. Sequence similarity between all the C-proteins of the RTX toxin 
family suggests that all the protoxins are modified in a similar manner. Thus 
CyaA protoxin has to be post-translationally modified by CyaC and is 
palmitoylated at Lys-983. It has not been established yet that CyaC has 
catalytic acyl chain transfer activity, but it is likely that, by analogy with HlyC 
activator of HlyA, the fatty acylation of proCyaA involves transfer of a fatty 
acyl moiety to proCyaA in a process involving association of the negatively- 
charged acyl ACP with the positively-charged CyaC, the latter providing 
recognition and interaction with specific proCyaA sequence.
Recently, Heveker et al. (1994 ) have demonstrated chemical fatty 
acylation of CyaA by using a water soluble compound, acylpyrophosphate. 
They showed that undirected transfer of lauric, myristic or palmitic acid chains 
to the CyaA protoxin was able to confer weak haemolytic and toxic activities 
to CyaA. The chemically-modified protoxin showed a specific requirement for 
Ca^+ ions for toxic activity like the wild type toxin. The toxic and haemolytic 
activities of the chemically-modified CyaA were low in comparison to CyaA 
modified in vivo, suggesting that in vitro fatty acylation of the protoxin 
involved random modification of nucleophilic residues present in the toxin in 
contrast to the in vivo modification of specific sites.
1.8.9 Role in pathogenesis o f pertussis
A clear contribution of B. pertussis CyaA toxin to virulence has been 
demonstrated and it is assumed to be an important colonization factor in B.
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pertussis infection. Mutants of B. pertussis deficient in active CyaA production 
were shown to be essentially avirulent after intranasal infection in infant mice 
and the bacteria were cleared more rapidly from the lungs (Weiss et aL, 1984; 
Goodwin and Weiss, 1990; Khelef et aL, 1994). CyaA is required for the 
bacteria to initiate infection and colonize the mouse and although CyaA and PT 
both elevate intracellular cAMP, it has been proposed that CyaA may be 
responsible for the initial rapid increase in cAMP in immune effector cells 
while PT amplifies the cAMP signal thereafter (Masure et a i ,  1987; Hanski, 
1989; Goodwin and Weiss, 1990). The increased intracellular concentration of 
cAMP caused by CyaA activity inside cells inhibits the normal physiological 
processes of phagocytic leukocytes such as chemotaxis and oxidative responses 
and it is supposed that impairment of immune effector cell function is the 
major contribution of CyaA to the pathogenesis of B. pertussis (Confer and 
Eaton, 1985 ; Pearson et a l ,  1987; Coote, 1996). Both invasive and enzyme 
activities of CyaA are required during initial colonization of the mouse 
respiratory tract, as mutant strains lacking either one of these functions but 
retaining the other are severely impaired in colonization (Khelef etal., 1994).
1,8.10 Immnnogenicity
Early experiments suggesting a protective role for CyaA include those of 
Brezin et al. (1987) who showed that CyaA enzymic activity neutralizing and 
non-neutralizing antibodies prevented the lethal effects of the haemorrhagic 
alveolitis in mice infected with B. pertussis. CyaA from B. pertussis of 45 or 
200 kDa stimulated a protective response that prevented death and bacterial 
colonization when mice were challenged intranasally with B. pertussis 14 days
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after the second injection with CyaA (Guiso et a l ,  1991). Passive and active 
immunization with CyaA significantly shortened the period of colonization of 
the mouse respiratory tract. Immunogenicity of CyaA depends on the CyaC- 
mediated post-translational modification of the toxin (Betsou et a i ,  1993) 
which is required for presentation of CyaA protective epitopes located in the C- 
terminal portion of the toxin to the immune system (Betsou et a i ,  1995). 
Experiments are required to test whether N-terminal or C-terminal portion of 
CyaA alone induces protection in mice.
Arciniega e ta l ,  (1991) reported that pertussis infection in man leads to the 
production of high titres of CyaA antibodies, and such antibodies also are 
produced after pertussis vaccination. However, it was reported that the anti- 
CyaA antibodies found in human serum during pertussis infection did not 
neutralise the catalytic and penetrative activities of the enzyme (Farfel et al., 
1990 ). The lack of neutralizing capacity does not indicate that these antibodies 
are not important for the host immunity because they may interfere directly 
with the penetration of the invasive CyaA into immune effector cells and thus 
may be important for local defence against the CyaA toxin in the respiratory 
tract (Hewlett gf a/., 1987; Betsou eta l., 1993).
The above work suggests that CyaA is a major toxin in the pathogenesis of 
pertussis and may be responsible for the local cytopathic syndrome in the 
respiratory tract. CyaA will act as a protective antigen against B. pertussis 
colonization in the murine model, but the efficacy of protection by CyaA was 
reported to be lower than the efficacy of the whole cell vaccine (Guiso et al., 
1991). The results suggest that CyaA could be a useful addition to an acellular 
vaccine, although this has been questioned because of its possible toxic effect 
and because of a reported immunological cross-reaction between the catalytic
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domain of CyaA and rat brain adenylate cyclase (Monneron eta l., 1988; Guiso 
eta l., 1991).
1.8.11 Adjuvant effects on antibody response
Investigations on the suppressive or stimulatory immunological effects on 
antibody response and sensitization for anaphylaxis of various components of 
B. pertussis demonstrated that PT is the main adjuvant component of 
B. pertussis (Munoz and Peacock, 1990; Samore and Siber, 1996). PT 
markedly increased lymphocytosis due to inhibitory effects on the migration of 
circulatory lymphocytes into the lymphoid organ, suppressed chemotaxis and 
phagocytosis by neutrophils and macrophages, stimulated a delayed type 
hypersensitivity (DTH) mediated by a T hl response and mediated passive 
cutaneous anaphylaxis due to enhancement of a specific IgE antibody response. 
It also enhanced class and subclass-specific antibody responses to co­
administered protein antigens such as tetanus, diphtheria toxoid or ovalbumin 
by stimulation of a Th2 response associated with lymphokine secretion 
(Samore and Siber, 1996; Barnard et a t ,  1996). The functional similarity 
between CyaA and PT in elevating intracellular cAMP suggests that some of 
the immunomodulatory effects such as adjuvanticity on antibody responses 
could be common to both toxin antigens. This feature was investigated for 
CyaA in this work.
MATERIALS AND METHODS
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2.1 BACTERIAL STRAINS
2.1.1 Bordetella pertussis
The B. pertussis strains used in this study are given in Table 1. Strain 
BPDE386 is an insertion mutant derived from the Tohama strain of
B. pertussis. It contains an oligonucleotide insertion which inactivates the 
expression of the activator gene (cyaC) but does not affect the expression of 
cyaA. Therefore this strain produces a full-length CyaA protoxin which has 
enzymic activity but no invasive or cytolytic activity (Barry e ta l., 1991). 
Strain BP348 (pRMBl) is a Tn5 insertion mutant of B. pertussis Tohama 
strain containing a recombinant plasmid (pRM Bl) encoding the entire cya 
locus. This strain produces active CyaA toxin which has both AC enzymic and 
cytotoxic activities (Rogel et al., 1989). B. pertussis 18323 strain is the 
reference strain of B. pertussis and was also used for mouse intranasal 
challenge and vaccine potency tests.
2.1.2 Escherichia coli
E. coli host strains for expression of pT7 vectors used in this study were 
two lysogens of bacteriophage ÀDE3 (BL21/DE3 and HM S174/DB3) 
(Novagen). Strain DH5aF'IQ (Gibco-BRL) was also used. Strains BL21/ DE3 
and HMS174/DE3 both contain ÀDNA expressing the T7 gene encoding T7 
RNA polymerase under the control of the inducible lacUVS promoter. Addition 
of IPTG to a growing culture induces the polymerase, which in turn transcribes 
the target DNA in the plasmid. E. coli strain BL21/DE3 lacks the Ion protease
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and ompT outer membrane protease that can degrade some recombinant 
proteins. Strain HMS174/ DE3 carries the recA mutation and has a markedly 
higher transformation efficiency than the BL21/DE3 strain. Strain DHSaF'IQ, 
in which the T7 promoter is transcriptionally silent, is more suitable for long 
term maintenance of plasmid preparations as they are more stable in this strain. 
Recombinant E. coli strains used in this study and their relevant characteristics 
are listed in Table 1.
The stock of the above bacterial strains and competent bacterial cells for 
transformation of plasmids were stored frozen at -70 "C in 50%(v/v) glycerol.
2.2 PLASMIDS
Plasmids used in this study and their relevant characteristics are listed in 
Table 1 and the structures are shown in Figs 4-6. These plasmids containing 
cya, Ikt and hyb genes were constructed and kindly provided by Dr. Gareth 
Westrop.
2.3 CULTURE CONDITIONS
Frozen cultures of B. pertussis cells were grown on Bordet Gengou (BG) 
medium (Gibco-BRL, Appendix I. A) containing 20 % (v/v) defibrinated horse 
blood (Becton-Dickinson), 1% (v/v) glycerol and relevant antibiotics for 72 h 
at 37 °C in a humidified box. The bacterial cells harvested from plates were 
subcultured in cyclodextrin liquid medium (CDL, Appendix I. B) with 10% 
(v/v ) bovine serum albumin (Sigma) in the presence of relevant antibiotics. 
Recombinant E. coli strains were grown at 37 °C for 24 h on 2xYT agar and
46
Table 1. Bacterial strains and plasmids used in this study
Strain or 
plasmid
Genotype Relevant Source or 
Phenotype reference
Bacterial strains: 
B. pertussis :
BP348 cyaA ::Tn5 CyaC, K m ^ 1
BP348 (pRMBl) cyaA ::Tn5 CyaA, CyaC, T c R 2
BPDE386
(cyoA+, cyaC+) 
AcyaC CyaA 3
BP 18323 wild type CyaA, CyaC 4
E, coli'.
BL21 P~ompl hsdSB (I'B" »i*B”) non-expression host 5
BL21/DE3
galdcm
F‘ompT hsdSB (rg  niB") T7 RNA polymerase 5
DHSa F'lQ**
gal dcm (ÀDE3 lysogen) 
F'08Odtoc ZDMISA IPTG inducible 6
HMS174/DE3
hsd R17 (r k-, mfc-) gal " 
F recA hsd R T7 RNA polymerase 5
P. haemolytica (P30)
(rkl2‘ m k i2+) Rif ^  (DE3) 
wild type; Al serotype LktA, LktC 7
Plasmids:
pRMBl cyaA^yaC CyaA,CyaC 2
pGW44 c)uA CyaA 8
pGW14 cyaC CyaC 8
pGW54 cyaC CyaC 8
pGW64 IktA LktA 9
pGW78 IktC LktC 9
pGWSO hyb I Hybl 9
pGW88 hyb 2 Hyb2 9
pCACT3 cyaA^pyaC CyaA,CyaC 10
* Ail the plasmids encode Amp ^  except pGW54 and pGW78 which are Cm R 
and pRMBl which encodes Tc% .^
Full Genotype: F'08Od/oc ZDM15 A(/ac ZYA-a/^F)U169 deo R rec A1 end 
A1 hsd R17 (rk-, mk ) gal “ pho A sup E441 '  thi -1 gyr A96 ret Al.
1. Weiss et 1983 2. Brownlie et a / .,1988 3. Barry et a t 1990 4. Glasgow 
University, Laboratory collection S. Novagen 6. Gibco-BRL 7. Saadati etal 1997 8. Westrop et a l 1996 9. Westrop et a l 1997 10. Betsou et al., 1993.
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Fig. 4
The structure of recombinant plasmids
Plasmid pGW14 was derived from T7 vector pT7-7 (obtained from I. Hunter,
Strathclyde University) and contains the cyaC ORF linked directly to the
translation initiation codon of the vector. The region of pGW14 including the
T7 promoter , the gene leader sequence and the cyaC ORF was subcloned into 
Cvector pACYjl84 (Chang and Cohen, 1978) to create pGW54. The orientation 
of the cyaC  sequence of pGW54 precludes the possibility of constitutive 
expression from the tet promoter of the vector. Plasmid pGW44 was derived 
from vector p E T lla  (Novagen) and contained the cyaA ORF linked directly to 
the translation initiation codon of the vector. Transcription of cyaA  is 
controlled by the T llac  promoter. Promoters indicated by PT7 and VTllac. 
Arrows shows orientation of promoters and ORFs. Restriction endonuclease 
site shown by Bg, Bglil; Bsp, BjpHi; Ev, EcoRY; Sm, Smal; H, HindUl; 
N,Ndel; A, Aatll and B, Batnlü. Restriction endonuclease site in parentheses 
were destroyed by ligation. The figure is based on data of W estrop et a i  
(1996).
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Fig. 5
The structure of recom binant plasmids (continued)
nThe construction of pGW44 (encoding cyaA), pW54 (cyaC), pGW64 (IktA) ad 
pGW78 (IktC) involved direct linkage of the cya (shown in red or blue bars) or 
Ikt (shown in green or yellow bars) gene sequence to the leader sequences of 
T7 vectors p E T lla  or pT7-7. The pGW80 (encoding hybl) and pGW 80 
(encoding hyb2) were constructed using PCR mutagenesis together with 
conventional subcloning procedures to link cyaA  and IktA gene sequences. 
Plasmids pGW54 and pGW78 derived from pACYC184 are compatible with 
plasmids pGW64, pGW44, pGW80 and pGW 88 derived from p E T lla , 
allowing co-expression of A and C genes in the same E. coli strain. Solid lines 
represent the T7 vectors pT7-7 (in pG54) or p E T lla  (in all other constructs) 
and broken lines the vector pACYC184. PT7 lac indicates the hybrid promoter 
composed of the T7 gene 10 promoter and the lac operator sequence from 
p E T lla  and pT7 indicates the T7 gene 10 promoter from pT7-7, A j ^ ,  gene for 
ampicillin resistance; C m ^, gene for chloramphenicol resistance; la d ,  gene for 
lac repressor. Arrows show the orientation of promoters and ORFs. Restriction 
endonuclease sites used to construct recombinant plasmids are indicated by 
symbols; A, Aatll', H, Hindlll'. M, Mlul: N, Ndel', Nc, A/coI; Nr, Nrul', P, Pvul; 
Ps, Pstl and X, Xhol.
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Fig. 6
Schematic representation o f the predicted structural organization and 
functional relationships in the CyaA , LktA and hybrid toxins derived 
from CyaA and LktA.
The positions of the domains in CyaA , LktA or hybrid toxins are shown. 
Num fc>)ers refer to amino acid residues. The position of lysine (K) residues that 
may be modified by C-mediated acylation are indicated. Residues 687 and 919 
of CyaA and 379 and 616 of LktA indicate the junction codons at which 
crossovers were made for the construction of hybrid toxins. The figure is based 
on data of Westrop etal. (1997).
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then transferred to 2xYT broth media (Sambrook et al., 1989, Appendix I. D 
and I. E) with relevant antibiotics.
2.4 PREPARATION O F CyaA UREA EXTRACTS
2.4.1 Native CyaA from  B. pertussis
B. pertussis BP348 (pRM Bl) and BPDE386 were lawned on BG agar in 
the presence of tetracycline (10 mg/ml) and kanamycin (20 mg/ml) for strain 
BP348 (pR M B l). Bacteria were harvested from two lawn plates, and 
transferred to 1 litre of CDL medium containing relevant antibiotics in a 2 litre 
dimpled flask. Flasks were incubated in an orbital incubator at 150 rpm for 
48 h at 37 °C, The morphology of cultured cells was checked by Gram stain for 
evidence of contamination. Cells were harvested by centrifugation at 9000 g 
for 30 min at 4  °C (Sorvall RC5B). Cell pellets (1 g wet weight ) were 
resuspended in 8 ml of UE buffer (pH 8.0) (Appendix II. F) containing ImM 
phenyl methyl sulphonyl fluoride (PMSF, Sigma) as a protease inhibitor and 
8M urea (BDH). Suspensions were stirred for 2 h at 4 °C and then centrifuged 
at 15000 g for 30 min at 4  °C. The supernatants were then cleared by further 
centrifugation at 160,000 g in an OTD-combi/A 148561 centrifuge for 1 h and 
the resulting urea extracts were stored at -20 °C in I ml aliquots.
2.4.2 Recom binant CyaA from  E, coli
Recombinant E. coli strains were constructed by transformation of E. coli 
BL21(for plasmids derived from vectors containing the lac promoter) or 
E. coli BL21/DE3 (for plasmids derived from T7 vectors).
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2.4.2.1 Preparation of competent bacterial cells
The E. coli host strain was subcultured from a glycerol stock on to 2xYT 
agar and was incubated overnight at 37 °C. A cell suspension from an 
overnight plate was prepared in 2xYT broth and colony morphology was 
checked for evidence of contamination. The cell suspension was inoculated 
into 50 ml 2xYT broth in a 250 ml dimpled flask to give a starting A650 of 
0.02. The flask was incubated with shaking at 130 rpm at 37 °C. When the 
culture had reached A650 of 0.3-0.6, 20 ml of the culture in a Falcon centrifuge 
tube was left on ice for 10 m in before the cells were harvested by 
centrifugation at 9000 g for 10 min at 4  °C in a MSE-6L centrifuge. The cells 
were then resuspended in 2 ml of ice-cold TSB pH 8.0 (Appendix II. K) and 
the cell suspension left on ice for 10 min. The competent cells could be stored 
in 200 pi aliquots at -20 '’C until required.
2.4.2.2 Preparation of plasmid DNA
Plasmid DNA was prepared according to the modified method of Ish- 
Horowicz and Burke (1981). A single colony from an overnight culture plate of 
recombinant E. coli strain was incubated overnight in 2 ml of 2xYT medium 
with relevant antibiotic at 37 °C with vigorous shaking. The resulting bacterial 
cells were centrifuged at 12000 g for 30 s at 4 °C. The pellet was aspirated and 
left to dry inverted on tissue paper and the cells then resuspended in 100 pi of 
ice-cold GTE buffer (Appendix II. L) by vigorous vortexing, and then 200 pi 
of ice-cold, freshly prepared NSD (Appendix II. M) was added and mixed by 
inverting five times. The suspension was mixed by gently vortexing after
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addition of 1 ml of KAC (Appendix II. N), left for 10 min on ice and then 
centrifuged at 12000 g for 5 min at 4  “C and the supernatant was stored at 
-20 °C.
2.4.2.3 Transformation o f E, coli host cells
Plasmid DNA (2 pi or 200 ng) was added to 200pl of competent cells and 
left on ice for 20 min before 800 pi TSB (Appendix II. K) containing 20 mM 
D-glucose was added. The cell suspension was incubated at 37 °C for 1 h with 
shaking (130 rpm). The transformed cells (100 pi) were spread on selective 
2xYT agar containing relevant antibiotics and incubated overnight at 37 °C.
2.4.2.4 Growth of recombinant E, coli strains
Isolated colonies from primary transformants were subcultured on to 
selective 2xYT agar and incubated overnight at 37 °C. Cell suspensions in 
2xYT broth from an overnight plate of recombinant E. coli strains were 
inoculated into 250 ml 2xYT broth containing relevant antibiotics in a 2 litre 
dimpled flask to give an OD at 650 nm of 0.02 and incubated at 37 °C with 
shaking, When the OD650 reached 0 .6 , isopropyl p-D-thiogalactopyranoside 
(IPTG,Sigma) was added at a final concentration of 1 mM to induce expression 
of the recombinant proteins. The growth was continued at 37 °C for 4  h. The 
cells were harvested by centrifugation at 9000 g for 10 min at 4  °C and the cell 
pellets were stored at -20 “C.
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2.42.5 Pi-eparation of urea extracts
For preparation of urea extracts of inclusion bodies from recombinant 
strains, the cell pellets were suspended in 25 ml (1/10 th volume of original 
culture) of TEN buffer (pH 8.0) (Appendix II. I) containing 1 mg/ml 
lysozyme and 5% (v/v) glycerol. After 1 h at 4 °C the cell suspension was 
sonicated using a sonicator (Vibra cell sonicator, Jencons Scientific) for 20 s at 
half maximal output to reduce viscosity and then centrifuged at 17,000 g for 
30 min. The cell pellet was resuspended in 5 ml of 8 M urea in TC buffer 
(pH 8.0) (Appendix II, J) and rotated for 4 h at 4 °C. The suspension was then 
cleared by centrifugation at 160,000 g for 1 h. The supernatants containing 
recombinant proteins were stored in 1ml aliquots at -20 °C.
2.5 PURIFICATION OF CyaA
2.5.1 DEAE sepharose column chromatography
The method is based on electrostatic attraction between D iethyl- 
aminoethyl (DEAE) Sepharose and CyaA protein acting as an anion. The 
protein could be eluted from the column efficiently by increasing the ionic 
strength at a constant pH. The purification method was modified from that of 
Sakamoto et a l  (1992). DEAE Sepharose CL4B (Pharmacia) (1.4 ml) was 
poured into a column (Econocolumn, 10 x 2.5 cm) and equilibrated with 10 ml 
DEQ buffer (Appendix II. F). Sodium chloride was added to 2 ml of urea 
extract to a final concentration of 150 mM, before loading the urea extract on 
to the equilibrated column. The column was washed with 10 ml of DEQ buffer
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and the flow through collected, before fractions were eluted with 4 x 1 ml DEL 
buffer (Appendix II. F).
2.5.2 Calmodulin-agarose affinity chromatography
The procedure was essentially that of Hewlett e /a /. (1991) and is based on 
the affinity of calmodulin for CyaA. CyaA urea extract was diluted with an 
equal volume of buffer A containing 3 mM CaCl2 (pH 8.0) (Appendix II. F) to 
give a final concentration of 4  M urea. The diluted urea extract (20 ml) was 
added to 2 ml calmodulin agarose (Sigma) previously washed with buffer A 
containing 3 mM CaCl2 - The mixture was rotated gently for 4 h at 4 °C and 
loaded onto a Econocolumn (10 x 2.5 cm). The column was washed with 3 bed 
volumes of buffer B (Appendix II, F) followed by 3 bed volumes of buffer A 
with 10% (v/v) BSA. In the final step, CyaA was eluted with 10 x 1ml of 
buffer A containing 8 M urea and 2% (v/v) Tween 20 (Sigma). The fractions 
were collected and assayed for protein content using absorbance at 280 nm 
and the degree of purity of the preparation was assessed by SDS-PAGE. 
Purified CyaA was stored at -70 °C in 1 ml aliquots.
2.5.3 Gel tiltration column chromatography
A Sephadex G-75 column (Pharmacia), bed volume of 2 ml, was poured in 
an Econocolumn (10 x 2.5 cm) and equilibrated with 10 ml of equilibrating 
buffer (pH 7.5) (Appendix II. F). The column was calibrated by measuring the 
elution volume of an excluded 5uJ«tr (Blue Dextran, 2000 KDa ) and an 
included dye (Phenol red, 1 KDa). Urea extract (2 ml) was diluted with an
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equal volume of equilibrating buffer, loaded onto the column and washed with 
3 ml equilibrating buffer. The CyaA was eluted with 5 ml of equilibrating 
buffer containing 150 mM Na Cl.
2.5.4 Electroelution o f CyaA from polyacrylamide gel slices
The method used was that of Leppard et a l  (1983). The urea extract of 
CyaA was subjected to SDS-PAGE in 10% polyacrylamide gel (Appendix 
II. A) and stained with coomassie blue for 10 min, before cutting the 200 kDa 
protein band from the gel. The gel slice was transferred to dialysis tubing 
containing 5 ml of electroeluting buffer (pH7.4) (Appendix II. F) and 
positioned in a horizontal electrophoresis chamber with electroeluting running 
buffer (pH 7.4) (Appendix II. F) before electroelution at 100 V for 3 h. The 
purified CyaA solution was removed from the dialysis tube and stored at 
-70 °C in aliquots.
2.5.5 Conceutratiou of purified CyaA by polyethyleue glycol
The fractions of purified CyaA were mixed and placed in a dialysis tubing 
in a tray. The dialysis tubing with sample was surrounded completely by 
polyethylene glycol (PEG, Sigma, mol. wt 15,000-20,000) at 4  °C . When the 
volume of the sample was reduced to approximately 1/10 th of the original 
volume, the sample was removed from the dialysis tube and stored at -70 °C in 
1 ml aliquots.
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2.5.6 Concentration of puritied CyaA by centrifugal concentrator
The mixed fractions of purified protein were poured into a centrifugal 
concentrator (Omega) with a 100 KDa cut-off membrane and centrifuged at 
4000 g for 15 min. The concentrated protein was removed from the portion of 
tube above the membrane.
2.6 PURIFICATION OF OTHER PROTEINS BY UREA WASHING 
OF INCLUSION BODIES
Insoluble recombinant protein after expression and induction of protein by 
IPTG in E. coli strain BL21/DE3 was accumulated mainly in the form of 
inclusion bodies. For proteins such as LktA, LktC and CyaC which could not 
be purified by affinity chromatography, partial purification was achieved by 
washing soluble protein from inclusion bodies of the expressed proteins. The 
cells were lysed by treatment with lysozyme followed by sonication as 
described previously (section 2.4.2.5), then the cell lysate was centrifuged at 
9000 g for 15 min at 4  °C. The pellet was suspended in 1 ml of deionized water 
and centrifuged at 27,000 g for 15 min at 4  °C. The pellet was then 
resuspended in 1 ml of 100 mM Tris-HCl (pH 8.5) containing 0.5 M urea and 
centrifuged at 27,000 x g for 15 min at 4  °C. The washing step was repeated 
with 1 M and 2 M urea. H ybl toxin was also partially purified by this method.
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2.7 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS
SDS-PAGE was done according to the method of Laemmli (1970) in a 
vertical slab gel apparatus (Protean; BioRad). Gel plates were assembled 
following the manufacturer's instructions. The polyacrylamide solution for the 
separating gel, containing 7.5% or 10% acrylamide (w/v) in resolving gel 
buffer (Appendix II, A), was poured between the plates about 4.5 cm below the 
top of the notched plate before overlaying the acrylamide solution with 
isobutanol. The gel was placed in a vertical position at room temperature until 
the gel had set (about 1 h), and then the overlay was poured off. The top of the 
separating gel was washed with distilled water and dried with the edge of a 
filter paper. The acrylamide solution for the stacking gel, containing 4.5 % 
acrylamide (w/v) in stacking gel buffer (Appendix II. A), was poured directly 
onto the polymerized separating gel and combs were placed into the gel 
solution. The gel was placed in a vertical position for 1 h until the stacking gel 
had set at room temperature and the comb was then carefully removed. The 
wells were immediately washed with distilled water and the gel was placed in a 
gel tank with running buffer (Appendix II. A). The samples and molecular 
weight standard (SDS-6H or SDS-7H, Sigma) were heated in solubilising 
buffer (Appendix II. A) at 85 “C for 10 min and loaded into the bottom of each 
well using a microlitre syringe or with a micropipetter fitted with a long narrow 
tip. Electrophoresis was started at 20 mA until the tracking dye had moved into 
the separating gel and then increased to 30 mA for about 5 h. When the 
tracking dye had reached the bottom of the gel, the power was turned off and 
the gel plates removed. The gel was stained with coomassie blue R-250
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(Sigma) staining solution (Appendix IL A) for 2 h and destained by several 
changes of destaining solution (Appendix IL A).
2.8 IMMUNOBLOTTING (WESTERN BLOTTING)
Immunoblotting was carried out according to the method of Towbin et al. 
(1979) in a Bio Rad Transblot apparatus. The proteins were separated in a 10% 
SDS-PAGE gel and then the gel was soaked in transfer buffer (Appendix II. D) 
for 10-20 min. Nitrocellulose membrane (Hybond-C super, Amersham) and 
absorbent paper (Whatman 3 MM) were cut to the size of the gel and soaked in 
transfer buffer for 2 min. The gel was placed between the membrane and the 
absorbant paper with one Scotch bright pad on each side and rolled over the 
gel-paper surface to create a good contact. The complete assembly was placed 
in a tank of transfer buffer with the Hybond membrane facing the anode. 
Proteins were transferred overnight with cooling at 20 mA or 2 h at 400 mA. 
The membrane was removed and washed with PBS (Appendix II. B) before 
staining with 0.5% Ponceau S in 0.1% (v/v) acetic acid (Sigma, Appendix 
II. D) for 3 min or until the protein bands were visualized. The position of the 
transferred proteins and the molecular weight standards were marked and then 
the membrane was destained completely with PBS. The membrane was 
blocked with blocking buffer (Appendix II. D) containing 0.1 % (v/v) Tween 
20 (Sigma) and 5% (w/v) dried skimmed milk in PBS with shaking at room 
temperature to prevent non-specific adsorption of the immunological reagents. 
The membrane was then washed twice for 5 min with 0.1% (v/v) Tween in 
PBS at room temperature with shaking. Primary antibody was diluted 1/1000 
in PBS and incubated with the blot for 1 h at room temperature with shaking.
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The membrane was then washed twice with PBS containing 0.1% Tween. 
HRP-conjugated secondary antibody (Scottish antibody production unit 
[SAPU]) was diluted 1/1000 in PBS and incubated with the membrane at room 
temperature. The membrane was then washed twice with PBS containing 0.1% 
Tween and developed with DAB (diaminobenzidine, Aldrich) solution 
(Appendix II. D) containing 0.03% (w/v) DAB, 98 ml PBS, 2 ml of aqueous 
l%(w/v) COCI2 and 100 pi of 30% hydrogen peroxide. The reaction was 
stopped after 3 min by dilution with distilled water and the membrane was 
stored at room temperature in the dark.
2.9 PROTEIN ESTIMATION
The protein concentration of preparations was determined according to the 
method of Bradford (1976). A concentration series (50, 100, 200, 400, 800 
pg/ml) of bovine serum albumin (BSA, Sigma) was prepared by diluting a 
stock of BSA (1 mg/ml) in 150 mM NaCl, Three dilutions of sample (l/IO , 
1/50 and 1/100) were prepared in the same diluent. Each dilution from both 
standards and samples (100 pi) were transferred to duplicate tubes (16 xlOO 
mm) before adding 5 ml of protein assay reagent (Appendix II. E) into each 
tube. Absorbance values of standards, samples and blank ( diluent) were read at 
595 nm. A standard curve was prepared by plotting the average A 595 nm for 
each BSA concentration. The absorbance values of samples were then read off 
against the standard curve to determine the protein concentration.
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2.10 DIALYSIS
This was done according to the method of Brownlie el aL (1988). Urea 
extracts of CyaA were diluted 1/20 in dialysis buffer (Appendix II. O) before 
dialysis to avoid protein aggregation. Diluted urea extract (1/20) was 
transferred into a dialysis membrane (size 1-8/32) and dialysed at 4  °C for 2 h 
with continuous stirring against dialysis buffer (Appendix II. O) or 25 mM 
HEPES ( Sigma, pH 7.5) for production of toxin in the absence of calcium and 
chloride ions. The dialysis buffer was changed twice with fresh buffer during 
dialysis. After 2 h, the sample was removed from the dialysis tube and kept on 
ice for assay.
2.11 ADENYLATE CYCLASE (AC) ENZYM IC ASSAY
AC enzymic activity assay was measured according to the method of 
Salomon et al. (1974). CyaA samples were diluted 1/10000 and 10 pi of 
sample with 80 pi of reaction mix (Appendix II, G) were preincubated in a 
water bath at 30 °C for 10 min. Substrate mix (10 pi) (Appendix II. G) 
containing 20 mM ATP and 3000 Ci/mmol ^^P-ATP (Amersham) was added 
and incubation continued for 15 min at 30 °C. The reaction was stopped by the 
addition of 200 pi of 0.5 M HCl before neutralizing with 200pl of 1.5 M 
imidazole (Sigma). The neutralised solution (0.5 ml) was loaded onto a 
polypropylene column (Bio Rad) containing alumina powder (Merck) and ^^P- 
cyclic AMP eluted with 3 ml of 10 mM imidazole pH 7 .6 . Eluted solution was 
added to scintillation solvent and ^^P radioactivity counted in a Packard 
scintillation counter. In this assay 32p_^xP is converted to ^^p .cydic  AMP.
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The latter is separated by elution from the alumina column (^^P-ATP is 
retained on the column).
2.12 HAEMOLYSIS ASSAY
Whole fresh heparinized sheep blood (Becton-Dickinson) was diluted 1/2 
in HH buffer (Appendix IT C) and layered on top of percoll (Sigma) with a 
density of 1.092 before centrifugation at 1200 g for 10 min. Percoll, plasma 
and leukocytes were removed and the pellet containing RBCs was washed in 
HH buffer until the supernate was clear. The RBCs were resuspended in HH 
buffer with 1 mM CaCl2- CyaA was diluted in serial two-fold dilutions in HH 
buffer starting with 1/20 dilution before transferring (50 pi) to a 96-well flat 
bottom microtitre plate (Nunclon Delta). The RBCs (50 pi of 5x10 ^ cells) 
were added to the microtitre plate and mixed gently with the toxin. HH buffer 
alone was used as a negative control and saponin 1% (v/v) as a positive 
control. The plate was then incubated overnight at 37 °C before centrifugation 
at 1500 g for 15 min. The supernate after centrifugation was carefully 
transferred to a clean microtitre plate and the absorbance at 540 nm was read 
on an Anthos 2001 ELISA reader. The assays were done in duplicate and the 
mean value of percentage haemolysis for each dilution was calculated.
2.13 PREPARATION OF CULTURED MAMMALIAN CELLS
Baby hamster kidney (BHK 21) cells were prepared by the method of 
We strop et aL (1994). The cells were passaged in tissue culture medium 
(pH 7.4) (Appendix I. H) for 48 h at 37 °C. Trypsinized cells were collected by
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centrifugation at 5000 g and resuspensed in HH buffer to give a concentration 
of 10 4 ceils/m i. Bovine lymphom a-derived (BL3) cells and mouse 
macrophage-derived (J774.2) cells were grown in tissue culture medium 
(Appendix I. I and J) for 48 h at 37 °C. The cells were pelleted at 5000 g and 
resuspended in fresh growth medium to give a concentration of 10 ^ cells/m l.
2.14 BHK CELL SPREADING (SHAPE CHANGE) ASSAY
Invasive CyaA activities were determined for BHK cells using a cell 
spreading (shape change) assay performed according to the method of Westrop 
et at. (1994). The wells of 24-well plastic tissue culture plates were coated with 
0.5 mi of fibronectin (25 pg/ml. Sigma) in HH buffer for 15 min. The wells 
were then coated with 0.5 ml of haemoglobin (0.5 mg/ml. Sigma) for 15 min. 
Urea extracts were diluted 1/20 in HH buffer containing 3 mM CaCl2 and 
serial 3-fold dilutions were prepared. Urea extract dilutions (250 pi) were 
mixed with an equal volume of BH K 2I(2xI0 4cells/ml) and transferred to 
coated wells. The plate was incubated at 37 °C for 2 h and the cells were fixed 
with 4% (v/v) formaldehyde (250 pl/well) for 15 min. The fixed cells were 
then stained with 1% coomassie blue and examined with the 40x objective 
under brightfield microscopy for stellation, either by eye or image analysis 
using a Leitz Diavert microscope equipped with a Hamamatsu Vidicon C l000 
camera and an Archimedes digitizer connected with an Archimedes 310 
microcomputer. This assay is based on the induction of a stellated morphology 
in BHK cells which results from intracellular cAMP elevation (Westrop et aL, 
1994).
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2.15 CHEMILUMINESCENCE INHIBITION (CL) ASSAY
The chemiluminescence assay was done according to Chang et al. (1986) 
and is based on measuring the inhibition of the response of bovine or rabbit 
neutrophils to PMA stimulation. Freshly heparinised bovine or citrated rabbit 
blood (15 ml) was layered carefully on top of 7 ml Histopaque (Sigma) and 
centrifuged at 830 g for 30 min at room temperature. Supernatant containing 
mononuclear cells, Histopaque and plasma were removed carefully. RBCs in 
the pellet were lysed by the addition of 10 ml of ice-cold lysis buffer 
containing 155 mM NH4 CI, 10 mM KHCO3 and ImM EDTA. The suspension 
was then centrifuged at 400 g for 5 min at 4 °C and the pellet containing 
neutrophils was suspended in HH buffer (pH 7.4). The viability of neutrophils 
was checked before CL assay by staining with 0.1% trypan blue dye. The CL 
assay was performed by mixing 1/20 dilution of CyaA urea extracts (50 pi) 
with 750 pi HH buffer containing neutrophils (SxlO^cells) and 100 pi of 
10"5 M 7-dimethylamino-naphthalene-1,2-dicarbonic acid hydrazide (DNDH, 
Boehringer Mannheim GmbH, Germany). Following incubation for 20 min at 
38 “C, the neutrophils were stimulated with 100 pi of 0.5 mg/ml opsonised 
zymosan (OZ ) (Sigma) or 1 pg phorbol myristate acetate (PMA, Sigma). The 
CL emission was then measured in mV at 38 °C with a Wallac luminometer 
connected to an IBM-PC computer with multi-use software (Bio-Orbit). The 
samples were assayed in duplicate and the mean value of percentage inhibition 
was calculated.
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2.16 MTT DYE REDUCTION ASSAY
Cytotoxic activity was determined by the MTT assay (Mosmann, 1983) 
using the cell titre assay (Promega) kit. This assay is based on the reduction of 
a yellow tétrazolium  dye (3-[4, 5-dim ethylthiazole-2-yl]-2, 5-diphenyl 
tétrazolium bromide, MTT) into insoluble purple formazan by dehydrogenases 
in active mitochondria of living cells. The activity of toxin on cells inhibits this 
reaction. Mouse macrophage-derived (J774.2) cells and bovine lymphoma 
derived (BL3) cells (3x10^ cells/ml) were prepared in RPMI medium (section 
2.13). Urea extracts were diluted in RPMI tissue culture medium in serial two­
fold dilutions starting with 1/20 dilution and 50 pi of each dilution transferred 
to the wells of 96-well flat bottom microtitre plates (Nunclon ), before the 
addition of 50 pl/well of cell supension (1x10 ^ cells/ml). The plate was 
incubated at 37 °C in a humidified box for 2 h before addition of 15 pl/well of 
MTT dye (Promega) and incubation continued at 37 °C in the humidified box 
for 4 h. The solubilization / stop solution (100 pl/well) (Promega) was then 
added and incubation continued at 37 °C in the humidified box overnight. The 
A540 nm was measured by ELISA reader.
2.17 IN VIVO ACTIVATION OF PROTOXINS
E. coli strain BL21(pCACT3) was constructed by transformation of 
pCACT3(cy<zA,cyaC) plasmid into competent E. coli BL21 cells. E. coli 
BL21/DE3 (pGW44) was constructed by transformation of pGW44 {cyaA) 
plasmid into competent E. coli BL21/DE3 cells and then the E. coli BL21/DE3 
(pGW44, pGW54) strain was constructed by transformation of pGW54 {cyaC)
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plasmid into competent E. coli BL21/DE3 (pGW44) cells. The transformed 
E. coli strains were grown and induced by addition of IPTG (section 2.4.2.4). 
The recombinant proteins were then extracted with urea from inclusion bodies 
from induced cell lysates (see section 2.4.2.5). H ybl, Hyb2 and LktA 
protoxins alone or activated in vivo by CyaC or LktC were also produced by 
this method, using BL 21/DE3 competent cells.
2.18 IN VITRO ACTIVATION OF PROTOXINS
2.18.1 Preparation of A and C toxin proteins and the activation 
component
ProCyaA, proLktA, proHyb2, CyaC and LktC were prepared from E. coli 
strains BL21/DE3 (pGW44), (pGW64), (pGW88), (pGW54) and (pGW78) 
respectively. Bacterial cells were grown in 2xYT broth containing ampicillin at 
37 °C to an A650 nm of 0.6 and recombinant protein induced by addition of 
IPTG. Induced cultures were centrifuged at 9000 g for 10 min and cell pellets 
were resuspended in 25 mM HEPES (pH 7.5) and lysed by sonication using a 
Micro processor sonicator for 3 x 20 sec with 40 sec intervals for cooling. The 
cell lysates were centrifuged at 17,000 g for 30 min at 4  °C and pellets were 
resuspended in 25 mM HEPES (pH 7.5), containing 8.0 M urea. Proteins were 
extracted by rotation at 4  °C for about 4  h and the urea extracts cleared by 
centrifugation at 160,000 g for 1.5 h. The urea extract supemates were stored at 
-20 “C.
The cytoplasmie activator factor (CAE) was prepared from E. coli BL21 
cells. E. coli BL21 was grown in 2xYT broth at 37 °C to late exponential phase
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(A650 nm of 1.5 ) and cells were harvested by centrifugation at 9000 g for 15 
min. The cell pellet was resuspended (10% w/v) in 25 mM HEPES (pH 7.5) 
and lysed by sonication as above. The cell lysate after sonication was 
centrifuged at 100,000 g and the supernate stored in 1ml aliquots at -70 °C. 
CAP was also prepared from cultures of B. pertussis BP348 and Pasteurella 
haemolytica (Ph30) strains in the same way.
2.18.2 In vitro activation reaction
The in vitro activation components (protoxin+C protein+CAF) were each 
diluted 1/20 in 25 mM Hepes (pH 7.5) and preincubated separately at 4  “C for 
30 min. The reaction was set up by mixing 50 yd of each component followed 
by incubation for 30 min at 4 °C. Aliquots were removed and assayed 
immediately for CyaA toxic activity. A  number of reactions were done in this 
way, varying different factors and reaction conditions such as incubation time 
and temperature, effect of different ions and EGTA, and alteration of in vitro 
activation components.
2.18.3 In vitro acylation of acyl carrier protein (ACP)
The reaction for enzymatic synthesis of Acyl-Acyl Carrier Protein (Acyl- 
ACP) was carried out according to the method of Rock et aL (1981). All the 
materials used in the acylation of ACP reaction were purchased from Sigma. 
The acylation reaction mix (Appendix II. P) (1 ml) contained 5 mM ATP, 
2 mM dithiothreitol (DTT), 2% (v/v) Triton X-100, 100 mM Tris-HCl 
(pH 8.0), 400 mM Li Cl, 160 pM fatty acid (sodium salt), 155 pM ACP-SH,
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10 mM MgCl2 and 3.0 units of acyl-ACP synthetase. It was incubated initially 
in a water bath at 37 °C for 3 h and then incubated for another 16 h at 30 “C. 
The acylated ACP was diluted 1/200 before use in in vitro activation in place 
of CAP.
2.19 ANTIBODIES
2.19.1 Production of anti-i'CyaA polyclonal antibody in rabbits
Urea extracts of active and inactive recombinant CyaA proteins were 
separated on 10% SDS-PAGE gels and stained with Coomassie blue R 250 for 
5 min until the 200 KDa protein band was visualized. The protein band at the 
200 KDa position was carefully cut out in 5mm strips. The strips were washed 
with deionized water and then destained for 20 min. The gel bands were 
crushed after washing in sterile PBS and then suspended in 2 ml of sterile PBS. 
The suspensions were centrifuged at 15,000 g for 30 min at 4 °C and the 
supernatants was stored at -20 °C. Before use, protein antigens were dialysed 
against PBS at 4 °C for 24 h and the supernatant from the dialysis sac 
emulsified in Freund's incomplete adjuvant (Sigma) in a 1:1 ratio. Two female 
New Zealand Albino rabbits were injected intramuscularly with 2 ml of CyaA 
antigen after bleeding for pre-immune sera. The immune sera were collected 1 
week after 4  booster injections at 4 week intervals. The immune sera were 
tested for specificity by immunoblotting and used as a reference serum in 
ELISA experiments. An immune serum against CyaC was prepared by the 
same method.
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2.19.2 Preparation of mouse reference antisernm raised against CyaA 
or ovalbumin
A reference antiserum for anti-CyaA and anti-Oa in ELISA was produced 
by immunizing mouse with the purified CyaA (PAR CyaA) or ovalbumin (Oa) 
according to the immunization schedule (section 2.21). Sera with high titres of 
anti-CyaA or anti-Oa for each specific immunoglobulin were pooled to make 
the reference sera.
2.19.3 Other antibodies
Monoclonal antibody (9D4) (lgG2a) raised against B. pertussis CyaA toxin 
was kindly provided by Dr. E. Hewlett, University of Virginia, USA. This 
MAh was used in immunoblots and reacted with CyaA. Monoclonal antibody 
2-5 (IgG) raised against CyaA toxin was kindly provided by Dr. N. Heveker, 
Pasteur Institute, Paris. This MAb reacted with the repeat region of LktA as 
well as that of CyaA. Rabbit polyclonal antibody raised against the 100-110 
KDa bands of rLktA from 7.5 % acrylamide gels were kindly provided by 
Dr. M. Saadati, Division of Infection and Immunity, Glasgow University. The 
convalescent serum from a rat infected by B. pertussis 18323, hyper immune 
serum from mice vaecinated with B. pertussis, anti-FHA and anti-PT 
polyclonal antibody raised against purified FHA and PT were kindly provided 
by Dr. E lizabeth Hall, Division of Infection and Im munity, Glasgow 
University. Polyclonal antibody raised against PRN in mice was kindly 
provided by Dr. M. Roberts, Veterinary Pathology Department, Glasgow
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University. These antibodies were used for screening for the presence of other 
B. pertussis components in purified preparations of CyaA by western blotting 
and ELISA. Anti-cytokine monoclonal antibodies were purchased from 
Pharmingen.
2.20 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Purified CyaA antigen was diluted with coating buffer (containing 50 mM 
sodium carbonate (Appendix II. H) to a concentration of 50 ^ig/ml and 100 fxl 
portions of diluted CyaA dispensed by a multichannel pipette into wells of a 
m icrotitre plate (Immulon-2, Dynatech). The plates were covered and 
incubated at 4 °C overnight in a humidified box, then washed carefully three 
times with washing buffer (Appendix II. H) containing 0.05% Tween 20 in 
PBS (pH 7.4). For each wash, wells were filled with washing buffer and 
allowed to stand for 1 min prior to draining. The plates were pounded on paper 
towels as a final step. The wells were then blocked by addition of 100 p.l/well 
of blocking buffer (Appendix 11. H) containing 0.05 % (v/v) Tween 20 and 2% 
(v/v) BSA in PBS (pH 7.4) and incubated for 1 h at 37 °C. The plates were 
washed three times and dried as above. The serum samples were diluted 1/1000 
in washing buffer and then 100 pl/well dispensed, except for the two last 
columns which were used for reference serum and buffer (as negative control). 
The plates were then incubated for 1 h at 37 °C before washing three times as 
above. The anti-mouse or anti-rabbit IgG-HRP-enzyme-conjugate (SAPU) at 
1/2000 dilution in washing buffer (100 pl/well) was added and then incubated 
for 1 h at 37 °C. The substrate solution (Appendix 11. H) for HRP-conjugate 
was prepared by dissolving 34 mg of ortho-phenyiene diamine (OPD, Sigma)
MATERIALS & METHODS 70 PART II
in 100 mi of citrate-phosphate buffer (Appendix II. H). The substrate solution
e(100 pi /well) plus 20 pi H2O2 was added and incubated at room temprature in 
the dark for 20 min. The reaction was stopped by addition of 50 pl/well of 12% 
H2SO4  and the absorbance values were measured at A 492 nm in the Anthos 
20001 ELISA reader. The above ELISA method was used for measuring IgG, 
IgG l, lgG2a, lgG2b and IgE antibodies to CyaA or Oa. EDRP-sheep anti-mouse 
IgG, IgG l, lgG2a, lgG2b and IgE were the conjugates used in ELISA, 
respectively. The conjugates and standard reference sera were purchased from 
Serotec (22 Oxford 0X 5 IJE, England).
2.21 INTRANASAL MOUSE PROTECTION TEST
The experimental protocol was performed essentially according to the 
method of Betsou etal. (1995).
b2.21.1 Preparation of CyaA and hyrid toxin vaccinesk
The crude and purified CyaA or hybrid toxins were prepared as active and 
inactive preparations depending on whether they had been made in the 
presence of C-protein or not (see sections 2.4 and 2.5). The vaccines were 
prepared by mixing gently 75 pg/ml CyaA or hybrid preparation with an equal 
volume of alhydrogel (2.5 mg/ml) kindly provided by Prof. D. Stewart-Tull, 
Division of Infection and Immunity, Glasgow University.
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2.21.2 Active immunization
Male 3-4 week old HAM ICR (CD-I) mice randomized in groups of ten 
were anaesthetized with halothane and vaccinated subcutaneously with 15pg
per mouse of crude or purified CyaA or hybrid vaccines or 1/5 human dose
b(HD) of adsorbed diphteria-tetanus-pertussis (DPT)-vaccine containing killed 
whole J5. pertussis (Welcome Trivax-AD) in PBS using two doses at a two 
week interval. One group of mice was vaccinated only with alhydrogel in PBS 
and one group of mice was left unvaccinated as controls.
2.21.3 Mouse intranasal challenge
B. pertussis 18323 was grown as a lawn on two BG plates for 24 h at 37 °C
in a humidified box. The growth was suspended in 1% (w/v) casamino acid
(Oxoid) in PBS (pH 7.3) and was made up to 10 opacity units (2 x 10 9 cfu/ml)
by comparison with the 5^h International Reference of Opacity (Perkins et al.,
1973). The challenge suspension was prepared by diluting 1/100 to give 2x10 7
cfu/ml and a sublethal dose of the challenge suspension (1x10 ^ cfu per mouse)
was instilled intranasally in 5 mice of each group one week after the second
vaccination. The weight of the mice before and at intervals up to 7 days aftercchallenge were recorded. Mice were sacrified 7 days after challenge and lung 
pathology and lung weight as % of body weight were determined. The lungs 
were removed aseptically and homogenized in a sterile Jencons homogenizer in 
1% (w/v) casamino acids in PBS. Neat, 10 and 10 ~4 dilutions of lung 
homogenates were cultured on BG agar at 37 °C in a humidified box and 
colonies were counted after 72 h.
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2.21.4 Preparation of immune sera
The 5 mice of each group which had not been challenged were 
anaesthetized with halothane and bled one week after the second vaccination, 
i.e. at the time that the other mice were challenged. The blood was allowed to 
clot at 37 °C for 1 h. The clot was then separated from the inside wall of the 
collection tube using a pasteur pipette and the samples placed at 4  “C overnight 
before collection of sera. The sera were cleared by eentrifugation at 10,000 g 
for 10 min and stored at -20 °C in 1ml aliquots.
2.22 Adjuvanticity of CyaA
A group of 20 mice were injected with ovalbumin (Sigma) 20 pg/mouse 
alone or with 15 pg/mouse of purified active or inactive recombinant CyaA. 
Two weeks after the first injection, 10 mice of each group were given a second 
injection. Sera were taken from 5 mice of each group at one week intervals 
after the first injection.
2.23 PREPARATION OF CYTOKINES
The cytokine assay was earned out according to the method of Redhead 
et al (1993). The spleens were removed aseptically from the mice vaccinated 
with purified active and inactive CyaA 7 days after the second immunization 
and a suspension of spleen cells prepared in RPMI 1640 medium (Gibco-BRL) 
with 10% (v/v) FCS, 1% (w/v) penicillin and 1% (w/v) fungizone by gentle 
homogenisation in a Jencons homogeniser. The suspension was layered over
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3 ml of heat-inactivated FCS for 10 min on ice to allow large debris to settle 
and then washed twice by centrifugation in RPMI medium at 350 g for 10 min 
at 4 °C. The cells were resuspended in 10 ml RPMI medium and counted. 
RPMI medium alone or ConA (20 pg/ml. Sigma) or CyaA (15 pg/ml) in RPMI 
medium was added to 1 ml of spleen cell suspension (1x10 7cells) in the wells 
of a 24 well tissue culture plate and incubated at 37 °C for 24 or 48 h in a 
humidified C 02 incubator. The cell cultures were centrifuged at 5000 g for 
10 min and the supemates collected and stored at -20 °C.
2.24 CYTOKINE ELISA
Cytokines were assayed with a Pharmingen kit. (Cambridge Bioscience) 
Microtitre plates (Dynatech Immunlon 4) were coated with 50 pi /well of anti- 
cytokine monoclonal antibody (2 pg/ml) in coating buffer (O.IM NaHC03, pH 
8.0) and incubated overnight at 4 °C. The plates were washed twice and 
blocked as described in section 2.15. The standard cytokines (Pharmingen) 
were diluted in 10% FCS in PBS (pH 7.4), according to kit instructions 
(10-2000 pg/ml). The standards and samples were added at 100 pl/well and 
incubated at 37 °C for 3 h before washing four times as before. Biotinylated 
anti-cytokine detecting monoclonal antibodies (Pharmingen) were diluted 
(0.5-4 pg/ml) in 10%FCS in PBS and added (100 pl/well ) before incubation at 
37 "“C for Ih. The plates were washed six times and then extravidin-peroxidase 
(2 pg/ml, Sigma) was added before incubation at 37 “C for 1 h. The plates were 
washed eight times and TMB substrate (Dynatech) at 100 pl/well was added 
before incubation for 30 min in the dark at room temperature. The plates were 
read at 630 nm in an ELISA reader with reference filter at 405nm.
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2.25 RADIAL IMMUNODIFFUSION ASSAY (RID)
RID for the measurement of the concentration of total IgG and IgG 
subclasses of serum was performed according to the method of Fahey and 
McKelvey (1965). It is based on the radial diffusion of an antigen or antibody 
from a cylindrical well through an agarose gel containing a suitable mono- 
specific antibody or anti-antibody. Therefore an antigen-antibody complex or a 
complex of antibody and anti-antibody is formed as a pp>cipitin ring. The RID 
kits were purchased from the Binding Site (Birmingham, U.K), Three dilutions 
of IgG and IgG subclasses standard calibrators (neat, 10% and 60%) and 1/10 
sera dilutions (5 pl/well) were added to the wells of an agarose gel plate and 
incubated at room temperature in a humidified box for at least 5 days until 
complete precipitin rings were formed. The square of the diameter of the 
precipitin  rings were plotted against their corresponding calibrator 
concentration. The concentration of antibody was read from the calibration 
curve and multiplied by 10 (dilution factor).
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3.1 PRODUCTION OF NATIVE CyaA FROM  B. pertussis
In order to produce high levels of CyaA toxin from B, pertussis 348 
(pRMBl) or BP DE386, the effect of growth conditions was investigated by 
altering the growth media, incubation time, temperature and aeration 
conditions. The maximum yield of CyaA toxin was obtained from cultures in a 
modified CDL medium supplemented with various amino acids, ions, vitamins 
and 500 pg/ml of methyl p cyclodextrin (Appendix L B and C) (section 2.3). 
The bacterial cultures were heavily inoculated from BG agar into 1 litre of 
modified CDL medium in a 2 litre dimpled flask and incubated at 37 °C for 24 
, 48 or 72 h with shaking at 150 rpm for high aeration or 120 h in static culture. 
Under these various conditions, the yield of CyaA presented in Table 2 was 
obtained.
CyaA extracted from B. pertussis 348 (pRMBl) or BPDE386 grown for 
48 h with shaking led to a maximum production of CyaA crude extract as 
shown in Table 2 and this procedure was adapted for routine production of 
CyaA. Purification of the CyaA by DEAE-sepharose column chromatography 
also gave maximum production of CyaA from the 48 h culture. Less CyaA was 
obtained from other cultures or cultures grown statically. The protein profiles 
of crude and purified preparations, as revealed by SDS-PAGE, are shown in 
Fig. 7.
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Fig. 7
SDS-PAGE analysis of crude and purified CyaA preparations from  
B, pertussis and E. coli strains
Crude urea extract (25 pg  protein/lane) and purified CyaA (4 pg  protein /lane) 
preparations were subjected to electrophoresis on 10% polyacrylamide gels 
and stained with coomassie blue (section 2.7). Arrows indicate the positions of 
molecular weight standards.
Lane 1 : 6H mol wt marker proteins
Lane 2 : CAN CyaA: Crude CyaA from B. pertussis 348 pRMB 1
Lane 3 : PAN CyaA: Purified CyaA from B. pertussis 348 pRMB 1
Lane 4 : CIN CyaA: Crude CyaA from B. pertussis DE386
Lane 5 : PIN CyaA: Purified CyaA from B. pertussis DE386
Lane 6 : CAR CyaA: Crude recombinant CyaA from E. coli BL/DE3
(pGW44,pGW54)
Lane 7 : PAR CyaA: Purified recombinant CyaA from E. coli BL/DE3
(pGW44,pGW54)
Lane 8 : CIR CyaA: Crude recombinant CyaA from E. coli BL/DE3
(pGW44)
Lane 9 : PIR CyaA: Purified recombinant CyaA from E. coli BL/DE3
(pGW44)
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3.2 PREPARATION OF CyaA FROM RECOMBINANT E. coli 
STRAINS
Active recombinant CyaA toxin was produced in E. coli to a high level 
using the T7 RNA polymerase expression system. Co-expression of cyaA  and 
cyaC in the presence of ImM IPTG in E. coli BL21/DE3 harbouring two 
separate compatible plasmids pGW44 and pGW54 produced biologically 
active CyaA protein comparable to native CyaA produced from B, pertussis. 
Strain BL21/DE3 (pGW 44, pGW 54) synthesised CyaA in an amount 
comparable to that expressed from the individual plasmid pGW44 in E. coli as 
shown in Fig.7. This indicated that the expression of one gene did not interfere 
with the expression of the other gene.
Large amounts of CyaA were extracted from induced cultures of strain 
BL21/DE3 (pGW44, pGW54), presumably as inclusion bodies which could be 
solublized with 8 urea. The resulting urea extracts of strain BL21/DE3 
(pGW44, pGW54 ) contained a 200 kDa protein which reacted with anti-CyaA 
polyclonal antibody in western blots (Eig. 8). The data in Figs. 7 and 8 
indicated that expression of the cyaA gene in the absence of the cyaC gene 
(BL21/DE3 (pGW44)) produced a CyaA protein with the same apparent 
molecular weight (200 kDa) as the active form of CyaA synthesised in strain 
BL21/DE3 (pGW44, pGW54).
The effect of cultural conditions on the yield of CyaA preparations from 
BL21/DE3 (pGW44) or BL21/DE3 (pGW44, pGW54)) is shown in Table 3. 
Maximum yield of crude and purified CyaA protein was obtained after 
induction of the cultures with IPTG for 4 h. Without IPTG addition, even at 
8 h, the yield of CyaA was greatly reduced.
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Fig. 8
Western blot analysis o f crude and purifîed CyaA preparations 
with rabbit anti-200 kDa CyaA polyclonal antibody.
Crude urea extract (20 /<g/lane) and purified CyaA by DEAE sepharose 
(4 protein/lane) preparations were subjected to electrophoresis on 
10% polyacrylamide gels and transferred to a Hybond C-super 
membrane (section 2.8). The nitrocellulose blots were probed with 
rabbit anti-200 kDa CyaA polyclonal antibody (section 2.19.1). Arrows 
indicate the positions of molecular weight standards.
Lane 1 CAN CyaA (Crude active native CyaA)
Lane 2 CIN CyaA (Crude inactive native CyaA)
Lane 3: CAR CyaA (Crude active recombinant CyaA)
Lane 4 CIR CyaA (Crude inactive recombinant CyaA)
Lane 5 PAN CyaA (Purified active native CyaA)
Lane 6 PIN CyaA (Purified inactive native CyaA)
Lane 7 PAR CyaA (Purified active recombinant CyaA)
Lane 8 PIN CyaA (Purified inactive recombinant CyaA)
(g
▼
' / I I
m
r.
g
I 
I
4 -
I oc
'3
80
O'!' S 'F
O '*o
'*■ S'CL II ^  
I—t ^  A o
i |
t
i i j
l o i - 1
I I Î I
^ ! ^ G ”
’ S-l5ÎIIIIIS’ ? ?S' fD 3IIIi
I
§Îi
P P P
T3 "O SJ XtO O O O
A. A. 4L. 4U
T) T) TJ nsO O O o
f
p  p\
 ^ g&
a
I I
!
Iw
f
«h-^
ff
b» i-iHQ X no no tjO O O O O
t t Ê
I
Î
g
Î
È
p
g
P
7|
p p
& & & $ &
s )—i 8 8 C
H
O
I
Iy !
;
Uj
pUl
tvi
g
io  o
t
NI—k
P
%
g pa 
= §S I
Î
I
I»
IIII 2,ÎÎ
1 1il Ia
I
S,
iI
S.IIg
[Çq
§
i
RESULTS 81 PART III
3.3 PREPARATION OF HYBRID TOXINS FROM RECOMBINANT 
E. coli STRAINS
Two hybrid toxin genes were constructed from IktA  and cyaA  genes 
(Westrop et al., 1997). The hybl gene (on plasmid pGW80) was derived from 
the cyaA and IktA genes by a cross over located between codons 687 (Ala) and 
688 (Ala) of CyaA and codon 378 (Ala) and 379 (Gly) of LktA. Hybl was 
expressed in E. coli BL21/DE3 harbouring pGW80 as a stable protein of 1262 
amino acids with enzymic AC activity. The N-terminal amino acid residues 
(1-687) were derived from CyaA and the C-terminal residues (688-1262) 
derived from LktA (residues 379-953). The hybl gene was derived from hyb 1 
by a second cross over located between codon 616 (Asp) and 617 (Asn) of 
LktA and codons 918 (Asp) and 919 (Val) of CyaA. Hyb2 was expressed in 
strain E. coli BL21/DE3 (pGW88) as a stable protein of 1713 amino acids 
with enzymic AC activity. In this construct, a highly conserved domain of 
CyaA (amino acid residues 688-918) had been replaced with amino acid 
residues 379-616 of LktA (Figs 5 and 6).
The cultures were grown in 2x YT medium to an A 650 of 0.7. Hybrid 
toxins as inclusion bodies were induced by addition of IPTG to the mid­
exponential cultures and incubation for a further 4 h. Urea extracts were 
prepared from cells expressing hyb 1 or hyb l together with cyaC or IktC genes 
as shown in Fig. 9. It is clear that the recombinant proteins were expressed in 
large amounts in E. coli and with the expected mol. wts of 200 kDa for CyaA 
and Hyb 2, 170 kDa for Hybl, 105 kDa for LktA, 21 kDa for CyaC and 19kDa 
for LktC (Fig. 10),
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Fig. 9
SDS-PAGE analysis of crude and purified hybrid toxin preparations 
from E, coli strains
Crude urea extract (25 pig protein/lane) and purified hybrid (6 pig protein/lane) 
preparations from E. coli strains were fractionated on 7.5% polyacrylamide 
gels and stained with coomassie blue. Arrows indicate the positions of 
molecular weight standards.
Lane 1 ; 6H Mol wt marker proteins
Lane 2 : Crude Hyb 2 from E. coli BL /DE3 (pGW88)
Lane 3 : Purified Hyb 2 from E. coli BL /DE3 (pGW88)
Lane 4  : Crude Hyb 2/LktC from E. coli BL /DE3 (pGW88,pGW78)
Lane 5 : Purified Hyb 2/LktC from E. coli BL /DE3 (pGW88,pGW78)
Lane 6 ; Crude Hyb 2/CyaC from E. coli BL /DE3 (pGW88,pGW54)
L ane 7 : P u rified  H yb 2/C yaC  from  E. co li BL /D E 3
(pGW88,pGW54)
Lane 8 : Crude Hyb 1/CyaC from E. coli BL /DE3 (pGW80,pGW54)
Lane 9 : Purified Hyb 1/CyaC from E. coli BL /DE3
(pGW80,pGW54)
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Fig. 10
SDS-PAGE analysis o f crude urea extracts of CyaA, Hyb2, H ybl and 
LktA preparations activated in vivo in E, coli by CyaC or LktC .
Crude urea extracts (gO ) were separated on a 7.5%
polyacrylamide gel and stained with coomassie blue. Arrows indicate the 
positions of molecular weight standards.
Lane 1 
Lane 2 
Lane 3 
Lane 4 
Lane 5 
Lane 6 
Lane 7 
Lane 8 
Lane 9 
Lane 10 
Lane 11 
Lane 12 
Lane 13 
Lane 14
7H Mol wt marker proteins
CyaA from E. coli BL /DE3 (pGW44)
CyaA/CyaC from E. coli BL /DE3 (pGW44,pGW54) 
CyaA/LktC from E. coli BL /DE3 (pGW44,pGW78) 
Hyb 1 from E. coli BL /DE3 (pGW80)
Hyb 1/CyaC from E. coli BL /DE3 (pGW80, pGW54) 
Hyb 1/LktC from E. coli BL /DE3 (pGW80, pGW78) 
Hyb2 from E. coli BL /DE3 (pGW88)
Hyb 2/CyaC from E. coli BL /DE3 (pGW88, pGW54) 
Hyb 2/LktC from E. coli BL /DE3 (pGW88, pGW78) 
LktA from E. coli BL /DE3 (pGW64)
LktA/CyaC from E. coli BL /DE3 (pGW64, pGW54) 
LktA/LktC from E. coli BL /DE3 (pGW64, pGW78) 
7H Mol wt marker proteins
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3.4 PURIFICATION OF CyaA FROM CRUDE EXTRACTS
Crude urea extracts from B. pertussis or recombinant E. coli strains were 
partially purified by DEAE-sepharose or calm odulin-agarose column 
chromatography (section 2.5). SDS-PAGE analysis and western blotting of 
crude and purified CyaA with monoclonal antibody 9D4 or rabbit polyclonal 
antiserum raised against the 200-kDa band indicated that the 200 kDa protein 
was present, but many other proteins and degradation products of CyaA of 
lower molecular weight were present in crude samples as shown in Figs 8 and 
10. These were removed by the various purification procedures (section 2. 5), 
to give a 9-26 fold increase in enzymic activity (Fig. 11 and 12, Table 4).
3.5 EFFECT OF DIALYSIS AND OTHER TREATMENTS ON 
INVASIVE ACTIVITY OF PAN CyaA
The purified active native CyaA (PAN CyaA) preparation from 
B. pertussis 348 (pRM Bl) in 8 M urea was dialysed against dialysis buffer 
(Appendix II. O) for 2 h or 24 h at 4  “C before measuring its invasive CyaA 
activity for BHK cells. The results showed a 12 and 19 % decrease in the 
invasive activity of CyaA at 2 and 24 h respectively in comparison with the 
invasive activity of CyaA after dilution to 0.2 M urea (Table 5). The loss of 
activity could be due to aggregation of CyaA toxin. The PAN CyaA was also 
stored at -70 °C for up to 12 months and assayed for its effect on BHK cells. 
After 2, 6 and 12 months, the loss of activity was about 5%, 8% and 12% 
respectively (Table 5). Three different treatments (BSA 10%w/v, ImM PMSF 
and Triton X-100 5% v/v) were included in the preparation and purification
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Fig. 11
SDS-PAGE analysis of crude urea extract and eluted fractions of purified 
CyaA prepared by DEAE sepharose column chromatography,
A crude urea extract of recombinant CyaA was purified with DEAE sepharose 
(section 2.5.1). Crude CyaA (25 pg  protein/ml), the column flowthrough 
(10 jig protein/ml) and the first three elution fractions (2,5 jig  protein/lane) 
were subjected to electrophoresis on a 10% polyacrylamide gel and stained 
with coomassie blue. Arrows indicate the positions of molecular weight 
standards with masses in kDa.
Lane 1 : Molecular weight marker proteins
Lane 2 : Crude CyaA from E, coli BL /DE3 (pGW44)
Lane 3 : Flow-through before elution
Lane 4 : First elution fraction
Lane 5: Second elution fraction
Lane 6 : Third elution fraction
KDa
205 ►
116 ►  
97 ►
66
CyaA
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Fig. 12
SDS-PAGE analysis of eluted fractions of purified CyaA prepared by 
calmodulin agarose column chromatography.
PAN CyaA was purified by calmodulin agarose column chromatography 
(section 2,5.2). Elution fractions (^0 p l / i n n e  .) were subjected to 
electrophoresis on a 7.5 % polyacrylamide gel and stained with coomassie 
blue. Arrows indicate the positions of molecular weight standards.
Lane 1-7 : First to seventh eluted (purified) fractions
KDa 
205 ►
116 ►  
97 ^
66 ►
CyaA
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Table 5.
Effect of dialysis, storage time at -70 °C and other conditions on invasive 
CyaA activity.
Conditions Concentration of PAN CyaA 
(/ig protein/ml) required for 
50%stellation of BHK cells ^
Dialysis time (h) at 4“C
2 4.15±0.78
24 4.42+0.42
Port f  Î catîô&î in the presence of:
PMSF 3.98+0.71
BSA 3.81±0.36
Triton X-100 3.90±0.83
Storage time (months) at -70 C
0 3.72+0.89
2 3.91±0.93
6 4.02+0.65
12 4.18+0.52
^Dataare the mean values ± SEM of 4 determinations.
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process of CyaA by addition to whole cells before extraction and then the 
samples were assayed for invasive activity. The inhibitors were removed 
before assay by dilution followed by dialysis against dialysis buffer for 2 h at 
4  °C. The data given in Table 5 show that cytotoxicity was decreased about 7% 
by the presence of PMSF, 2% by BSA and 5% by Triton X-100, indicating that 
these substances, which were used in an attempt to reduce the degradation of 
CyaA protein, did not improve the yield or activities of the CyaA preparation.
3.6 PURIFICATION OF HYBRID TOXINS FROM CRUDE UREA 
EXTRACTS
The Hyb2 crude extracts were purified by the same purification steps as 
used for purification of CyaA, first by calmodulin agarose and then by DEAE 
-sepharose chromatography. As demonstrated in Figs 9 and 10 by SDS-PAGE, 
many proteins, including a 200 kDa protein and smaller proteins possibly 
resulting from degradation of the 200 kDa protein were present in crude 
extracts containing Hyb2 toxin. The purification of H ybl crude urea extracts 
was mainly achieved with calmodulin affinity chromatography. As shown in 
Fig. 9, the Hybl and Hyb2 proteins could be purified free of these smaller 
degradation products.
3.7 PREPARATION AND PARTIAL PURIFICATION OF LktA, 
LktC AND CyaC FROM RECOMBINANT E. COLI STRAINS
Partially purified LktA was obtained by expression of the recombinant 
protein as inclusion bodies in recombinant E. coli strain HM S174 harbouring
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plasmids pGW 64 and pGW78. These carried the IktA and IktC genes 
respectively and produced the toxic form of LktA. Soluble contaminant 
proteins were removed by washing in 2M urea, and then the partially purified 
LktA was extracted from the inclusion bodies in 8M urea (Fig. 13). The LktC 
or CyaC proteins were partially purified by the same procedure, as shown by 
SDS-PAGE analysis (Fig. 13 ) .
3.8 SUMMARY OF SDS-PAGE ANALYSIS OF A AND C PROTEIN 
PREPARATIONS
CyaA and Hyb2 proteins migrated in gels at around 200 kDa, Hybl at 170 
kDa, LktA at 105 kDa, CyaC at 21 kDa and LktC at 19 kDa positions (Figs 7,
9 and 10). The major band differences associated with contaminating proteins 
between the profiles of B. pertussis pRMB 1 (CAN CyaA) and B. pertussis 
DE386 (CIN CyaA) urea extracts were seen at 29 kDa and 14 kDa (Fig 7 , 
lane 2 and 4), whereas the major band differences visualized in recombinant 
urea extracts represented expression of C proteins (CyaC at around 21 kDa or 
LktC at about 19 kDa) with the A proteins.
3.9 SUMMARY OF IMMUNOBLOTTING OF CyaA AND HYBRID 
PREPARATIONS
Generally, for crude preparations probed with anti-CyaA antibody, a 
profile with a band of 200 kDa and smaller degradation products were 
observed as previously reported (Rogel et a l, 1989). A cross-reaction with 
degradation products was reduced by purification of CyaA (Fig. 8). Western
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Fig. 13
SDS-PAGE analysis o f CIR CyaA, CIR LktA, CyaC and LktC used for 
in vitro activation of protoxins.
Inclusion bodies containing insoluble proteins were washed with 0.5 M and 
2M urea as described in Material and Methods (section 2,6). Urea extracts 
prepared after washing of inclusion bodies of CyaA (20 /^g/lane), LktA (10 
Jig) ,CyaC and LktC (10 /^g/lane) were separated on a 10% polyacrylamide 
gel and stained with Coomassie blue. Arrows indicate the positions of 
molecular weight standards .
Lane 1 : 6H Mol wt marker proteins
Lane 2 ; Urea extract of CyaA from E. coli BL 21/DE3 (pGW44) after
washing with 2M urea 
Lane 3 : Urea extract of CyaC from E. coli BL 21/DE3 (pGW 14)
after washing with 0.5 M urea
Lane 4  : Urea extract of CyaC from E. coli BL 21/DE3 (pGW14) after
washing with 2M urea 
Lane 5 : Urea extract of LktA from E. coli BL 2 1/DE3 (pGW64) after
washing with 2M urea 
Lane 6 : Urea extract of LktC from E. coli BL 21/DE3 (pGW78) after
washing with 0.5M urea 
Lane 7 : Urea extract of LktC from E. coli BL 21/DE3 (pGW78) after
washing with 2M urea
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blot of crude and purified CyaA from B. pertussis pRMB 1 was also probed 
with antiserum raised in rats against whole cell sonicate antigen prepared from 
the B. pertussis strain 18323, or with polyclonal antiserum raised in mice 
against purified FHA, PT or PRN or with monoclonal 9D4 antibody to CyaA. 
A major band of 200 kDa and some minor bands, presumably of degradation 
products with smaller molecular weight, were visualized in profiles probed 
with anti-CyaA antibody ( Fig. 14, lanes 3 and 4) or anti-whole cell antibody 
(Fig. 14, lanes 1 and 2). The finding that antisera to B. pertussis whole cells 
cross-reacts strongly with a band at a 200 kDa suggests that CyaA is a major 
immunogen of the whole cell preparation. However, there was no obvious 
cross reaction of the other antibodies at the molecular weights expected for 
FHA (210 kDn), PT (105 kDa) or PRN (69 kDa) (Fig. 14, lanes 6, 7 and 8), 
indicating that the purified CyaA was free of these antigens. Hyb2, H ybl, 
CyaA and LktA were immunoblotted with rabbit anti-CyaA polyclonal 
antiserum or rabbit anti-LktA polyclonal antiserum. The data shown in Fig. 15 
indicated that anti-CyaA polyclonal antibody recognised Hyb2 in Western 
blots but failed to react with H ybl. Interestingly, the anti-LktA rec ognised 
Hybl, but not Hyb2. These data indicated that the immunodominant region of 
CyaA or LktA was in the C-terminal region.
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Fig. 14
Western blot analysis of CAN CyaA and PAN CyaA preparations using 
sera raised against B. pertussis 18323 whole cells, CyaA, PT, FHA and 
PRN polyclonal antibodies.
Crude urea extract of CyaA (25 /tg/lane) and purified CyaA (4.5 /<g) 
preparations form B. pertussis 348 pRM Bl were fractionated on a 10% 
polyacrylam ide gel and transferred to nitrocellulose membrane. The 
nitrocellulose strips were probed with sera collected from rats vaccinated with 
B, pertussis 18323 whole cells (lane 1-2), anti-CyaA polyclonal (lane 3-4), 
anti-CyaA monoclonal 9D4 (lane 5), anti-PT (lane 6), anti-FHA (Lane 7) and 
anti-PRN polyclonal antibodies (Lane 8). The numbers on the left of the blot 
indicate molecular weight markers in kDa.
Lane 1 : Crude CyaA from B. pertussis 348 pRMBl
Lane 2-8 : Purified CyaA from B. pertussis 348 pRMB 1
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Fig. 15
W estern blot analysis of crude CyaA, LktA and hybrid preparations using 
anti-C yaA  polyclonal an tise ru m  (Panel A) or an ti-L k tA  polyclonal 
antiserum  (Panel B).
Crude urea extract (30 pig protein/lane) of CyaA, LktA and hybrid preparations 
from recombinant E. coli strains were separated on a 7.5% polyacrylamide gel 
(Panel A) or 10% polyacrylamide gel (Panel B). The resolved proteins were 
immunoblotted with anti-CyaA polyclonal antiserum (Panel A) or with 
anti-LktA polyclonal antiserum (Panel B). The numbers on the left of the blot 
indicate molecular weight.
PanelA: Blotted with anti-CyaA polyclonal
Lane 1 : CyaA
Lane 2 : CyaA+CyaC
Lane 3 : CyaA+LktC
Lane 4 : Hyb 1
Lane 5: Hyb 1+CyaC
Lane 6 : Hyb 1+LktC
Lane 7 : Hyb2
Lane 8 : Hyb2+CyaC
Lane 9 : Hyb 2 -hLktC
Panel B: Lane 1-9 : in the same order as above, blotted with anti-LktA 
Lane 10; LktA
Lane 11 : LktA+CyaC
Lane 12: LktA+LktC
KDa 
2 0 5  ^
116 ►
97 ►
66 ►
4 5  ►  
2 9  ►
1 2 3 4 5  6 7  8 9
CyaA,Hyb2
B
MW KDa 1 2 3  4  5 6 7 8 9  10 11 12
4 5  ►  
36  ►
2 9  ►  
24  ►
Hybl
LktA
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3.10 CHARACTERIZATION OF CyaA, LktA AND HYBRID 
TOXINS
3.10.1 Enzymic AC activity
AC activity of crude urea extract (CAN CyaA) and purified (PAN CyaA) 
from B. pertussis (pRM Bl), crude urea extract (GIN CyaA) and purified (PIN 
CyaA) from B. pertussis BPDE386, crude urea extract (CAR CyaA) and 
purified (PAR CyaA) from E, coli BL21/DE3 (pGW44, pGW54) or crude urea 
extract (CIR CyaA) and purified (PIR CyaA) from E. coli BL21/DE3 (pGW44) 
preparations was determined (section 2.11). The levels of enzymic activity of 
various preparations were in the range of 66-76 p,mol cAMP/min/mg protein 
for urea extracts and 304-674 for purified samples (Table 6). It should be noted 
that smaller molecular weight forms of these proteins would still possess AC 
enzymic activity if derived from the N-terminal end of the proteins. The 
amount of AC active peptides could be gauged from the activity of the 200 kDa 
protein eluted from a gel slice. This showed a 1.4-fold increase in AC enzymic 
activity over protein purified from calmodulin-sepharose chromatography, a 
2-fold increase over the calmodulin affinity chromatography purified protein 
and 2.7-fqld increase over DEAE sepharose purified protein (Table 4).
3.10.2 Invasive activity of CyaA for BHK cells
Invasive activity of crude urea extracts and purified CyaA preparations 
from B, pertussis and recombinant E. coli strains were measured by a cell 
spreading assay (section 2.14). The assay is based on the morphological effect
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of the toxin on BHK21 cells. Untreated BHK cells or cells treated with CIN 
CyaA, PIN CyaA, CIR CyaA, PIR CyaA or LktC-modified CyaA, even at high 
concentrations showed bipolar fibroblast morphology (non-stellated cells), but 
after treatment with CAN CyaA, PAN CyaA, CAR CyaA, PAN CyaA or ImM 
dibutyryl cAMP with O.lmM IBMX, the cell morphology was changed from a 
fibroblast shape to a stellated or arborized shape as shown in Fig. 16. The 
stellation of BHK cells was thus related to the elevation of intracellular cAMP 
after entry of the mature, cell invasive CyaA toxins.
The dose responses of BHK cells to various CyaA preparations are shown 
in Fig. 17. The protein concentrations of these preparations required for half 
maximal stellation of BHK cells are shown in Table 6. These results also show 
that the invasive activity of recombinant CyaA was comparable to that of 
native CyaA toxin, although the native toxin was reproducibly slightly more 
active.
3.10.3 Haemolytic activity of CyaA preparations for sheep 
erythrocytes
Haemolytic activity of crude and purified CyaA toxin preparations from 
B. pertussis and recombinant E. coli strains for sheep erythrocytes was 
determined (section 2. 12). The results indicated that haemolytic activity of 
CAN CyaA and PAN CyaA were approximately 1.9-fold and 2-fold greater 
than CAR and PAR CyaA (Table 6, Fig. 18). PAR CyaA (pCACTB) showed 
slightly higher haemolytic activity than PAR CyaA (Table 6). These 
differences in haemolytic activity may be related to differences in maturation 
of the toxins by the C proteins in the different bacterial cells. Even at high 
concentration, no haemolysis was detected for CIN CyaA or PIN CyaA.
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Fig. 16
Typical morphology of BHK cells after treatment with PAR CyaA and 
PIR CyaA.
Baby hamster kidney (BHK 21) cells were spread on fibronectin in HH buffer 
for 90 min at 37 °C, then fixed and stained with coomassie blue.The 
morphology of BHK cells after treatment with PAR CyaA and PIR CyaA was 
viewed in a bright field microscope with a 40x objective.
A
B
C
D
Normal BHK cell in HH buffer as negative control
BHK cell in presence of ImM dibutyryl cAMP and 0.1 mM IBMX
BHK cell after treatment with inactive recombinant CyaA
BHK cell after treatment with active recombinant CyaA
B.3JÈ£" T^
3^.
c 1)
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Fig. 17
Dose response o f BHK cell stellation fo r CyaA p rep a ra tio n s  from  
B, pertussis and  recom binant E. coli strains.
The invasive activity of various dilutions of crude and purified CyaA 
preparations from B. pertussis and recombinant E. coli strains was determined 
for BHK 21 cells using the cell spreading assay. A  visual scoring system of 
30 randomly picked cells was used to measure % stellation. The results 
represent the mean of four determinations ± SEM.
Panel A :
1 CAN CyaA
2 CIN CyaA
3 CAR CyaA
4 CIR CyaA
Panel B :
1 PAN CyaA
2 PIN CyaA
3 PAR CyaA
4 PIR CyaA
100 1
8 0 :
70 -
30 :
20 -
20 30 40 50 60 70 80 90 100
Crude CyaA (/ig protein/ml)
1
2
3
4
B
100 1
90 -
80 :
7 0 -
II
3 0 :
2 0 -
10
9 105 81 2 74
Pure CyaA {ji% protein/ml)
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Fig. 18
Dose response of sheep erythrocytes to haemolysis by CyaA preparations 
from B, pertussis and recombinant E, coli strains.
The haemolytic activity of various dilutions of crude and purified CyaA 
preparations were determined in 2-fold serial dilutions using sheep 
erythrocytes. Percentage haemolysis was measured in duplicate for each 
dilution of sample. The results represent the mean of four determinations 
±SEM.
Panel A :
1 CAN CyaA
2 CIN CyaA
3 CAR CyaA
4 CIR CyaA
Panel B :
1 PAN CyaA
2 PIN CyaA
3 PAR CyaA
4 PIR CyaA
o70 -
60 -
5 0 -
40 -
30 -
2 0 -
10  -
0 10 20 30 7040 50 60
Crude CyaA (/ig protein/ml)
1
2
3
4
B
I
80 1
70 -
60 -
50 -
40 -
30
2 0 -
10  -
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Pure CyaA {ji% protein/ml)
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3.10.4 Haemolytic activity of recombinant LktA and hybrid toxins
The haemolytic activity of recombinant LktA modified by LktC was 1.9- 
and LktA modified by CyaC was 1.4-fold lower than CyaA modified by CyaC 
according to the protein concentrations required for 20% haemolysis (Tables 6 
and 7). Thus CyaC modification enhanced the haemolytic activity of LktA for 
sheep erythrocytes. In contrast, the CyaC-modified Hyb 2 showed 2.4-fold 
lower haemolytic activity than the LktC-modified Hyb2, suggesting that LktC 
modification was conferring some enhancement in haemolytic activity to Hyb2 
(Fig. 19, Table 7). The haemolytic activity of LktC-modified Hyb2 was 4-fold 
higher than that of LktC-modified LktA (Table 7). No haemolytic activity was 
detected for PIR Hybl and PIR Hyb2 or PIRHybl activated by either CyaC or 
LktC, non-modified LktA or the urea extraction buffer diluted in the same way 
as the toxin dilutions in the assay.
3.10.5 Development of the MTT assay
Cytotoxicity or cell killing ability of CyaA preparations on eukaryotic cells 
was determined by the MTT assay based on the inhibition of the ability of 
active mitochondria in living cells to reduce tétrazolium dye solution. In order 
to obtain a significant A 540 absorbance reading the effect of a constant amount 
of toxin on different cell numbers of J774.2 or BL3 cells was assayed after 
incubation for two hours with toxin. It was found that 3x10^ cells would be 
necessary to give sufficient metabolic activity in order to convert enough 
tétrazolium dye into formazan product (data not shown). The assay was also set 
up for various incubation times for both CyaA and LktA with 3x10^ cells at
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Fig. 19
Dose response of sheep erythrocytes to haemolysis by hybrid toxin 
preparations from recombinant E. coli strains.
The haemolytic activity of 2-fold serial dilutions of purified hybrid 
preparations from recombinant E. coli strains was assayed for sheep 
erythrocytes. Percentage haemolysis was determined in duplicate for each 
dilution of sample. The results represent the mean of four determinations 
±SEM.
Panel A : Purified hybrid preparations from
1 Hyb 1 : Recombinant E, coli BL21/DE3 (pGW80)
2 Hybl/CyaC; Recombinant E. coli BL21/DE3 (pGW80, pGW54)
3 Hybl/LktC; Recombinant E. coli BL21/DE3 (pGW80. pGW78)
4 PAR CyaA (pCACT3): Recombinant E. coli BL21(pCACT3)
Panel B : Purified hybrid preparations from
1 Hyb2: Recombinant E. coli BL21/DE3 (pGW88)
2 Hyb2/CyaC: Recombinant E  coli BL21/DE3 (pGW88, pGW54)
3 Hyb2/LktC: Recombinant E. coli BL21/DE3 (pGW88. pGW78)
I8 0 -,
7 0 -
60 -
50 -
40 -
3 0 -
20  -
10  -
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1
2 
3
4
Hybrid (/#g protein/ml)
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20 -
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37 °C. The results indicated that incubation of cells with toxin for 2 h was 
sufficient for maximum activity against BL3 cells as shown in Fig. 20. J774.2 
cells were very much less susceptible to attack by LktA.
3.10.6 Cytotoxic activity o f various CyaA and hybrid toxin  
preparations on J774.2 or BL3 cells
The effect of CyaA preparations from B. pertussis or recombinant E. coli 
strains and hybrid toxins on cell killing of mouse macrophage-derived (J774.2) 
cells or bovine lymphoma-derived (BL3) cells were determined by the MTT 
assay. The cytoxicity of CAN CyaA or PAN CyaA preparations on both cell 
types was slightly higher than that of CAR CyaA or PAR CyaA (Table 6, Figs. 
21 and 22). PARCyaA showed 5 or 6 fold higher cytoxicity on J774.2 cells 
than Hyb2 modified either by LktC or CyaC (Tables 6 and 7), However, it was 
noticeable that Hyb2 modified by LktC had noticeably increased activity 
against BL3 cells compared to J774.2 cells whereas Hyb2 modified by CyaC 
had roughly comparable activities in both cell types (Figs 23 and 24, Table 7) 
In addition LktC-modified LktA showed comparable cytotoxicity for BL3 cells 
compared to CyaC-modified CyaA (CAR CyaA), but no obvious cytotoxicity 
was detected for J774.2 cells, indicating the specificity of LktA for ruminant 
cells (Tables 6 and 7). It should be noted that LktA modified by CyaC showed 
greater toxic activity towards BL3 cells than LktA modified by LktC, This was 
in keeping with its greater haemolytic activity. No cytotoxic activity on both 
cell types was detected for PIR H ybl, Hybl modified by CyaC or LktC, PIR 
Hyb2, non-modified LktA or urea extraction buffer diluted in the same way as 
the toxin dilutions in the assay.
RESULTS 105 PART III
Fig. 20
Effect of incubation time on cell killing of CyaA and LktA preparations 
from recombinant E. coli strains .
The cytotoxicity of crude recombinant CyaA and LktA preparations was 
determined for mouse macrophage-derived (J774.2) (Panel A) and bovine 
lymphoma-derived (BL3) cells (Panel B) by the MTT assay (section. 2.16). 
The results represent mean of duplicate determinations.
Panel A,B:
1 CAR CyaA
2 LktA/LktC
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Time (h)
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Fig. 21
Cytotoxicity of CyaA preparations from B. pertussis and recombinant 
E, coli strains on mouse macrophage-derived (J774.2) cells
The cytoxicity of various dilutions of crude and purified CyaA preparations 
were determined for mouse macrophage-derived (J774.2) by the MTT assay 
(section 2.16). The samples were diluted in 2-fold serial dilutions in growth 
medium and incubated with cells for 2h at 37 °C. The results are the mean 
values of four determinations ±SEM.
Panel A :
1 CAN CyaA
2 CIN CyaA
3 CAR CyaA
4 CIR CyaA
Panel B :
1 PAN CyaA
2 PIN CyaA
3 PARCyaA
4 PIR CyaA
100 1
90
80-I 70-60 -
50-
10  30
20
50 6020 30 4010
CyaA (/<g protein/ml)
1
2
3
4
B
100 n
90 :
80 -
70-
60 -
50
•* 40 :
3  30 =
2 0 -
10
6532 41
1
2
3
4
CyaA (/fg protein/ml)
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Fig. 22
Cytotoxicity of CyaA preparations from jB. pertussis and recombinant 
E, coli strains on bovine lymphoma-derived (BL3) cells
The cytoxicity of various dilutions of crude and puified CyaA preparations 
were determined for bovine lymphoma-derived (BL3) cells by the MTT assay 
The samples were diluted in 2-fold serial dilutions in growth medium and 
incubated with cells for 2h at 37 °C. The results represent the mean values of 
four determinations ±SEM.
Panel A :
1 CAN CyaA
2 CIN CyaA
3 CAR CyaA
4 CIR CyaA
Panel B :
1 PAN CyaA
2 PIN CyaA
3 PAR CyaA
4 PIR CyaA
100 -]
90 :
8 0 -I 70
50
6010 400 20 30 50
Crude CyaA (/fg protein/ml)
1
2
3
4
B
100 -]
90 -
80 -
70
60
2 0 -
63 4 50 1
Pure CyaA (/ig protein/ml)
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Fig. 23
Cytotoxicity of hybrid toxin preparations from recombinant E. coli 
strains on mouse macrophage-derived (J774.2) cells
The cytoxicity of various dilutions of purified hybrid toxin preparations were 
determined for mouse macrophage-derived (J774.2) cells by the MTT assay. 
The samples were diluted in 2-fold serial dilutions in growth medium and 
incubated with cells for 2h at 37 °C. The results represent the mean values of 
four determinations ±SEM. Panel A shows H ybl preparations with active 
CyaA as a control and panel B shows Hyb 2 preparations.
Panel A ;
1 Hybl
2 Hybl/CyaC
3 Hybl/LktC
4 PAR CyaA: from recombinant E.coli BL21(pCACT3)
Panel B :
1 Hyb 2
2 Hyb 2/CyaC
3 Hyb 2/LktC
100 -]
90
80 -I 7 0 -60 -
40
3
2 0 -
2 63 50 41
1
2
3
4
Hybrid l(/ig  protein/ml)
B
100 - ]
90 -
80 -
7 0 -
3 60 -
50
40
!
#  20 Î
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Fig. 24
Cytotoxicity of hybrid toxin preparations from recombinant E. coli 
strains on bovine lymphoma-derived (BL3) cells
The cytoxicity of various dilutions of purified hybrid toxin preparations 
were determined for bovine lymphoma-derived (BL3) cells by the 
MTT assay. The samples were diluted in 2-fold serial dilutions in 
growth medium and incubated with cells for 2h at 37 °C. The results 
are the mean values of four determinations ±SEM.
Panel A :
1 Hybl
2 Hybl/CyaC
3 Hybl/LktC
4  PAR CyaA: from recombinant E, coli BL21(pCACT3)
Panel B :
1 Hyb2
2 Hyb2/CyaC
3 Hyb2/LktC
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3.10.7 Chemiluminescence inhibition (Cl) by CyaA preparations
The chemiluminescence inhibition by CyaA preparations for bovine and 
rabbit neutrophil responses to opsonised zymosan stimulation were determined 
(section 2. 15). The chemiluminescence response of bovine and rabbit 
neutrophils to zymosan stimulation after treatment of the neutrophils for 20 
min with PAN CyaA or PAR CyaA was shown to be > 98% inhibited, whereas 
PIN CyaA or PIR CyaA possessed only low Cl activity at the highest 
concentration tested (Figs. 25 and 26), It should be noted that the residual urea 
(20 mM) in the preparations had little inhibitory effect on the Cl response.
3.11 SUMMARY OF IN VIVO ACTIVATION OF CyaA, LktA, and 
HYBRID TOXINS BY C PROTEINS
Active recombinant CyaA (PAR CyaA) produced in vivo by co-expression 
of cyaA  and cyaC in E. coli BL21/DE3 (pGW44, pGW54) showed comparable 
cytotoxicity on J774.2 and BL3 cells to B. pertussis pRMB 1 CyaA (PAN 
CyaA), but slightly weaker haemolytic activity. An extract prepared from
E. coli BL21/DE3 (pGW44, pGW78) strain, expressing cyaA and IktC, showed 
no haemolytic or cytotoxic activity on J774.2 or BL3 cells. These results 
clearly demonstrated the specificity of LktC (Tables 6 and 7). An extract 
prepared from E. coli HMS174/DE3 strain harbouring plasmids pGW64, 
pGW78, expressing IktA and IktC, was cytotoxic for BL3 cells, but not for 
J774.2 cells, and showed a low haemolytic activity with sheep erythrocytes. 
The cytotoxicity on BL3 cells and haemolysis with sheep erythrocyte of an 
extract from E. coli HMS174/ DE3 (pGW64, pGW54), co-expressing IktA and
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Fig. 25
Effect o f CyaA preparations from B, pertussis and recombinant E. coli 
strains on chemiluminescence (CL) response of rabbit neutrophils to 
opsonised zymosan.
The chemiluminescence inhibition of 1/40 dilution of purified CyaA 
preparations was determined for rabbit neutrophils using the CL inhibition 
assay (section 2.15). Rabbit neutrophils (5xl0^/ml) were incubated with 
samples for 30 min at 38 °C before addition of opsonised zymosan. 
CL emission was measured in mV at 38 °C in a Wallac 1251 luminometer 
running on multi-use software. The results represent the mean values of four 
determinations ±SEM. 20 mM urea was used a control as this was the final 
concentration in samples containing toxin.
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1 PAR CyaA
2 PIRCyaA
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Fig. 26
Effect of CyaA preparations from B, pertussis and recombinant E, coli 
strains on chemiluminescence (CL) response of bovine neutrophils to 
opsonised zymosan.
The chemiluminescence (CL) inhibition of 1/40 dilution of purified CyaA 
preparations were determined for bovine neutrophils using the CL inhibition 
assay. Bovine neutrophils (SxlO^/ml) were incubated with samples for 30 min 
at 38 °C before addition of opsonised zymosan. CL emission was measured in 
mV at 38 °C in a Wallac 1251 luminometer running on multi-use software. 
The results are the mean values of four determinations ±SEM.
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cyaC were slightly higher than that of LktA/LktC but there was no activity 
against J774.2 cells. These results showed two things. First, that CyaC was 
non-specific in its activation of A proteins, and was equally active against 
CyaA and LktA and second, that LktA modified by CyaC still retained its 
specificity for ruminant cells.
The hybrid toxin genes derived from IktA and cyaA  genes showed a 
slightly different pattern of activation by C proteins. Extracts from E. coli 
BL21/ DE3 expressing H ybl, Hybl/CyaC, Hybl/LktC, Hyb2, Hyb2/CyaC or 
Hyb2/LktC all had enzymic activity, but only Hyb2/LktC or Hyb2/CyaC 
showed haemolytic or cytotoxic activity. These activities, however were lower 
than those of active CyaA toxin. Interestingly, whereas LktC was unable to 
activate CyaA, it was able to activate Hyb2 where the region believed to be 
involved in the activation process in CyaA had been replaced by that of LktA. 
Indeed, activation by LktC was greater than that by CyaC as evidenced by 
greater haemolytic activity against sheep erythrocytes and greater toxicity to 
BL3 cells. Toxicity towards J774.2 cells was roughly the same for LktC or 
CyaC activated Hyb2, suggesting LktC activation bestowed some ruminant- 
specific target cell specificity on Hyb2.
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3.12 IN VITRO ACTIVATION OF CyaA, LktA AND HYBRID  
TOXINS BY C-PROTEINS
3.12.1 In vitro activation components
The activation components used in activation reactions were inactive CyaA 
(proCyaA), inactive LktA (proLktA), inactive Hyb2 (proHyb2), C proteins 
(CyaC or LktC) and cytosolic activating factor (CAP). ProCyaA, CyaC, 
proLktA, LktC and proHyb2 were prepared in 8M urea, 25 mM HEPES pH 7.5 
from cellular extracts of induced cultures of E. coli strains BL21/DE3 
(pGW44) expressing cyaA, BL21/DE3 (pGW14) expressing cyaC, HMS174/ 
DE3 (pGW64) expressing IktA, HMS 174/ DE3 (pGW78) expressing IktC and 
BL21/DE3 (pGW88) expressing hybl (section 2.17). All proteins expressed as 
inclusion bodies were partially purified by washing of the inclusion bodies 
with 0.5 M and 2 M urea rather than by calmodulin affinity or DEAE 
sepharose chromatography (section 2.6). The reasons for this were two fold. 
Firstly, LktA and the C proteins could not be purified by the procedures used 
for CyaA and it was thought best to prepare all the proteins in the same way. 
Secondly, purified CyaA was time-consuming to prepare and it was considered 
best to retain this for immunological studies where quite large amounts were 
required. The SDS-PAGE profiles of some of these partially purified proteins 
are shown in Fig. 13. CAF was prepared from cultures of E. coli BL21, 
B. pertussis 348 lacking an active cyaA  gene and P. haemolytica (Ph 30) which 
does not express LktA (Saadati et a l,  1997). Urea extracts of partially purified 
proteins were diluted and used directly in the activation reaction instead of 
attempting to remove urea by dialysis, as dialysis of urea extracts resulted in
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aggregation of CyaC protein (data not shown) and therefore the loss of its 
activation ability.
3.12.2 Kinetic study of in vitro activation of proCyaA by CyaC
The length of incubation time and temperature dependence of the in vitro 
activation were examined for CyaC activation of CyaA (Fig. 27). It was shown 
that obvious erythrocyte haemolysis or BHK cell stellation in the presence of 
Ca2+ was observed rapidly within 10 min. Later time points indicated that the 
activation reaction occurred most rapidly at 37 °C, but the activity declined 
markedly after 10 min. Although the initial rate of reaction was slower at 25 “C 
and 4 °C, the activated CyaA appeared to be more stable at these temperatures, 
particularly at 4 °C. The lowest extent of activation was achieved at 42^C. 
These data indicated the extreme lability of the activated toxin.
3.12.3 Activity of in vitro-activated proCyaA, LktA and Hyb2
Pro CyaA, CyaC and CAF, 20-fold dilutions of each, were mixed and 
incubated at 4 °C and after 30 min the reaction mix was assayed for invasive, 
haemolytic and cytotoxic activities and chemiluminescence inhibition (Cl) of 
rabbit or bovine neutrophils. As described in the previous section, proCyaA 
incubated with CyaC and CAF became activated and was active in the 
invasive, haemolytic, cytotoxic and Cl assays (Table 8 ). The in vitro activated 
CyaA showed a high level of Cl of bovine and rabbit neutrophils. The dose 
responses of in vitro-activated CyaA are shown in Figs 28-33. With an 
incomplete in vitro activation mix lacking CAF, there was little stellation with 
BHK cells, a background level of haemolysis with sheep erythrocytes, a low
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Fig. 27
Temperature and time dependence of in vitro activation of CyaA by 
CyaC.
In vitro activation reactions were performed in 150 jA of 25mM HEPES 
(pH 7.5) containing CyaA from E. coli BL21/DE3 (pGW44),CyaC from E. 
coli BL21/DE3 (pGW14) and E. coli BL21 SlOO cytosolic activating factor 
(CAF) (section 2.18.1). Replicate activation reaction mixes, one reaction for 
each time-point were incubated at 4 °C, 25 °C, 37 °C and 42 “C and then used 
in the haemolysis and BHK cell spreading assays (section 2.14). The results 
represent the mean values of duplicate determinations.
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Fig. 28
Dose response of BHK cell stellation by in vitro-activated CyaA.
In vitro activation reactions were set up in 150 jA of 25mM HEPES (pH 7.5) 
containing increasing concentrations of CyaA from E. coli BL21/DE3 
(pGW44) with constant concentrations of CyaC from E. coli BL21/DE3 
(pGW14) or LktC from E, coli BL21/DE3 (pGW78) and E. coli BE 21 SlOO 
cytosolic activating factor (CAF) at 4  °C for 30 min and then serial two fold 
dilutions of in vitro-activated CyaA were assayed using the BHK cell 
spreading assay. The results represent the mean values of 8 determinations 
(four separate experiments determined in duplicate).
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2 CyaA + LktC+CAF
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Fig. 29
Dose response of haemolysis o f sheep erythrocytes by in vitro-activated 
CyaA, LktA and Hyb2 preparations.
In vitro activation reactions were carried out as described in the legend to 
Fig. 28 and then various dilutions of in vitro activated CyaA were assayed 
using the haemolysis assay (section 2,12). The results represent the mean 
values of 4 determinations ± SEÎM.
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2 CyaA + LktC+CAF
3 CyaA + HEPES buffer pH 7.5 
Panel B :
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3 Hyb2+HEPES buffer pH 7.5
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Fig. 30
Dose response of J774.2 cell toxicity by in vitro-activated CyaA, LktA 
and Hyb2 preparations.
In vitro activation reactions of CyaA, LktA or Hyb2 by C proteins were 
performed as described in legend to Fig. 28. Serial two fold dilutions were 
tested in the MTT assay with J774.2 cells (section 2.16). The results 
represent the mean values of 4  determinations ± SEM.
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Fig. 31
Dose response of BL3 cell toxicity by in vitro-activated CyaA, LktA and 
Hyb2 preparations.
In vitro activation reactions were performed as described in the legend to 
Fig. 28 and then various dilutions were assayed with BL3 cells in the MTT 
assay (section 2.16). The results represent the mean values of 4 determinations 
(two separate experiments performed in duplicate).
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Fig. 32
Effect of in vitro-activated CyaA or LktA on the chemiluminescence 
response of rabbit neutrophils to opsonised zymosan.
In vitro activation reactions were carried out as described in the legend to 
Fig. 28, and then various dilutions of in vitro activated CyaA and LktA were 
assayed with rabbit neutrophils in the CL inhibition assay (section 2.15). The 
results represent the mean values of 4  determinations ±SEM (two separate 
experiments done in duplicate).
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Fig. 33
Effect of in vitro-activated CyaA or LktA on the chemiluminescence 
response of bovine neutrophils to opsonised zymosan.
In vitro activation reactions were performed as described in the legend to 
Fig. 28, and then various dilutions of in vitro-activated CyaA and LktA were 
assayed with bovine neutrophils in the CL inhibition assay (section 2,15). 
The results are the mean values of 4 determinations ± SEM (two separate 
experiment performed in duplicate).
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level of chemiluminescence inhibition of bovine and rabbit neutrophils and a 
background level of cell killing of J774.2 or BL3 cells . CyaA plus CAF alone 
was also examined and again showed a background level of activity in all 
assays. Thus in vitro activation of proCyaA required CyaC and a component 
(s) in CAF.
Dialysis of cytosolic factor (CAF) with a membrane having a high Mr 
(>200kDa) cut-off point resulted in the loss of CAF and loss of activation 
ability, but dialysis with a membrane of low Mr (<14kDa) cut-off did not result 
in the loss of all CAF activity. This showed that CAF was a dialysable 
cytosolic factor of molecular weight >14 kDa and <200kDa (Table 8).
The in vitro activation of LktA and Hyb2 were also examined under the 
same conditions. The complete activation mix of LktA, LktC and CAF was 
active in the haemolysis assay with sheep erythrocytes and cytotoxic assay 
with BL3 cells. The LktC-activated LktA was not cytotoxic for the mouse 
macrophage cell line J774.2 in the MTT assay, but it did inhibit the CL 
response of rabbit neutrophils to OZ stimulation as well as being active against 
the CL response of bovine neutrophils (Figs 32 and 33, Table 9 ).
3.12.4 Trans-activation of CyaA, LktA and Hyb2 by CyaC and LktC
Trans-activation of CyaA, LktA or Hyb2 by CyaC or LktC was tested. The 
CyaC-activated LktA in vitro was haemolytic on sheep erythrocytes and 
cytotoxic for BL3 cells. LktC could not activate CyaA to an appreciable extent 
in the cell invasive, haemolytic or cytotoxic assays (Figs 28-31), but there was 
noticeable activity in the Cl assays with both bovine and rabbit neutrophils 
(Figs 32 and 33). CyaC gave some activation to LktA for all the assays tested
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(Figs 28-33). LktA showed no cytotoxicity for J774.2 cells irrespective of 
which C protein was used (Fig. 30). LktA activated by either C protein was 
active for cytotoxicity on BL3 cells, although LktC produced a more active 
toxin (Fig. 31. Therefore activation of LktA by CyaC did not alter the 
specificity of the active LktA for ruminant cells as was found for the in vivo 
produced toxin (section 3.11). LktC activated Hyb2 to a noticeably higher 
extent than CyaC for haemolysis of sheep erythrocytes which was similar to 
that found in vivo (Tables 7 and 9). Hyb2 toxin activated by CyaC or LktC 
protein showed similar low cytotoxicity for J774.2 cells, but LktC-activated 
Hyb 2 was more active for BL3 cells. Again this was found in vivo (section 
3.11).
3.12.5 In vitro activation with in vitro acylated acyl-AGP
The experiments described in section 3.12.3 showed that the cytosolic 
activating factor could be lost by dialysis. Previous work on HlyC activation of 
HlyA had shown that acyl-ACP was a cofactor in the activation reaction 
(Hardie et al., 1991; Issartel et al., 1991). This was investigated here for CyaC 
activation of CyaA and LktC activation of LktA (Tables 10-13). Commercial 
ACP, charged in vitro with palmitic acid, was able to act as a cofactor in place 
of CAF to activate CyaA or LktA (Tables 10-13). When the activating 
component of CAF had been removed by dialysis, the dialysed CAF could still 
act as source of acyl-ACP synthetase if used in the reaction to charge ACP in 
vitro instead of commercial acyl-ACP synthetase (section 2.18.3) (Table 10). If 
either palmitic acid or acyl-ACP synthetase were left out of the reaction to
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Table 10.
In vitro activation of CyaA protoxin by acyl cairier protein
charged with various acyl groups
Activation reaction mix Cytotoxic activity ® 
/ig protein/ml for 
50% cell killing of
J774.2 BL3
CyaA+CyaC+ACP 
+ACP synthetase+PA
18.43±3.70 23.61±2.19
CyaA+CyaC+ACP 
+ACP synthetase+MA
26.57±4.83 34.58±3.15
CyaA+CyaC+ACP 
+ACP synthetase+LA
>32 >48
CyaA+CyaC+ACP 
+ACP syiithetase+SA
>47 >59
CyaA+CyaC+ACP 
+ACP synthetase+PLA
>29 >38
CyaA+CyaC+ACP 
+ACP synthetase+OA
>57 >61
CyaA+CyaC+ACP 
+ACP synthetase
>168 >174
CyaA+CyaC+dHCAF
+ACP+PA
33.34+2.83 38.43+4.15
CyaA+CyaC >175 >184
^Results are the mean values ± SEM of 4 determinations.
dHCAF= CAF diaiysed with a membrane of high M r (200 kDa) cut-off ACP= 
Commercial acyl carrier protein, AGP synthetase= Commercial acyl carrier 
protein synthetase, PA=Palmitic acid, MA=Myristic acid, LA= Laurie acid, SA= 
stearic acid, OA= Oleic acid, PLA= Palmitoleic acid.
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Table 12.
In vitro activation of LktA protoxin by acyl carrier protein charged
with various acyl groups
Activation reaction mix Cytotoxic activity 
f t g  protein/ml for 
50% cell killing of 
J774.2 BL3
LktA+LktC+ACP 
+ACP synthetase+PA
>61 36.43+2.19
LktA+LktC+ACP 
+ACP synthetase+MA
>74 47.90+2.52
LktA+LktC+ACP 
+ACP synthetase+LA
>76 59.32±3.79
LktA+CyaC+ACP 
+ACP synthetase+SA
>81 62.41±4.27
LktA+LktC+ACP 
+ACP synthetase+PLA
>71 51.26+1.62
LktA+LktC+ACP 
+ACP synthetase+OA
>78 66.31+3.47
LktA+LktC+ACP 
+ACP synthetase
>184 >162
LktA+LktC >286 >175
^Results are the mean values ± SEM of 4 determinations.
ACP= Commercial acyl carrier protein, ACP s y n t h e ta s e ™  
Commercial acyl carrier protein synthetase, PA=Palmitic acid, 
MA=Myristic acid, LA= Laurie acid, SA= stearic acid, OA= Oleic 
acid, PLA= Pahnitoleic acid.
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Table 13.
In vitro activation of hybrid 2 protoxin by acylation with various acyl
groups
Activation reaction mix Cytotoxic activity 
/fg protein/ml for 
50% Cell killing of 
J774.2 BL3
Hyb2+CyaC+CAF >111 >104
Hyb2+CyaC+ACP 
+ACP synthetase+PA
>132 >124
Hyb2+CyaC+ACP 
+ACP synthetase+MA
>146 >138
Hyb2+CyaC+ACP 
+ACP synthetasei LA
>152 >150
Hyb2+CyaC+ACP 
+ACP synthetase+PLA
>149 >144
Hyb2+LktC+CAF 98.83 46.43
Hyb2+LktC+ACP 
+ACP synthetase+PA
>115 75
Hyb2+LktC+ACP >137 >129
Hyb2+LktC+ACP 
+ACP synthetase+LA
>152 >144
Hyb2+LktC+ACP 
+ACP synthetase+PLA
>148 >136
Hyb2+LktC+ACP 
+ACP synthetase
>172 >161
^Results are the mean values ± SEM of 4 determinations.
ACP= Commercial acyl carrier protein, ACP synthetase- Commercial 
acyl carrier protein synthetase, PA=Palmitic acid, MA=Myristic acid, 
LA= Laurie acid, PLA= Palmitoleic acid.
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acylate ACP in vitro, then no activation of either toxin was observed when the 
reaction mix was added to the C proteins (Tables 10 and 11).
In further experiments, the effect of altering the fatty acid used by acyl- 
ACP synthetase to charge ACP was investigated (Tables 10, 12 and 13). The 
principal reason for doing this was to see if changing the fatty acyl group on 
the active toxin had any effect on target cell specificity of the toxin, 
particularly for LktA which is normally ruminant cell-specific. The data 
showed that charging ACP with palmitic acid created the most effective acyl- 
ACP for the in vitro activation of both CyaA and LktA by their respective C 
proteins (Tables 10 and 12). Other fatty acids used were less effective. For the 
fatty acids that were suitable, in all cases the CyaC-activated CyaA was more 
active against J774.2 cells than against BL 3 cells (Table 10). The fatty acid 
preference for charging either CyaA or LktA was PA>MA>PLA>LA> OA and 
SA, indicating that CyaC and LktC exhibited the same fatty acid preference for 
their action (Tables 10 and 12). LktA charged with either PA, MA, PLA or LA 
was inactive against J774.2 cells, indicating no alteration in the target cell 
specificity of the toxin dependent on the activating acyl group (Table 12). The 
same pattern of fatty acid preference for in vitro activation of Hyb2 with both 
C proteins was observed (Table 13), although Hyb2 activated by CyaC was 
barely active. As with the situation in vivo, Hyb2 activated by LktC was more 
active and again showed greater activity towards BL3 cells than J774.2 cells.
3.12,6 Effect of various CAF preparations on in vitro activation
Cellular extracts were obtained from cultures of B. pertussis 348 and
F. haemolytica (Ph30 isolate) and tested as sources of CAF in the activation
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reaction in place of the E. coli CAF. None of the extracts was haemolytic on its 
own. The results are summarised in Table 14 and show that other Gram- 
negative bacteria could be used as a source of CAF in activation reactions with 
roughly equal efficiency.
3.12.7 Effect o f chloride ions and EGTA on in vitro activation
Previously reports had indicated that CF ions were inhibitory for the in 
vitro activation of proHlyA by HlyC (Hardie et aL, 1991). Results given in 
Table 14 show that chloride ions had a marked inliibitory effect on activation 
of proCyaA by CyaC, but the inclusion of EGTA (5 mM) increased activation 
efficiency by approximately 15%.
3.13 IMMUNOLOGICAL PROPERTIES OF CyaA AND HYBRID 
TOXINS
3.13.1 Mouse weight gain test for toxicity
The effect of vaccination of mice with CyaA preparations from 
B, pertussis strains and recombinant E, coli strains at a dose of 15 pg 
protein/mouse was studied over 21 days post-vaccination. Male 3-4 week old 
CD-I mice were randomised in groups of 10 and injected subcutaneously with 
two doses of vaccines at a two week interval. The mice were examined and 
weighed over 21 days, especially during the first 3 days after each vaccination. 
Any deaths or changes in weight by comparison with control groups were 
recorded. The experiment was performed twice (Experiments 1 and 2) and the
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data for the two separate experiments are shown in Figs 34 and 35. The results 
indicated that all mice in each group gained weight over of the 21 day post­
vaccination period and no deaths were recorded. There was some indication 
overall that the active CyaA, whether native or recombinant, had a slightly 
detrimental effect on mouse weight gain. In a similar experiment (Experiment 
3) the effect of vaccination with the hybrid toxin preparations Hybl and Hyb 2 
was compared with PAR CyaA (Fig. 36, Panel A). Hybrid toxins showed no 
toxicity in mice over the 21 day post-vaccination period and, in this 
experiment, neither did the active CyaA.
3.13.2 Mouse protection with CyaA and hybrid preparations
The protective activities of CyaA and hybrid preparations were examined 
by their abilities to protect mice against intranasal challenge with B. pertussis 
18323. The mice were vaccinated with two doses of vaccine preparation and 
were challenged intranasally with a sublethal dose of approximately 
lO^cfu/mouse B. pertussis 18323 one week after the second vaccination 
(section 2.21.3). The experiments were performed twice (Experiments 1 and 2). 
At 7 days post-challenge 5 mice were sacrificed and weighed individually. 
Their lung pathology, lung weight and lung counts of B. pertussis were 
determined. Mouse weight gain data, the results of lung counts and weight of 
lungs as percentage body weight for each experiment are given in Tables 15-17 
and shown in Figs 36-38.
After challenge, mice vaccinated with active CyaA (CAN CyaA, PAN 
CyaA, CAR CyaA and PAR CyaA), active Hyb2 (PAR Hyb2/CyaC or PAR 
Hyb2/LktC) or whole- cell DPT vaccine ( Experiments 1, 2 and 3) continued to
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Fig. 34
Mouse weight gain after vaccination with crude or purified CyaA  
preparations, whole cell DPT vaccine or alhydrogel (Experiment No.l).
Male HAM ICR (CD-I) mice, 3-4 weeks old, randomised in groups of 10, 
were vaccinated subcutaneously twice at a two week interval with 15 pig 
protein/mouse of crude or purified CyaA preparation from B. pertussis or 
recombinant E. coli strains. The CyaA was absorbed on 250 pg  alhydrogel. 
Control mice were vaccinated with 1/5 th human dose/mouse of commercial 
whole cell DPT vaccine or 250 pg  alhydrogel. The mice were weighed at 
intervals after vaccination.
Panel A ;
1 CAN CyaA
2 CIN CyaA
3 PAN CyaA
4 PIN CyaA
5 Whole cell DPT vaccine
6 Alhydrogel alone
Panel B :
1 CAR CyaA
2 CIR CyaA
3 PAR CyaA
4 PIR CyaA
5 Control (no vaccination)
Second vaccination
First vaccination
V
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Fig. 35
Mouse weight gain after vaccination with crude or purified CyaA  
preparations, whole cell DPT vaccine or alhydrogel (Experiment No. 2).
Experiment No. 2 was carried out under the same conditions as Experiment 
No.l (see legend of Fig.34).
Panel A :
1 CAN CyaA
2 CIN CyaA
3 PAN CyaA
4 PIN CyaA
5 Whole cell DPT vaccine
Panel B :
1 CAR CyaA
2 CIR CyaA
3 PAR CyaA
4 PIR CyaA
5. Alhydrogel alone
Second vaccinationI
First vaccination
 ^ 4 :I
&
0 5 10 15 20 25 30
Day
1.CAN CyaA
2.CIN CyaA
3.PAN CyaA
4.PIN CyaA
5.WCV
B
I Second vaccination
First vaccination
5 :
4 :I
I
10 20 25 300 5 15
1.CAR CyaA
2.CIRCyaA
3.PAR CyaA
4.PIR CyaA
5.ALH
Day
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Fig. 36
Weight gain o f mice vaccinated vyith purified hybrid 1 or hybrid 2 or 
CyaA preparations , whole cell DPT vaccine or alhydrogel for 3 weeks 
before challenge and for one week after challenge.
Male HAM ICR (CD-I) mice, 3 weeks old, randomised in groups of 10, were 
vaccinated subcutaneously twice at a two week interval with 15 /<g/mouse of 
purified hybrid or CyaA preparations from recombinant E, coli strains 
absorbed on 250 /ig alhydrogel, 0.2 human dose/mouse of whole cell DPT 
vaccine or 250 /<g alhydrogel.
Panel A,B : Mouse weight gain before challenge (A) or after challenge (B)
1 Pure Hyb 2 from E. coli BL2I/DE3 (pGW88)
2 Pure Hyb 2/CyaC from E. coli BL21/DE3 (pGW88,54)
3 Pure Hyb 2/LktC from E. coli BL21/DE3 (pGW88,78)
4 Pure Hyb 1 from E. coli BL21/DE3 (pGW80,54)
5 Pure CyaA from E. coli BL21 (pCACT3)
6 Alhydrogel
B101 Second vaccination
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First vaccination
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Fig. 37
Weight gain of mice vaccinated ivith crude or purified CyaA preparations, 
whole cell DPT vaccine or alhydrogel, after challenge with B, pertussis 
18323 (Experiment No. 1).
The mice, randomised in groups of 5 were challenged intranasally with
B. pertussis 18323 (10 ^ cfu/mouse), one week after the last vaccination with
crude or purified CyaA preparations or whole cell DPT vaccine or alhydrogel. 
The mice were weighed daily for one week after challenge .
Panel A :
1 CAN CyaA
2 CIN CyaA
3 PAN CyaA
4 PIN CyaA
5 Whole cell DPT vaccine
6 Alhydrogel alone
Panel B :
1 CAR CyaA
2 CIR CyaA
3 PAR CyaA
4 PIR CyaA
5 Control (no vaccination, no challenge)
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Fig. 38
W eight gain o f mice vaccinated with crude or purified CyaA  
preparations^ whole cell DPT vaccine or alhydrogel, after challenge with 
B, pertussis 18323 (Experiment No. 2).
Experiment No.2 was done under the same conditions as Experiment N o.l 
(see legend of Fig. 37)
Panel A :
1 CAN CyaA
2 CIN CyaA
3 PAN CyaA
4 PIN CyaA
5 Whole ceil DPT vaccine
Panel B :
1 CAR CyaA
2 CIR CyaA
3 PAR CyaA
4 PIR CyaA
5 Alhydrogel
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Table 15.
Active protection against intranasal challenge with B . p e r tu s s i s  18323 strain 
by vaccination of mice with various CyaA preparations from B . p e r tu s s i s  and 
recombinant E . c o l i strains (Experiment No. 1).
Vaccine
preparation
Mean lung weight (g) as 
%of body weight ^
Mean or median 
B . p e r tu s s i s  count 
(cfu/lung ) ^
PAN CyaA 0.73±0.02 (2.60±0.11)x103
CAN CyaA 0.81±0.03 (5.260+ 0.82)x103
PIN CyaA 1.29±0.04 1.70x10^ (median)
CIN CyaA 1.13±0.02 (1.64±0.15)x106
PAR CyaA 0.89±0.02 (3.52±0.33)x103
CAR CyaA 1.02±0.04 (5.50±0.24)x103
PIR CyaA 1.37±0.03 4.50x10^ (median)
CIR CyaA 1.33±0.0S 3.50x10^ (median)
Alhydrogel 1.45±0.02 (4.94±0.64)xl0<>
WCV 0.93±0.02 (4.78+ 1.17)x103
Control b 0.71+0.01 <25
a. Results are the mean values fix)ni 5 individual mice ± SEM or median values for 
lung cou frits in the cases with counting recoided from confluent culture plates.
b. Controls non-vacciiiated and non-challenged
141
Table 16.
Active protection against intmnasal challenge with B . p e r tu s s i s  18323 strain 
by vaccination of mice with various CyaA preparations from B . p e r tu s s i s  and 
recombinant E . c o l i strains (Experhnent No. 2).
Vaccine
preparation
Mean lung weight (g) as 
%of body weight ®
Mean
B . p e r tu s s i s  count 
(cfu/lung ) ^
PAN CyaA 0 .8 2 * 0 .0 5 ( 0 .6 8 ± 0 .1 8 ) x l 0 3
CAN CyaA 0 .9 7 * 0 .0 4 ( 0 .8 3 ± 0 .2 1 ) x 1 0 3
PIN CyaA 1 .4 2 * 0 .0 3 ( 4 .2 2 ± 0 .3 8 ) x 1 0 6
CIN CyaA 1 .2 5 * 0 .0 5 ( 3 .7 6 ± 0 .2 6 ) x l0 ^
PAR CyaA 1 .0 1 * 0 .0 4 ( 0 .9 1 * 0 .2 8 ) x l 0 3
CAR CyaA 1 .1 1 * 0 .0 6 ( 2 .7 6 ± 0 .2 5 ) x 1 0 3
PIR CyaA 1 .4 5 * 0 .0 6 > 2 .5 x 1 0 6
CIR CyaA 1 .3 1 * 0 .0 6 > 2 .5 x 1 0 6
Alhydrogel 1 .4 5 * 0 .0 7 (5 .7 3 ± 0 .4 2 ) x 1 0 6
WCV 0 .8 4 * 0 .0 1 < 0 .5 x 1 0 3
^Results represent the mean values from 5 mdividual mice ±SEM
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Table 17.
Active protection against intranasal challenge with B . p e r tu s s i s  18323 strain 
by vaccination of mice with purified CyaA and hybrid preparations from 
recombinant E . c o l i strains (Experiment No. 3).
Vaccine
preparation
Mean lung weight (g) as 
%of body weight ^
Mean
B . p e r tu s s i s  count 
(cfu/lung ) ^
Hyb2 1 .4 7 * 0 .0 7 > 2 .5 0 x 1 0 7
Hyb2/LktC 0 .9 4 * 0 .0 1 ( 1 .2 6 *  0 .1 5 ) x 1 0 4
Hyb2/CyaC 1 .0 0 * 0 .0 1 ( 1 .5 7 *  0 .1 3 ) x l ( H
Hybl/CyaC 1 .3 7 * 0 .1 0 > 2 .5 0 x 1 0 7
PIR CyaA 1 .3 9 * 0 .0 6 > 2 .5 0 x 1 0 7
PAR CyaA 0 .8 6 * 0 .0 3 ( 0 .S 9 * 0 .1 6 ) x 1 0 4
PAR CyaA( pCACT3) 0 .9 1 * 0 .0 2 ( 0 .9 9 *  0 .1 2 ) x 1 0 4
Alhydrogel 1 .5 5 *  0 .0 9 > 2 .5 0 x 1 0 7
WCV 0 .8 7 * 0 .0 2 (0 .3 6 * 0 .0 5 ) x 1 0 4
^Results represent the mean value from 5 individual mice ± SEM .
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gain weight in a similar manner to those that were left as non-vaccinated, non- 
challenged controls. The mice vaccinated with both crude or purified inactive 
CyaA or alhydrogel alone lost weight quite markedly. Two deaths were 
recorded in the group vaccinated with alhydrogel two days after challenge, but 
no deaths were observed in groups vaccinated with CIN, PIN, CIR or PIR 
preparations.
The lungs of mice vaccinated with any of the inactive toxin preparations as 
well as those mice vaccinated only with alhydrogel showed extensive 
consolidation (greyish discoloured areas) in all lobes of the lungs, whereas the 
mice vaccinated with active toxins as well as the mice vaccinated with whole 
cell DPT vaccine showed little sign of consolidation (data not shown).
The lung weight data and lung counts of B. pertussis for experiments 1 and 
2 are presented in Tables 15 and 16. There were clear differences in the lung 
weight as a percentage of body weight (up to 2 fold) of mice vaccinated with 
any of the inactive toxins (i.e. CIN, CIR, PIN and PIR CyaA) and alhydrogel 
compared to mice vaccinated with any of the active toxins (i.e. CAN, CAR, 
PAN, PAR CyaA) and whole cell DPT vaccine as well as non-vaccinated, non­
challenged control mice. The lung counts of B. pertussis from mice vaccinated 
with any of the inactive toxins and alhydrogel showed up to 3 logio differences 
compared to mice vaccinated with active toxins or whole cell vaccine. The 
results from the second experiment were consistent with the first experiment.
The lung counts of mice vaccinated with Hyb2 modified with LktC or 
CyaC indicated that this hybrid toxin was protective whether modified by 
CyaC or LktC (Table 17). Interestingly, the CyaC-modified Hyb2 seemed to be 
slightly less protective than the LktC-modified form, which paralleled the 
slightly lower toxicity of this hybrid (Table 7). Modified H ybl showed no
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protective activity. Lack of time did not allow the experiment with the hybrid 
toxins to be repeated. Taken together, these experiments indicated that only 
active toxins, as well as whole cell vaccine, were protective, as indicated by the 
low lung weight, low bacterial numbers in the lung and lack of effect on mouse 
weight gain compared to non-vaccinated, control mice.
3.14 ANTIGENICITY OF CyaA AND Hyb PREPARATIONS
3.14.1 Immunoblotting of purified CyaA with various mouse sera
Western blot analysis of purified CyaA with 1/1000 dilution of sera of 
mice vaccinated with purified CyaA preparations are shown in Figs 39 and 40. 
As is evident from the figures, antisera from mice vaccinated with PAN CyaA 
or PIN CyaA showed strong cross-reaction with the major 200 kDa CyaA band 
and bands of lower M r (presumably degradation products of CyaA). There was 
a slight indication of cross reaction of PAN and PIN CyaA preparations with 
antibodies present in mice vaccinated with whole cell vaccine although the 
bands did not correspond to the CyaA bands (Fig. 39, lanes 9 and 10), and this 
was also apparent with PAR and PIR samples (Fig. 40 lanes 5 and 11).
3.14.2 Development of ELISA for detection of antibodies to CyaA 
toxin or ovalbumin
In order to determine the concentration of CyaA or ovalbumin suitable for 
coating antigen in ELISA, the wells of ELISA Dynatech Immulon-2 plates 
were coated with different dilutions of PAR CyaA or ovalbumin and the
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Fig. 39
Western blot analysis of purified CyaA preparations using sera from  
mice vaccinated with PAN CyaA, PIN CyaA, DPT and alhydrogel.
Purified CyaA (5 p g protein/lane) preparations from B, pertussis or 
recombinant E. coli strains were subjected to electrophoresis on a 10% 
polyacrylamide gel and transferred to a Hybond C-Super membrane. The 
nitrocellulose was cut into strips and probed with sera collected from groups 
of 5 mice in experiment No. 1 on day 7 after the second dose of vaccine i.e. 
at the time of challenge of identical groups of mice. Mice were vaccinated 
with various purified CyaA preparations from B. pertussis plus alhydrogel, 
whole cell DPT vaccine or with alhydrogel alone. The numbers on the left of 
blots indicate the positions of molecular weight standards.
A: Antigen preparation B: Probed with sera from
bound to nitrocellulose mice vaccinated with:
Lane 1 : PAN CyaA PAN CyaA
Lane 2 : PIN CyaA PAN CyaA
Lane 3: PAR CyaA PAN CyaA
Lane 4  : PIR CyaA PAN CyaA
Lane 5 : PAN CyaA PIN CyaA
Lane 6 : PIN CyaA PIN CyaA
Lane 7: PAR CyaA PIN CyaA
Lane 8 : PIR CyaA PIN CyaA
Lane 9 : PAN CyaA DPT vaccine
Lane 10 : PIN CyaA DPT vaccine
Lane 11 ; PAN CyaA Alhydrogel
Lane 12: PIN CyaA Alhydrogel
©4
oe
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Fig. 40
Western blot analysis o f purified CyaA preparations using sera from  
mice vaccinated with PAR CyaA, PIR CyaA, DPT and alhydrogel.
Purified CyaA (5 /<g protein/lane) preparations from B, pertussis o r 
recombinant E. colt strains were subjected to electrophoresis on a 10% 
polyacrylamide gel and transferred to a Hybond C-Super membrane. The 
nitrocellulose was cut into strips and probed with sera collected from groups 
of 5 mice in experiments No. 1 on day 7 after the second dose of vaccine i.e. 
at the time of challenge of identical groups of mice. Mice were vaccinated 
with various purified CyaA preparations from recombinant E.coli strains plus 
alhydrogel, whole cell DPT vaccine or with alhydrogel alone. The numbers on 
the left of blots indicate the positions of molecular weight standards.
A: Antigen preparation B: Probed with sera from
bound to nitrocellulose mice vaccinated with:
Lane 1 : PAN CyaA PAR CyaA
Lane 2 : PIN CyaA PAR CyaA
Lane 3: PAR CyaA PAR CyaA
Lane 4 : PIR CyaA PAR CyaA
Lane 5 : PAN CyaA DPT vaccine
Lane 6 : PIN CyaA Alhydrogel
Lane 7: PAR CyaA PIR CyaA
Lane 8 : PIR CyaA PIR CyaA
Lane 9 : PAR CyaA PIR CyaA
Lane 10 ; PIR CyaA PIR CyaA
Lane 11 : PAR CyaA DPT vaccine
Lane 12: PIR CyaA Alhydrogel
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routine ELISA procedure using a 1/2000 dilution of anti-CyaA antiserum or a 
1/1000 dilution of mouse anti-Oa antiserum was followed (section 2.20). In 
this experiment, the ELISA dose response curves for titrated antigens indicated 
that 5 jxg of CyaA antigen or 100 pg of ovalbumin was the best concentration 
for coating antigen in ELISA plates .
3,14.3 Mouse IgG antibody response to CyaA or Hyb antigens
The antigenicity of CyaA and Hyb preparations in mice vaccinated with 15 
pg protein/mouse absorbed on 250 pg alhydrogel were determined by ELISA. 
Sera from individual mice of each group were assayed by ELISA. Examples of 
the IgG anti-CyaA antibody titrations by ELISA with antisera raised against 
various antigens are shown in Figs 41 and 42.
The antibody titres were determined in ELISA U/ml of neat mouse sera by 
assigning an arbitrary unitage of 100 ELISA U/ml to a pooled reference 
antiserum (section 2.19.2). By interpolating at OD 0.5, the antibody titre in 
ELISA U/ml was calculated from the ratio of test serum titre to reference 
serum titre and multiplying by a factor of 100. As is evident from data given in 
Tables 18 and 19, all CyaA preparations were highly antigenic in stimulating 
anti-CyaA IgG antibody responses in mice. In addition serum raised to whole 
cells of B, pertussis in the rat (provided by Dr. E. Hall) also showed the 
presence of a low level IgG antibody which reacted with CyaA. No cross­
reaction was evident with antisera raised to PT, FHA or PRN, indicating that 
the CyaA coating antigen was free of these antigens (Fig. 42). As is also 
evident from Table 19, the hybrid toxins Hybl and Hyb2, also raised anti-
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Fig, 41
Examples of ELISA for Mouse IgG antibody responses to crude and 
purified CyaA antigens from B. pertussis and E. coll strains at the time of 
challenge (Experiments No, 1 and 2).
Male HAM ICR (CD-I) mice, 3 weeks old, randomised in groups of 10, were 
vaccinated subcutaneously twice at a two week interval with 15 pg  
protein/mouse of crude or purified CyaA preparations from B. pertussis or 
recombinant E. coli strains absorbed on 250 pg  alhydrogel. Serum IgG 
antibody responses were measured in individual sera by ELISA 7 days after 
the second vaccination, using PAR CyaA as coating antigen.
Panel A: Examples of ELISA to measure Serum IgG anti-CyaA antibody
in sera of individual mice vaccinated with :
1 PAN CyaA
2 PIN CyaA
3 PAR CyaA
4 PIR CyaA
5 Reference anti serum (anti-CyaA polyclonal antibody)
6 Pooled normal (unvaccinated ) mouse serum
Panel B: Examples of ELISA to measure Serum IgG anti-CyaA antibody
in sera of individual mice vaccinated with;
1 CAN CyaA
2 CIN CyaA
3 CAR CyaA
4 CIR CyaA
5 Reference antiserum (anti-CyaA polyclonal antibody)
6 Pooled normal (unvaccinated ) mouse serum
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Fig. 42
IgG ELISA for antigen content of purified CyaA preparations from  
B.pertussis strain 348 pRM Bl.
PAN CyaA was used as a coating antigen in ELISA plates and serum IgG to 
this antigen was measured in various sera raised against B. pertussis 
components (FHA, PT, PRN) or whole B. pertussis 18323 cells (see section
2.19.3 for source of these sera).
Antiserum raised against
1 PAN CyaA from B.pertussis 348 pRMB 1 in mice
2 Purified filamentous ; haemagglutinin (FHA) in mice
3 Purified pertussis toxin (PT) in mice
4 Purified pertactin toxin (PRN) in mice
5. Whole B. pertussis cells in rats
6 Reference antiserum (anti CyaA polyclonal antibody)
7 Pooled normal (unvaccinated ) mouse serum
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Table 18.
IgG anti-CyaA antibody titres in sera of mice vaccinated with various 
CyaA antigens were detected in ELISA with PARCyaA as a coating 
antigen.
Sera IgG-anti CyaA antibody titres 
ELISA units/ml  ^
Experiment 1 Experiment 2
PAN CyaA 83.07+3.35 78.37±2.19
PIN CyaA 75.89+2.62 72.23+2.54
CAN CyaA 71.36±3.18 73.86±3.73
CIN CyaA 68.80±2.14 66.59+2.21
PARCyaA 67.34±1.72 71.08±2.49
PIR CyaA 80.36±3.55 66.32±2.31
CAR CyaA 65.81±2.24 62.29+1.68
CIR CyaA 73.08±3.75 64.18±1.42
WCVb 18.48+1.73 26.40±1.15
Control ^ NDd NO
a. Antibody titres (ELISA units/ml) were expressed as the mean value 
of 5 individual mice sera ± SEM.
b.WCV= Commercial whole cell DPT vaccine (Welcome Trivax-AD)
c. Controls non-vaccinated and iion-challenged mice d. ND= not 
detected.
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Table 19.
IgG anti-CyaA antibody titres in sera of mice vaccinated with various 
CyaA and Hyb antigens were detected in ELISA with PARCyaA as a 
coating antigen.
Sera IgG-anti AC antibody titres 
ELISA units/ml ^
PAR pCACT3 75.49±2.81
Hyb2 66.59±2.17
Hyb2/LktC 73.31±2.59
HybZ/CyaC 69.08±2.42
Hybl/CyaC 61.32±1.64
Alhydrogel ND
WCV 11.83+1.71
a. Antibody titres (ELISA units/ml) were expressed as the mean value 
of 5 individual mice sera ± SEM.
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CyaA antibody levels comparable to those from mice vaccinated with the 
CyaA antigens.
3.15 ADJUVANTICITY OF CyaA ON ANTIBODY RESPONSES 
TO OVALBUMIN
In order to investigate a possible adjuvant effect of CyaA on the antibody 
response, mice were vaccinated twice, with a two week interval, with PAR 
CyaA or PIR CyaA with or without ovalbumin as the test antigen. Sera were 
taken over a period of four weeks at one week intervals starting from day 7, in 
two identical experiments (Experiments 4 and 5) (section 2.22). The sera were 
then titrated by ELISA and the data for two separate experiments are shown in 
Figs 43 and 44.
As is evident from the data (Figs 43 and 44, Panel A), the primary IgG 
anti-Oa antibody response was enhanced 2-3-fold in mice vaccinated with Oa 
and PAR CyaA compared with the mice vaccinated with Oa alone. The 
adjuvant effect of PIR CyaA was not as obvious. The secondary IgG anti-Oa 
antibody response was increased about 4.8 fold in the mice vaccinated with Oa 
and PAR CyaA compared with the mice receiving Oa alone. In control mice 
for these experiments i.e. non-vaccinated animals, the anti-Oa and anti-CyaA 
antibody levels were below the limit of detection (i.e. A 492 <0,5).
The IgG subclasses and IgE anti-Oa antibody responses in sera from 
Experiments 4 and 5 taken at 7 days after the second injection were also 
determined. Results are shown in Tables 20 and 21. These titres are calculated 
relative to the IgG subclasses and IgE titres in a pooled reference mouse serum 
(section 2.19.2) (100 U/ml) and so the antibody level for one immunoglobulin
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Fig. 43
Effect of purified CyaA preparations from recombinant E. coli strains on 
primary and secondary anti-Oa or anti-CyaA antibody responses 
(Experiment No. 4).
Male HAM ICR (CD-I) mice, 4 weeks old, randomised in groups of 20, were 
vaccinated subcutaneously twice with a two week interval, with 15 ^g  
protein/mouse of PAR CyaA or PIR CyaA preparations from recombinant E. 
coli strains with or without 20 /ig ovalbumin/mouse, or with 20 pLg 
ovalbumin/mouse alone. Anti-Oa or anti-CyaA serum IgG antibodies were 
measured by ELISA (section 2.20). Ovalbumin (Oa) was used as coating 
antigen in ELISA for results shown in Panel A, whereas PAR CyaA was used 
as coating antigen for results shown in Panel B.
Panel A: Mouse anti-Oa IgG antibody in sera from mice vaccinated with
1 Ovalbumin (Oa)
2 PIR CyaA with Oa
3 PAR CyaA with Oa
Panel B: Mouse anti-CyaA IgG antibody in sera from mice vaccinated 
with
1 PARCyaA
2 PIR CyaA
3 PIR CyaA with Oa
4 PAR CyaA with Oa
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Fig. 44
Effect of purified CyaA preparations from recombinant E, coli strains on 
primary and secondary anti-Oa or anti-CyaA antibody responses 
(Experiment No. 5).
Experiment No, 5 was carried out under the same conditions as Experiment 
No. 4 (see legend of Fig. 43).
Panel A: Mouse anti-Oa IgG antibody in sera from mice vaccinated with
1 Ovalbumin (Oa)
2 PIR CyaA with Oa
3 PAR CyaA with Oa
Panel B: Mouse anti-CyaA IgG antibody in sera from mice vaccinated 
with
1 PAR CyaA
2 PIR CyaA
3 PIR CyaA with Oa
4 PAR CyaA with Oa
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can not be related to that for other immunoglobulin classes. The IgG and IgGl 
anti-Oa antibody responses were markedly enhanced in groups of mice 
vaccinated with PAR CyaA with Oa compared to control groups vaccinated 
with Oa alone or Oa with FIR CyaA, The IgG2a response was also increased 
but to a lower extent and IgG2b antibody was not detectable in any sera. Anti- 
Oa antibody response was not detectable in control mice (i.e. non-vaccinated 
mice) or those which had received PAR CyaA alone (data not shown). Similar 
to the IgG l antibody response, the IgE anti-Oa antibody response was 
significantly increased in mice that were primed in the presence of active CyaA 
compared to a control group who received Oa alone. With Oa and PIR CyaA, 
there appeared to be some enhancememnt of the anti-Oa IgE response, 
compared to mice given Oa alone, and this enhancement was also evident in 
the IgG subclass responses.
The primary and secondary IgG anti-CyaA antibody responses were also 
evaluated in sera from Experiments 4 and 5 taken over a period of four weeks 
at one week intervals starting from day 7. The primaiy IgG anti-CyaA antibody 
response was enhanced 1.7 fold in mice primed with PAR CyaA compared 
with the mice vaccinated with PIR CyaA (Figs 43 and 44, Panel B). The 
secondary IgG anti-CyaA antibody was increased about 2.6 fold in mice 
vaccinated with PAR CyaA compared to mice given PIR CyaA alone (Figs 43 
and 44, Panel B). Ovalbumin had no adjuvant effect on the response to CyaA. 
The IgG subclasses and IgE anti-CyaA antibody responses in sera from 
Experiments 4 and 5 taken at 7 days after the second injection were also 
determined. Interestingly, the IgG and IgGl anti-CyaA antibody responses in 
the groups of mice receiving PAR CyaA alone were enhanced significantly 
compared with mice given PIR CyaA alone (Tables 22 and 23). IgG2a anti-
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CyaA responses were enhanced to a lower extent, whereas the IgE anti-CyaA 
antibody responses in mice who had received PAR CyaA alone were enhanced 
markedly compared with mice which had received PIR CyaA alone or with Oa 
(Tables 22 and 23).
The total serum concentration of IgG, IgG l and IgG2a in sera of mice at 7 
days after the second vaccination (Experiments 4 and 5) were also measured by 
radial immunodiffusion (Figs 45-47). In all cases, the immunoglobulin levels 
were significantly higher in mice injected with PAR CyaA plus Oa than in 
mice injected with PIR CyaA plus Oa. The immunoglobulin levels in mice 
injected with PAR CyaA alone were lower than those in mice given the two 
antigens together but they were consistently higher than in mice given PIR 
CyaA alone or control mice ( non-vaccinated mice) (Figs 46 and 47). IgG 2b 
antibodies were not detectable at the lowest dilution tested (l/IO) in any of the 
sera (data not shown).
3.16 CYTOKINE PRODUCTION FROM SPLEEN CELLS
Spleens of 5 mice primed with PAR CyaA or PIN CyaA (Experiments 4 
and 5) were removed at 7 days after the second vaccination and homogenised 
together aseptically. The spleen cells were cultured in the presence of active 
and inactive CyaA, ConA was also used as a positive control and urea in tissue 
culture medium as another control (section 2.23). The supernatants were 
collected from a portion of the culture after 24 h and 48 h and assayed by 
cytokine ELISA (section 2.24). The cytokine responses at 24 h after in vitro 
activation of spleen cells was very low in both experiments (data not shown). 
The cytokine response at 48 h of spleen cells taken from mice vaccinated with
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Fig. 45
e
Measurinent of total IgG concentration by radial immunodiffusion in 
sera of mice vaccinated with recombinant CyaA preparations.
IgG Standards (60% and 10% v/v) and serum samples were loaded on to 
the wells of agarose gel plates (section 2. 25). After the required diffusion 
time, antibody in serum or IgG standards had reacted with the anti-IgG 
antibody in the gel and formed precipitin rings. The ring diameters were 
measured and the concentration of the IgG in serum samples was read off 
a standard curve.
1. IgG Standard (60%)
2. IgG Standard (10%)
3. Pooled sera of mice vaccinated with Oa alone
4. Pooled sera of mice vaccinated with Oa and PIR CyaA
5-9. Sera of 5 individual mice vaccinated with Oa and PAR CyaA 
10-14. Sera of 5 individual mice vaccinated with PAR CyaA alone
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Fig. 46
Effect of purified CyaA preparations from recombinant E, coli strains on 
total serum IgG, IgG l, IgG2a (Experiment No. 4).
Male HAM ICR (CD-I) mice, 4 weeks old, randomised in groups of 20, were 
vaccinated subcutaneously twice at a two week interval with 15 ^g  
protein/m ouse of PAR CyaA or PIR CyaA with or without 20 pig 
oValbumin/mouse, or with 20 pig ovalbumin/mouse alone. Total serum IgG, 
IgG l, IgG2a in sera of 5 mice of each group at one week after the second 
vaccination were measured by radial immunodiffusion (RID) (section 2.25). 
Data are mean values ± SEM from 5 individual mouse sera.
Panel A,B,C ; Mouse total serum IgG (Panel A), IgG l (Panel B), IgG2a 
(panel C) antibody in sera from mice vaccinated with;
1 Control mice (non-vaccinated and non-challenged)
2 Ovalbumin (Oa) alone
3 Oa with PIR CyaA
4 Oa with PARCyaA
5 PIR CyaA alone
6 PAR CyaA alone
I
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3
2
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Fig. 47
Effect of purified CyaA preparations from recombinant E, coli strains on 
total serum IgG, IgGl, IgG2a (Experiment No. 5).
Experiment No. 5 was carried out under the same conditions as Experiment 
No. 4 (see legend of Fig. 46).
Panel A,B,C : Mouse total serum IgG (Panel A), IgG l (Panel B), IgG2a 
(panel C) antibody in sera from mice vaccinated with:
1 Control mice (non-vaccinated and non-challenged)
2 Ovalbumin (Oa) alone
3 Oa with PIR CyaA
4 Oa with PARCyaA
5 PIR CyaA alone
6 PAR CyaA alone
3Sera
□□
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either active or inactive CyaA, and stimulated in vitro with various stimuli are 
shown in Table 24. Spleen cells stimulated with Con A generally showed high 
levels of production of all cytokines except IL 5. Spleen cells from mice 
vaccinated with PAR CyaA, in nearly every case, gave high cytokine 
responses. With FIR CyaA as vaccine, responses were lower, but higher than 
those of cells from non-vaccinated mice. Spleen cells stimulated with either Oa 
or urea as controls generally showed low or undetectable cytokine responses. 
The results show that PAR CyaA was more active than PIR CyaA in both 
priming and stimulating spleen cells for cytokine responses.
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4.1 PRODUCTION OF CRUDE UREA EXTRACTS OF CyaA, LktA 
AND HYBRID TOXINS
4.1.1 Production of CyaA from B, pertussis strains
The first preparations of CyaA prepared by different investigators from 
crude extracts of whole B. pertussis wild type organisms or concentrated 
culture supernates were reported to contain multiple forms of toxin with 
molecular weights ranging from 45 kDa to 206 kDa. In later work, the toxin 
was extracted with urea which stabilised the 200 kDa form of the enzyme and 
allowed it to be purified (Hewlett et a l ,  1989; Rogel et al., 1989). In the 
present study, B. pertussis recombinant strain BP348 (pRM Bl) was used 
(Brownlie et at., 1988). This strain produces large amounts of CyaA encoded 
by the cosmid pRM Bl and cells were extracted with urea to minimise 
degradation of the toxin. The 200 kDa toxic form of CyaA was the main 
product detected in the crude extracts as confirmed by the SDS-PAGE analysis 
and immunoblotting with monoclonal or polyclonal antibodies (Figs 7, 8 and 
14). The large amounts of CyaA in crude extracts enabled purification of 
sufficient amounts of the 200 kDa form for investigation of its toxic and 
protective activities.
The production of CyaA was optimised by the addition of MepCD to the 
culture medium and by growth of the culture for 48 h (Table 2). The 
degradation of the toxin was minimised by adding BSA to culture medium 
during growth and the addition of PMSF during processing stages for 
purification of the toxin (Tables 5). Under these conditions, the level of the 
toxic form of CyaA produced by B. pertussis strain BP348 (pRMBl) was about
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10-fold higher than that from the wild type B. pertussis strains. This finding 
was consistent with the yield of the CyaA from strain BP348 (pRM Bl) as 
previously reported by Brownlie e ta l  (1988).
Strain BP DE386, a mutant defective in the activator gene {cyaC) produced 
a good yield of CyaA of 200 kDa in urea extracts (CIN CyaA) which was 
indistinguishable from the active toxin by SDS-PAGE (Fig. 7). It exhibited a 
comparable level of the enzymic activity to that of strain BP348 (pRMBl) but 
had no detectable haemolytic activity on sheep erythrocytes, no toxic activity 
on J774.2 cells and no invasive activity on BHK21 cells, even at the highest 
levels tested (Figs. 17, 21 and 22, Table 6). This is in keeping with previous 
work by Hewlett et al. (1993). These investigators showed that inactive CyaA 
from BPDE386 underwent a calcium dependent conformational change and 
bound to target cells in a manner comparable to active CyaA, but this was not 
sufficient for pore forming insertion and translocation of the toxin into target 
cells, and thus it had no cytolytic activity. Hewlett et at. (1993) suggested that 
the CyaC modification of CyaA is probably critical for conferring an exact 
conformational change on the CyaA molecule to allow it to participate directly 
in pore forming events which translocate the CyaA molecule into the target 
cells.
4.1.2 Production of CyaA and LktA from recombinant E, coli strains
Inactive recombinant CyaA of 200 kDa was initially produced in low 
amounts from the urea cell extracts of a protease-defective recombinant E. coli 
strain H1469 (pRMB3) which expressed the cyaA gene on pRMBl (Brownlie 
et a l , 1988). They reported that the CyaA produced by this strain showed
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enzymic activity in the presence of exogenous CaM protein, but no invasive 
activity was detected.
Sebo et al. (1991) reported high level production of active recombinant 
CyaA toxin of 200 kDa produced from the urea extract of recombinant E. coli 
BL21 (pCACT3) where the cyaA  and cyaC genes were co-expressed in 
pCACT3 from the lac promoter. It had a comparable level of toxic activity as 
well as enzymic activity to that of native CyaA toxin from the natural producer 
B. pertussis, but only a weak haemolytic activity (4-10 fold reduction) (Sebo 
etal., 1991; Betsou e ta l ,  1993; Hackett e ta l ,  1995).
In the present study, a T7 RNA polymerase expression system was used 
which had been developed in this laboratory for the production of a large 
amount of the active recombinant CyaA toxin in E. coll A high level of active 
recombinant CyaA toxin of 200 kDa was produced by co-expression of the 
cyaA and cyaC genes from the protease defective E. coli strain BL21/DE3 
harbouring two separate compatible plasmids, pGW44 and pGW54 (Westrop 
et al., 1996). This strain produced CyaA and CyaC in comparable amounts to 
that produced from the strains BL21/DE3 (pGW44) or BL21/DE3 (pGW54) 
carrying the plasmids separately (Figs 7 and 13). The urea extracts of strain 
BL21/DE3 (pGW44, pGW54) had similar invasive, toxic and enzymic 
activities to urea extracts of strain BL21 (pCACT3), but slightly lower 
haemolytic activity. The inactive recombinant CyaA of 200 kDa produced 
from the urea extract of E.coli BL21/DE3 (pGW44) had a high level of 
enzymic activity, but no toxic or haemolytic activities (Fig 18, 21 and 22, 
Table 6) which was comparable with the CyaA produced by B. pertussis BP 
DE386 defective in the cyaC gene.
DISCUSSION 169 PART IV
A similar system based on T7 vectors of the translational fusion type was 
used for production of active recombinant LktA by co-expression of IktA and 
IktC genes from separate compatible plasmids by E. coli HMS174 /DE3 
(pGW64, pGW78). The yield of LktA protein was less than expected when 
compared to the production of CyaA in the same T7 expression system (Fig. 
10) The urea extracts of recombinant active LktA contained a 105 kDa LktA 
protein and 19 kDa LktC protein as judged by SDS-PAGE analysis and 
immunoblotting with polyclonal antibody raised against recombinant LktA in 
rabbits (Figs 10, 13 and 1 5 .8 ). An inactive LktA protein was also produced 
from recombinant strain HMS174/DE3 (pGW64) which was indistinguishable 
from active recombinant LktA by SDS-PAGE but lacked LktC protein in urea 
extracts (Fig. 10). No detectable toxic activity was found in urea extracts of 
this recombinant inactive LktA even at high concentrations (Figs 30. B and 
31. B, Table 11).
4,1,3 Production of hybrid toxins from recombinant E. coli strains
In order to investigate the structure-function relationships of the CyaA 
toxin, two hybrid toxins (Hybl and Hyb2) were produced in E. coli by 
expression of chimeric constructs containing products of both the cyaA and 
IktA genes (see section 3.3). Urea extracts of Hybl toxin were prepared from 
cells of strain BL21/DE3 (pGW80, pGW54) by co-expression of hybl and 
cyaC or strain BL21/DE3 (pGW80, pGW78) by co-expression of hybl and 
IktC genes. Stable proteins of 150 kDa were produced with comparable AC 
enzymic activity to that of CyaA, but no detectable haemolytic or toxic activity 
(Figs 9, 19, 23 and 24, Table 7). Hyb2 toxins were prepared as urea extracts
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from strain BL21/DE3 (pGW88, pGW54) by co-expression of hybl and cyaC 
genes or strain BL21/DE3 (pGW88, pGW78) by co-expression of hybl and 
IktC genes. These appeared as stable proteins of 200 kDa as judged by SDS- 
PAGE and immunoblotting (Figs 9, 10 and 15. A). Again these hybrid toxins 
had AC enzymic activity comparable to CyaA and they also possessed and 
partial haemolytic and toxic activity. This is discussed more fully in section 
4.3.
4.2 PURIFICATION OF CyaA AND HYBRID PREPARATIONS
4.2.1 Purification of CyaA from B. pertussis strains
This study describes the purification of CyaA from strain BP348 (pRMBl) 
with toxic, haemolytic and enzymic activities, and CyaA from strain BPDE386 
with enzymic activity but no detectable toxic or haemolytic activities. In this 
work, the CaM agarose and DEAE-sepharose methods were chosen for 
purification of CyaA because these methods were expected to yield a high level 
of purified toxins with low amounts of degradation products, in keeping with 
previous reports (Sebo et al., 1991; Sakamoto et a l ,  1992). The purified CyaA 
preparations both contained a major polypeptide of 200 kDa, although some 
minor peptides of lower molecular weight were still present as judged by SDS- 
PAGE analysis and imm unoblotting with monoclonal and polyclonal 
antibodies. This is consistent with data from previous investigators (Bellalou 
et al., 1990 a). The presence of other protein components of B. pertussis such 
as FHA, PT and PRN was checked by immunoblotting with anti-FHA, anti-FT 
and anti-PRN antibodies and no detectable impurities were found (Fig. 14 ).
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4.2.2 Purification of CyaA from recombinant E. coli strains
Toxic and non-toxic forms of recombinant CyaA were purified from crude 
urea extracts of inclusion bodies formed in E. coli strains by the convenient 
procedure of DEAE sepharose chromatography. Large quantities were obtained 
mainly as a polypeptide of 200 kDa with only a few degradation products as 
judged by immunoblotting with polyclonal antibody raised against 200 kDa 
CyaA in rabbits. The purified toxic form of CyaA could not be distinguished 
from the non-toxic form according to size of the polypeptides on SDS-PAGE 
gels (Figs 7).
4.2.3 Purification of hybrid toxins from recombinant E. coli strains
Hybl toxin was purified from inclusion bodies as a major polypeptide of 
150 kDa protein, with few degradation products, from crude extracts of 
recombinant E, coli strains harbouring only one plasmid pGWSO (hybl) or two 
plasmids pGW80 and pGW78 (IktC) or pGW54 (cyaC) by calmodulin affinity 
chromatography as judged by SDS-PAGE analysis or immunoblotting. 
Calmodulin affinity chromatography was used here because DEAE-sepharose 
was less effective at purification of this hybrid, presumably because it lacked 
the large number of glycine-aspartate repeat units of the C-terminal end of 
CyaA which formed the main basis of attraction of CyaA to the DEAE- 
sepharose. The C-terminal portion of Hybl was derived from LktA which has a 
fewer of these repeat units (Lally et at., 1994). Hyb2 toxin was purified by 
DEAE sepharose chromatography as this protein possessed the C-terminal
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region of CyaA. Purified Hyb2 toxin was detected mainly as a 200 kDa 
polypeptide according to SDS-PAGE analysis (Fig. 9).
4,2.4 Purification of CyaC, LktC and LktA
These proteins were partially purified from urea extracts of inclusion 
bodies from recombinant E. coli strains by urea washing of the inclusion 
bodies which removed contaminating soluble protein from the insoluble 
proteins of the inclusion bodies. The molecular weight of CyaC and LktC were 
21 kDa and 19 kDa respectively, according to SDS-PAGE analysis and had 
very few contaminating polypeptides present (Fig. 13). The molecular weight 
of both active and inactive recombinant LktA was 105 kDa as judged by SDS- 
PAGE analysis and immunoblotting (Figs 10 and 15. B ), but this preparation 
still had some contaminating polypeptides.
4.3 PROPERTIES OF CyaA AND HYBRID PREPARATIONS
4.3.1 AC Enzymic activity of CyaA and hybrid toxins
In this study, the AC specific activity of the urea extract of CyaA from 
B. pertussis BP348 (pRM Bl) was significantly higher than that reported for 
either the wild-type B. pertussis or strain BPDE386 (Brownlie et a l ,  1988). 
This increase in the specific activity was almost certainly due to a gene dosage 
effect where the presence of several copies of pRMB 1 carrying the cyaA gene 
in each cell would increase the amount of CyaA protein overall. The AC
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specific activity of purified toxin was enhanced 10-fold due to the removal of 
impurities from the urea extracts of inclusion bodies (Table 6 ).
The enzymic specific activity of toxic 200 kDa form of CyaA from the 
crude urea extracts of recombinant E. coli was lower than that of the non-toxic 
200 kDa recombinant form of CyaA. This was probably due to the fact that the 
active form was produced by co-expression of CyaA and CyaC from two 
separate plasmids whereas the inactive form was produced by expression of 
cyaA alone from one plasmid. In the later case there would undoubtedly be a 
higher copy number of the CyaA-encoding plasmid. It was almost certainly not 
due to toxic effects of active CyaA in the cells because the protein was induced 
by IPTG addition. The enzymic activity of the Hybl was higher than that of 
Hyb2 toxin, which was probably due to the fact that it is a smaller protein 
(Table 7). Storage of purified CyaA in 8M urea at -70 °C did not reduced the 
enzyme activity (Table 5).
4.3.2 Haemolytic activity of CyaA, LktA and hybrid toxins
It has been reported previously that purified B. pertussis CyaA had 
comparable cell invasive AC activity and a 4-fold higher haemolytic activity 
on sheep erythrocytes than that of partially-purified CyaA recombinant toxin 
from E. coli, and thus the ratio of the haemolytic activity to cytotoxic activity 
of the recombinant active CyaA expressed in E. coli was markedly lower than 
that of CyaA from B. pertussis (Sebo et a l ., 1991; Benz et a l ,  1994; Hewlett, 
1995). Hackett et al. (1995) have shown that whereas the CyaA from 
B. pertussis is exclusively palmitoylated at Lys-983, the recombinant CyaA 
from E. coli represented a heterogeneous mixture of CyaA proteins with 13%
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myristoylated and 67% palmitoylated at Lys-983 and an additional 67% 
palmitoylated at Lys-860. Thus the differences in the haemolytic.toxic activity 
ratios of recombinant CyaA compared to B. pertussis CyaA could be due to 
these differences in the chemical nature of the acylation.
In the present study, the purified recombinant CyaA (PAR CyaA) had 
significantly weaker haemolytic activity compared to the haemolytic activity of 
purified CyaA from B. pertussis BP348 (pRMBI)(PAN CyaA) (Fig. 18, Table 
6), confirming previous work. The recombinant CyaA protein co-expressed 
with LktC had no haemolytic activity on sheep erythrocytes which is in 
keeping with previous reports that indicated the strong specificity conferred by 
LktC. For example, HlyA could not be activated by LktC (Forestier and Welch, 
1990). The haemolytic activity of the recombinant LktC-modified LktA on 
sheep erythrocyte was low, which was also consistent with a previous report 
(Forestier and W elch, 1990), whereas the CyaC-modified LktA showed 
markedly higher haemolytic activity for sheep erythrocytes than LktC-modified 
LktA. This may be due to differences in the way in which these C proteins 
modify the protoxins, for example, by adding different acyl groups. This was 
investigated in the in vitro activation experiments and is discussed below 
(section 4. 4).
The CyaC-modified or LktC-modified H ybl showed no haemolytic 
activity on sheep erythrocytes. Although LktC was unable to activate CyaA, it 
was more efficient at activating Hyb2 than CyaC. This indicates that a domain 
between amino acids 379 and 616 of LktA is required for recognition by LktC 
and that Lys-554 in LktA is a likely activation site, although recent data have 
indicated that it may not be the only site in the complete LktA toxin (Pellett 
and Welch, 1996). The CyaC-modified Hyb2 had lower haemolytic activity for
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sheep erythrocytes than that of LktC-modified Hyb2 (Fig. 19, Table 7). The 
fact that LktC- or CyaC-modified Hyb2 had significantly lower haemolytic 
activity than CyaC-modified CyaA, suggest that the reduction in haemolytic 
activity could be due to inefficient acylation of the Hyb2 protein molecules or 
due to efficient acylation but in a manner which either creates a conformational 
change in the hybrid protein that functions poorly as a haemolysin. 
Alternatively, creates a variety of acylated derivatives could be produced only 
some of which are capable of functioning efficiently to form pores in 
erythrocytes. This is in keeping with dissociation of the haemolytic activity 
from its invasive activity (Bellalou et al., 1990 b; Iwaki et al., 1995). The 
haemolytic activity of CyaA, LktA and hybrid toxins was stable for up to 
6 months when stored as 8M urea extracts at -70 °C.
4.3.3 Cytotoxic activity of CyaA, LktA and hybrid toxins
The cytotoxic activity of the recombinant toxic form of CyaA against 
bovine-derived BL3 and mouse-derived J774.2 cells was shown to be 
comparable to that of B. pertussis CyaA (Figs 21 and 22, Table 6). The CyaC- 
modification was required for cytotoxic activity of CyaA, whereas the LktC- 
modification did not activate CyaA. Again, CyaC was able to activate LktA 
protoxin efficiently without affecting the specificity of the modified LktA for 
ruminant cells. The toxin was still fully active against BL3 cells of ruminant 
origin, but showed no activity against J774.2 cells of murine origin. As was 
found for the haemolytic assay, LktC was more efficient at activating Hyb2 
than CyaC with regard to activity against BL3 cells and there was some 
evidence that LktC modification bestowed a degree of target cell specificity
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because LktC-modified Hyb2 was more active against BL3 cells of ruminant 
origin than against J774.2 cells, whereas the CyaC-modified Hyb2 had a 
similar activity against both cell types. These observations indicated a
( C
noticeable change in target cell specifity of the LktC-modified Hyb2 compared 
to the CyaC-modified hybrid. This may indicate that the mode of activation by 
LktC may have an influence on the target cell specifity of the native LktA toxin 
which is only active against ruminant cells. However, the LktC-modified Hyb2 
was still not ruminant specific which shows that other features of the LktA 
protein, not contained in Hyb2, are necessary for this phenotype.
4,4 IN VITRO ACTIVATION OF CyaA, LktA AND HYB2
Barry et al. (1991) reported that B. pertussis adenylate cyclase protoxin 
required post-translational activation by the product of the cyaC gene (CyaC 
protein) in order to acquire haemolytic and toxic activities,. Similarly, the other 
members of the RTX toxins such as the HlyA of E. coli or LktA of 
P. haemolytica require activation by C-proteins. Issartel et al. (1991) reported 
that activation of proHly by HlyC was achieved by the transfer of a fatty acyl 
group from acyl carrier protein to proHIyA. By analogy to the HlyA activation 
system, B. pertussis CyaA protoxin activation also could involve fatty 
acylation. Hackett et al., (1994) have demonstrated that CyaA was modified in 
vivo by amide linked paltimoylation of the s-amino group of Lys-983. Because 
of the limitations in the in vivo studies of activation for examining the 
mechanism of protoxin activation, the in vitro approach to understanding the 
activation mechanism which converts inactive protoxins to the cell invasive 
toxins was investigated.
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In the present study, an in vitro system was developed in order to examine 
the mechanism of CyaC-dependent acylation of proCyaA and LktC-dependent 
activation of LktA. The in vitro activation of HlyA by HlyC was the only in 
vitro system described when this work was undertaken, and although the in 
vivo acylation of CyaA had been confirmed by Hackett et a l  (1994), it was 
only assumed that LktA was modified in a similar manner. It was hoped to 
relate biological activity to the manner in which the toxin is activated and 
finally to investigate the effect of variation of the modifying fatty-acyl group or 
C-proteins on target cell specificity and toxic activity of CyaA and LktA.
Previous work on in vitro activation of proHlyA by HlyC had shown a 
requirement for overproduction and purification of HlyA and HlyC from 
recombinant E. coli strains (Hardie e ta l ,  1991). In the present study, proCyaA 
and CyaC were overproduced by using the E. coli T7 expression system for the 
cyaA and cyaC genes and purified from inclusion bodies. The inclusion bodies 
were washed with IM  urea in HEPES buffer to remove any contaminating 
soluble proteins and then the aggregated insoluble proteins were solubilized 
with 8M urea in HEPES buffer to obtain partially purified preparation of CyaA 
and CyaC. They were prepared in urea and HEPES, because Cl" ions and Tris 
were found to be inhibitory for the activation reaction of HlyA by HlyC. In 
fact, in our system, EGTA was found to be beneficial for activation (Table 14), 
indicating that the binding of Ca^+ by proCyaA is not necessary for activation 
by CyaC. This would suggest that the two post-translational requirements of 
proCyaA activation, Ca^+ binding and CyaC-dependent modification are 
completely independent of each other.
The purified CyaA preparations were not used in the assays because it was 
found in early experiments that the partially purified CyaA, prepared by
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washing of inclusion bodies, did not contain any contaminating CAF; CyaA 
and CyaC mixed in the absence of CAF produced no active toxin (Table 8). 
The purified CyaA was kept for immunological studies as large amounts were 
needed for this work. When only the partially purified CyaA and CyaC were 
incubated together, no active CyaA protein was generated, but active CyaA 
toxin was generated when 20-fold dilutions of the 200 kDa proCyaA and 
21 kDa CyaC proteins were mixed with a 20 fold dilution of a cytosolic (S I00) 
extract (CAF) of E. coli (Tables 8). The fact that proCyaA, produced from 
intracellular inclusion bodies, could be activated indicated that the 
CyaB/CyaD/CyaE-dependent secretion process was not involved in the 
activation of CyaA. Dilution to remove excess urea was favoured instead of 
dialysis of the urea extracts before use in the activation reaction because 
dialysis resulted in protein aggregation, particularly of CyaC, and the extent of 
activation was markedly reduced. The cellular factor (CAF) required for 
activation was lost if the E. coli SlOO extract was dialysed with a membrane of 
high Mr (200 kDa) cut-off before addition to the activation mix and only a low 
level of cytotoxic activity of CyaA was generated. Dialysis of the cellular 
factor (CAF) with a membrane having a low M r cut off (<14 kDa) allowed 
retention of most of the activating factor, and thus approximately the same 
level of cytotoxic activity was achieved as with undialysed CAF (Table 8). 
SlOO extracts of B. pertussis strain BP348, which is defective in CyaA 
production, and of P. haemolytica (Ph30) lacking LktA were also used in the 
activation reaction as a source of cellular factor and supported the activation 
(Table 14). These findings indicated that the cellular factor had a low 
molecular mass which was consistent with a requirement for acyl -ACP in the 
activation reaction (Hardie et a l ,  1991; Issartel et a l ,  1991). This was
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supported by additional experiments, where commercial acyl-ACP, charged in 
vitro with various fatty acids, was able to act as a co-factor to activate CyaA 
(Table 10). The results demonstrated that acylation conferred cytotoxic and 
haemolytic activities upon the protoxin, and the level of the activation 
depended upon the fatty acid tested, with palmitoylation showing highest 
activity and myristoylation showing less activity with the other fatty acids 
producing very low activity. Fatty acid preference for the acylation reaction 
with CyaA was palm itic acid (PA, C l6 )>  myristic acid (MA, C l4)> 
palmitoleic acid (PLA, C l6 .l)>  1 auric acid (LA, C%2)>oleic acid (OA, 
C l8,l)>stearic acid (SA, C l8 .l)  (Tables 10). These fatty acids were chosen 
because they were commercwlly available and were convenient to solubilise 
for use in the in vitro activation reactions. These observations indicated that the 
chain length or the rigidity of the fatty acids could effect the interaction of the 
toxin with target cells. The results are similar to those reported by Issartel etal. 
(1991) for acylation of HlyA by HlyC. In their studies, however, after acylation 
of ACP in vitro with a range of fatty acids, myristoylated ACP was the most 
active in the conversion of proHlyA to a haemolytic toxin with palmitoleic acid 
next, closely followed by palmitic acid with lauric acid and cis-octadecenoic 
acid showing much less activity. In both cases, however, the C l4  and C l6  fatty 
acids proved most efficient at activating the CyaA and HlyA protoxins. 
Whichever fatty acid addition was used in the in vitro activation reaction of 
CyaA by CyaC, the in vitro-modified CyaA showed greater cytotoxicity for 
J774.2 cells than BL3 cells. This was true also for CyaA activated in vivo by 
CyaC (Table 6). The in vitro activation of CyaA by LktC revealed no 
activation which was also true of the in vivo situation.
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The partial purification of LktA and LktC was also achieved by washing 
inclusion bodies. The in vitro activation of LktA as another member of RTX 
family of toxins was investigated to compare the in vitro activation of LktA 
with that of CyaA and to examine the effect on the biological activity of 
heterologous activation of the protoxins CyaA and LktA by LktC and CyaC 
respectively. CyaA was not activated by LktC, but LktA was activated by 
CyaC as well as by LktC, again showing the high specificity of LktC compared 
with CyaC, which was apparent from the in vivo activation. It was interesting 
to see that the specificity of LktC for ruminant cells was preserved in this in 
vitro reconstituted system.
It was found that LktA in vitro-activated by LktC or CyaC showed marked 
inhibition of rabbit neutrophil chemiluminescence, whereas the native LktA 
had very little effect on rabbit neutrophils, even at the highest concentration. 
Moreover the in vitro activated LktA inhibited the CL response of rabbit 
neutrophils to a 10-fold greater extent than the in vivo activated form. However 
in vitro activated LktA retained specificity for BL3 cells with regard to 
cytotoxicity as measured by the MTT assay. These data showed apparently that 
active LktA produced by in vitro activation or partially purified from inclusion 
bodies from E. coli had an effect on the zymosan-induced chemiluminescence 
response of rabbit neutrophils which was not exhibited by the native LktA 
toxin found in the culture medium after growth of P. haemolytica. The reason 
for this loss of target cell specificity by recombinant LktA is not clear as it was 
only observed in the chemiluminescence inhibition (CLI) assay. No activity of 
LktA toxins from whatever source was observed in the MTT cytotoxicity assay 
against J774.2 cells. The result implies that the toxins are triggering different 
types of responses in the target cells which are detected in the respective
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assays. The MTT cytotoxicity assay is measuring the killing capacity of the 
toxin whereas the CLI assay is measuring inhibition of the respiratory burst. It 
is possible that the recombinant LktA toxins can bind to rabbit neutrophils and 
inhibit their response to opsonised zymosan but can not penetrate the cells in 
order to kill them. The native LktA, on the other hand, can not interact with 
rabbit neutrophils in such a way as to inhibit the respiratory burst. All the RTX 
toxins in their host strains are exported from the cell and it is possible that this 
process is crucial in some way for determining the final properties of the 
toxins. For example, there is evidence to suggest that LPS may become closely 
associated with the toxins, perhaps as they are exported from the cell 
(Czuprynski and Welch, 1995). The synthesis, export and activity of HlyA are 
closely linked to LPS biosynthesis. RTCH is a transcriptional activator of the 
rfa operon which encodes enzymes for the synthesis of the LPS core, but it also 
activates the hly operon (Bailey et aL, 1992). Inactivation of rfaP, one of the 
genes of the rfa operon, causes a loss of extracellular HlyA activity associated 
with aggregation of HlyA (Stanley et a l ,  1996). Interestingly, a similar 
phenomenon to that seen here was reported h y T u  et al. (1994) working with 
the ApxIIA toxin of A. pleuropneumoniae. The ApxIIA toxin, when expressed 
in E. coli existed in two forms: the intracellular form had both haemolytic and 
cytolytic properties, but the secreted form was cytolytic, but non-haemolytic. 
This indicated that during the secretion process, the conformation of the toxin 
was altered so that it lost haemolytic activity.
The order of fatty acid preference for the in vitro activation of LktA was 
the same as that of CyaA by in vitro activation. Thus the C-proteins do not 
differ in fatty acylation preference and the precise nature of the acyl group 
added was not important for cell specificity (Tables 10-12). The in vitro
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activation of Hyb2 with regard to fatty acid preference, whether activated by 
CyaC or LktC was the same as LktA or CyaA (Table 13). In fact, the biological 
activity of in vitro-activated Hyb2 followed the same pattern as Hyb2 activated 
in vivo. Hyb2 activated in vitro by LktC had greater activity against BL3 cells 
than J774.2 cells, whatever fatty acid was used, but Hyb2 activated in vitro by 
CyaC was less active, and had similar cytotoxicity against both cell types 
which was the same as the in vivo situation (Table 7).
Kinetic studies revealed that the haemolytic activity of the in vitro- 
activated CyaA toxin was highly labile (Fig. 27). The initial rates of activation 
appeared to increase with increasing temperature from 4 °C to 37 °C, indicating 
that the interaction between the activation components is more ionic than 
hydrophobic. Maximal rates were obtained after 10 min incubation at 37 °C 
and after 30 min at 24 °C and 4  °C. However, the haemolytic activity was 
rapidly lost after a long period of incubation of the activation components and 
little or no haemolytic activity was detected after incubation for 60 min . The 
reason for this decline or loss of activity is not clear, but it appears to be 
temperature dependent and may be due to loss of the modifying acyl group or it 
may be due to the aggregation of the toxin.
In vitro activated CyaA was assayed by using various assays for 
invasiveness, cytotoxicity and haemolytic activity (Table 9). When the ratio of 
protein concentrations required for 50% haemolysis and 50% stellation or 
cytotoxicity for different cell types were compared to that of in vivo activated 
CyaA, the level of haemolytic activity observed for the in vitro-activated CyaA 
was less than 10% of that expected from its invasive CyaA activity. This may 
be due to lack of specificity inherent in an in vitro sytem using a crude SlOO 
extract as a source of acyl-ACP and fatty acids. Because the CyaA toxin
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contains 47 lysine residues, it is reasonable to suppose that several residues are 
randomly acylated in vitro and the modification results in a mixture of 
differently modified populations, which may have different toxic and 
haemolytic activities.
Heveker et al. (1994) observed similar differences in invasive and 
haemolytic activities for CyaA activated in vitro by chemical acylation of 
proCyaA toxin using water soluble acyIpyrophosphates. This system leads to 
random acylation of multiple lysine residues and the active toxin probably 
represents a sub-population that is able to assume a physiologically active 
conformation. The chemically myristoylated toxin showed 10-50 fold lower 
haemolytic activity than toxin modified in vivo by co-expression of cyaA and 
cyaC in E. coli.
4.4.1 Overall conclusions
The capacity to express the A  and C genes for CyaA and LktA separately 
in E. coli mean that each protoxin could be co-expressed with a heterologous C 
protein. It was found that LktC could not interact with CyaA to produce an 
active toxin, indicating complete specificity of LktC for LktA. On the other 
hand, CyaC was able to activate LktA to produce an active toxin which showed 
that CyaC was less specific than LktC in its activity. CyaC-modified LktA 
however was still completely ruminant-cell specific indicating that the manner 
of acylation of the protoxin had no effect on target cell specificity. This was 
borne out also by the in vitro activation studies where, regardless of the fatty 
acyl group used to charge the LktA protoxin, no change in target cell 
specificity was detected.
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Incorporation of a 238 amino acid sequence, spanning part of the 
activation region of LktA, into CyaA allowed LktC to interact with the Hyb2 
molecule to produce a partially active toxin. Thus this sequence must contain 
the modification site for LktA and presumably has a structural conformation 
different to that of equivalent region in CyaA. This region presumably defines 
part of the domain determining ruminant target cell specificity to LktA. Hyb2 
constitutes a good starting point for creation of a completely ruminant-specific 
adenylate cyclase toxin. The ability to define in general terms the region 
specifying cell tropism in RTX toxins may have wider implications because it 
may allow the creation of cell specific toxins for selective destruction of cells 
or for delivery of specific antigenic determinants to specific cell types.
4.5 PROTECTION PROPERTIES OF CyaA, H ybl AND Hyb2 IN 
MICE
4.5.1 Extent of toxicity of toxin preparations in mice
The data presented in this study (Figs 34 and 35) from the weight-gain test 
(toxicity test) following immunization with active and inactive B. pertussis 
CyaA preparations, shows that there was a small effect of each toxin on mouse 
weight gain. This may have been due to impurities of preparations with other 
B. pertussis antigens such as LPS, even in small amounts in the purified 
preparations, because the non-toxic form of B. pertussis CyaA exhibited the 
same pattern of toxic effects. The crude extract preparations were more toxic 
than purified CyaA, and the crude extract from B. pertussis showed more 
toxicity than crude extract from E. coli, again indicating the effect of impurities
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in crude preparations. There was, however, no marked differences between 
mice vaccinated with the active invasive toxin and those given the inactive 
non-invasive toxin. This indicated that, at least at the dosage used here, active 
CyaA was not creating a toxic physiological response.
4.5.2 Protective activities of CyaA from B. pertussis strains
Guiso et ah  (1989) demonstrated that passive immunization with 
monoclonal and polyclonal anti-CyaA antibodies raised against the purified 
45 kDa catalytic fragment of CyaA in mice, protected mice passively against 
lethal intranasal challenge with B. pertussis and B. parapertussis. This 
indicated that protection might occur either by antibody inhibiting penetration 
of the CyaA into the host cell lymphocytes or by inhibiting bacterial 
colonization, but not by inhibiting the catalytic activity of the enzyme in the 
host cells because the monoclonal anti-CyaA had no inhibitory effect on the 
catalytic activity of the enzyme. They also reported that active immunization 
with 45 kDa CyaA purified from culture supernate and with catalytic activity 
but no cytotoxic activity in vitro protected mice against intranasal or 
intracerebral challenge with B. pertussis or B. parapertussis as efficiently as 
whole cell vaccine (Guiso et al., 1991). This suggested that the major 
protective epitopes of CyaA were located on the N-terminal region of the 
enzyme. In subsequent reports, active immunization with purified B. pertussis 
CyaA of 200 kDa, but which still contained several lower molecular weight 
degraded proteins, protected mice as efficiently as whole cell vaccine against 
B. pertussis and B. parapertussis colonization in the murine intranasal model, 
although only the activated toxin was effective and inactive toxin made in
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E. coli was not protective (Guiso et al., 1991; Betsou et al., 1993). This 
indicated that CyaC-mediated modification of CyaA was important not only for 
invasive activity of the protein but also for its protective activity. Betsou et al 
(1995), by analysis of the protective activity of different purified truncated 
proteins derived from recombinant CyaA, showed that the important protective 
epitopes were located at the C-terminal end of CyaA in the last 800 residues 
which contradicted the earlier report by the same group (Guiso et a/., 1991) that 
they were N-terminally located. They explained this apparent anomaly by 
suggesting that the 45 kDa preparation used in the previous work was 
contaminated with C-terminal fragments with no AC enzymic activity. These 
fragments spanned the modification and repeat region of the CyaA and were 
cleaved from the rest of the CyaC-modified CyaA molecule during secretion of 
the toxin.
In the present study, the crude extract of active B. pertussis CyaA, as well 
as purified active B. pertussis CyaA, both with M r of 200 kDa, exhibited 
protective activity in mice against intranasal challenge with B. pertussis strain 
18323 similar to the protective efficacy of the whole-cell DPT vaccine. This 
was shown by the low lung; body weight ratio, low bacterial numbers in the 
lungs and the minor effect on mouse weight gain (Figs 37 and 38, Tables 15 
and 16 ), compared to mice vaccinated with either crude or purified inactive 
CyaA of 200 kDa expressed in strain B. pertussis DE386. These had no 
protective activity against B. pertussis colonization in mice confirming, with 
native CyaA, that CyaC-mediated modification of CyaA toxin is critical for its 
protective activity. Presum ably the CyaC m odification creates an 
immunodominant epitope (s) required for protective activity probably by
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changing the conformation of the CyaA protein molecule in such a way that the 
protective epitope (s) is now presented to the immune system.
The protective effect of active CyaA could be due to antibodies preventing 
CyaA acting on alveolar macrophages which would normally allow 
multiplication of B. pertussis on the surface of the respiratory epithelium early 
in the infection. This study, as well as previous work strongly suggests that 
CyaA should be considered as a useful component of an acellular vaccine, 
because of the presumed important role of immunity to CyaA in preventing 
colonization. The purified CyaA showed little evidence of toxicity but any 
possible effects would be minimised by site-specific mutation that either 
abolishes AC enzymic activity or prevents pore formation. However, the means 
by which CyaA promotes a protective immune response is not clear. It is a 
toxin that penetrates target cells and it is possible that it may be presented via 
the MHC class I antigen presentation pathway which is important for cell 
mediated immunity. This point was investigated to some extent in this work 
(see section 4.8).
4.5.3 Protective activities o f recom binant CyaA and hybrid toxins 
from  E. coli strains
Betsou et al. (1993) showed that a purified preparation of active CyaA 
derived from recombinant E. coli containing a major polypeptide of 200 kDa 
and several proteolytic fragments exhibited protective activity, but to a lesser 
extent than that of native CyaA, against B. pertussis colonization in the 
intranasal mouse model. They suggested that this may have been related to its
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lower haemolytic activity. They also found that purified inactive recombinant 
CyaA of 200 kDa had no protective activity.
In the present investigation, the protective activity of crude extracts and 
purified preparations of recombinant active CyaA of 200 kDa synthesised in 
E. coli showed a similar pattern of protective activity to that of the native CyaA 
or the whole-cell DPT vaccine against intranasal challenge with B. pertussis in 
mice. As was found with inactive native CyaA, inactive recombinant CyaA 
was not protective.
The hybrid toxins Hybl and Hyb2 were also evaluated for their protective 
activity against B. pertussis challenge. Preliminary experiments with Cya C- or 
LktC-mediated H ybl toxins showed that it had no protective activity and 
exhibited a similar pattern of response in mice to inactive CyaA. The Cya C- or 
LktC-modified Hyb2 toxins were, however somewhat protective against 
B. pertussis challenge, and with the LktC-modified Hyb2 showing the better 
protective properties. Thus this hybrid toxin, which showed only 5% of the cell 
invasive activity of active CyaA, acted nevertheless as a protective antigen. 
This indicated that much of the protective epitope(s) structure determined by 
the C-terminal portion of CyaA had been retained even though part of the C- 
modification region spanning 238 amino acids had been replaced by the 
equivalent region from LktA. The CyaC- or LktC-modified Hyb2 toxin is 
suggested as a candidate for inclusion in future recombinant pertussis vaccines, 
since it exhibited no significant cytoxicity and may represent a safe vaccine 
component with efficient protective activity.
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4.6 ANTIBODY RESPONSES TO CyaA AND HYBRID TOXINS IN 
MICE
4.6.1 Anti-CyaA antibody response
Betsou et al. (1995) showed that anti-B. pertussis CyaA polyclonal 
antibody used in Western blots recognized recombinant CyaA polypeptide of 
200 kDa as well as the purified B. pertussis CyaA polypeptide. Antiserum from 
infants, children, or adults infected with B. pertussis, and obtained between 4 
and 8 weeks from the beginning of the cough, was shown to recognize 
B. pertussis CyaA or E. coli CyaA (Betsou et a i, 1993). Similarly, sera from 
mice infected with strain B. pertussis 18323 recognized B. pertussis CyaA or
E. coli CyaA, and thus both types of toxin were immunologically similar in 
Western blotting. In addition, the presence of antibodies neutralizing CyaA 
toxin activity is not a reliable measure of the induced protection against 
B. pertussis infection because a truncated-recombinant CyaA protein, which 
was not protective at all, induced a strong neutralizing antibody response 
(Betsou et al., 1995). No inhibition of the CaM-dependent AC activity by anti- 
CyaA antibodies has been observed (Rogel et a l ,  1988). Thus antibodies 
directed mainly against C-terminal hemolysin portion of CyaA are able to 
neutralize its haemolytic activity but not the enzymic AC activity of its 
N-terminal domain (Betsou et al., 1995). However, antibodies against a 
truncated protein consisting of the N-terminal domain and the last 217 amino 
acids of the CyaA molecule were able to neutralize both enzymic and cytotoxic 
activity of the recombinant active CyaA (Betsou et a l ,  1995). Farfel et al. 
(1990) reported that anti-CyaA antibodies were produced in man during
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pertussis infection in titres higher than after vaccination, but these antibodies 
did not neutralise the enzyme activity or penetration activity of CyaA. This 
does not rule out the possibility that locally produced antibodies neutralise the 
enzymic and invasive activities and may be important for defence against the 
CyaA toxin in the respiratory tract.
In the present study, mice developed strong specific IgG antibody 
responses against the active or inactive form of CyaA toxin 21 days post­
vaccination with CyaA preparations, and the dominant subclass was IgGl, Low 
titres of IgE specific for CyaA were also induced in mice after immunization 
with active and inactive CyaA toxins (Tables 20-23). In these mice the higher 
ratio of IgG l to IgG2a specific for CyaA and the lack of an IgG2b specific 
antibody response indicated a Th2 cell response to CyaA toxin which enhances 
the secretion of IgGl by induced B-lymphocytes. These findings indicated that 
a strong Th2-enhanced antibody response following immunization with CyaA 
toxin may be responsible for the reduction in the level of B. pertussis 
colonization in respiratory tracts of mice, perhaps by interaction of CyaA- 
specific antibody with the CyaA toxin which stops its entry into immune 
effector cells.
4.6.2 Immunoblot analysis of anti-CyaA immune sera
The immunoblot study of sera from the mouse protection experiments 1 
and 2 raised against crude and purified preparations of CyA either from 
B. pertussis or recombinant E. coli strains, and probed against purified CyaA 
preparations demonstrated the presence of antibodies to the 200 kDa toxin in 
all sera taken 21 days after first immunization. The sera also reacted with
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proteins of lower molecular weights (Figs 39 and 40) that were presumably 
breakdown products of the CyaA molecule in the preparations. A monoclonal 
antibody specific to the enzymic domain of the CyaA molecule also recognized 
these proteolytic fragments indicating that they contained the N-terminal 
domain of CyaA.
The sera raised against either the purified non-toxic or the toxic form of 
recombinant CyaA of 200 kDa recognised both toxic or non-toxic forms of 
recombinant CyaA as well as toxic or non-toxic forms of CyaA purified from 
B, pertussis, indicating that all recombinant CyaA preparations and B, pertussis 
CyaA preparations were immunologically similar in W estern blots. This 
indicates that certain epitopes are the same in all CyaA preparations. In 
addition, immunoblotting of antisera raised against purified B. pertussis CyaA 
preparations did not recognize FHA or PT or PRN, indicating the absence of 
these factors in the purified preparations of CyaA toxins.
The CyaA-specific polyclonal antibody raised against purified recombinant 
CyaA in mice recognized Hyb2 in Western blots as well as CyaA, but failed to 
recognize H ybl. This indicated that the anti-CyaA antibodies were directed 
predominantly against epitopes present in the C-terminal domain of CyaA or 
conformational epitope(s) formed when the C-terminal region, the modification 
regions and N-terminal domains are intact. This observation was in keeping 
with previous findings by Betsou et al. (1995), who reported that truncated 
recombinant CyaA proteins were recognized by the polyclonal sera of
B. pertussis infected humans or mice as long as they contained the C-terminal 
800 amino acids. This indicated that the intact modification and repeat region 
in the last 800 amino acid residues of the CyaA molecules are essential for a 
protective antibody response. The sera raised in the rabbit against LktA
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recognized LktA and H ybl, but failed to recognize the Hyb2 protein. This 
indicated again that the immunodominant region of LktA was in C-terminal 
region, within the last 575 amino acids. The data as a whole showed the 
immunological relatedness between the two proteins of the RTX family of 
cytolytic toxins and addressed the importance of the C-terminal repeat region 
as the immunodominant region of both toxins.
4.7 ADJUVANTICITY OF CyaA
Bottomly (1988) showed that the use of Alum as an adjuvant may induce a 
Th2 response and production of IL-4 and IL-10 which in turn could down- 
regulate the T hl response and enhance the antibody response. The present 
work also showed that Alum had an adjuvant effect on the antibody response to 
CyaA, because a higher level of antibody response to CyaA was detected in 
sera of mice when both active and inactive CyaA were co-administrated with 
Alum (Experiments 1 and 2) compared with adminstration of CyaA alone 
(Experiments 4  and 5). Interestingly, in the mouse protection experiments 
(1 and 2) the administration of active CyaA even with alum in mice showed a 
higher anti-CyaA antibody response compared with adminstration of inacive 
CyaA with alum. For this reason, the present study examined the adjuvant 
effect of active CyaA alone on the antibody response to itself and to another 
protein antigen (Oa) administrated at the same time.
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4.7.1 Effects of CyaA on primary and secondary anti-Oa responses
The present study has shown that the co-adminstration of invasive CyaA 
with a protein antigen such as ovalbumin in mice enhanced several-fold the 
specific IgG, IgG l and IgE antibody responses to Oa compared with 
adminstration of Oa alone. The Ig2a anti-Oa response was enhanced 2-3 fold, 
whereas IgG2b was not detectable in any sera (Figs 43 and 44, Table 20 and 
21). Interestingly, such an enhancement in antibody response to active CyaA 
was not observed with the inactive form of CyaA, indicating that invasive 
activity of CyaA toxin on the T helper lymphocytes may be responsible for the 
enhancement effect on the antibody responses to Oa, The findings also suggest 
that the effect of CyaA on antibody responses may not be specific to Oa, but 
similar experiments with other immunizing antigens will need to be done. The 
more interesting test will be to study any enhancing effect of CyaA on the 
antibody response to PT, FHA and PRN in future acellular vaccines. It has 
been reported previously that PT can enhance antibody responses to another 
antigen (Samore and Siber, 1996). The adjuvant effect of both CyaA and PT 
could be due to the fact that they both increase the level of intracellular cAMP 
in the target cells or immune effector cells. It has been reported that cAMP 
upregulates IL4 and IL5 production by activated CD4+ T cells (Lacour et al, 
1994).
4.7.2 Effects of CyaA on primary and secondary anti-CyaA responses
The primary and secondary IgG anti-CyaA responses were enhanced in 
mice vaccinated with PAR CyaA compared with mice vaccinated with PIR
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CyaA or PIR CyaA with Oa, although the antibody response to PAR CyaA 
alone was lower compared to antibody response to PAR CyaA with alum. 
These findings indicate that activity of active form of CyaA may stimulate a 
greater Th2 response than the inactive form of CyaA.
4.8 EFFECTS OF CyaA ON CYTOKINE PRODUCTION
It was reported by Redhead et aL (1993) that infection in the mouse or 
vaccination with whole cell vaccine induced a strong activation of the typel 
CD4+ T helper cells (Thl response) associated with the induction of cell 
mediated immunity. High levels of IL-2 and INF-y and low levels of IL-4 were 
produced and there was little antibody production. This work suggested that 
phagocytic cells such as macrophages and neutrophils were being activated 
under these conditions. Immunization with acellular vaccines containing 
mainly PT induced a strong antibody response (humoral immunity) and 
production of high levels cytokines such as 11-4 and IL-5 associated with the 
activation of type 2 CD4+ T cells (Redhead et al,, 1993).
In this preliminary study, the effect of CyaA toxin on cytokine release 
from spleen cells of mice immunized with CyaA, was investigated and 
provided indirect evidence for the induction of a predominantly Th2 
lymphocyte response by CyaA although there was low level production of 
cytokines associated with a Thl response as well. The spleen cells from mice 
immunized with active toxin produced high levels of IL-4 and IL-5 and IL-10 
after in vitro stimulation with CyaA toxin for 48 h and low levels of INF-y and 
IL-2, indicating a mixed, but predominantly Th2 response to the toxic form of 
CyaA. The cytokine response of spleen cells of mice immunised with inactive
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CyaA was similar, but the cytokine levels were lower (Table 24). These 
findings, suggest that the invasive CyaA toxin may stimulate or activate Th2 
lymphocytes directly, or indirectly via other cytokines, to secrete IL-4 and IL-5 
which then induce B lymphocytes to produce IgG l. The possibility that, 
because of its cell invasive nature, the CyaA toxin also stimulates a T h l 
response requires further investigation.
4.9 OVERALL CONCLUSIONS
The work on the immunogenicity of the CyaA toxin showed clearly that 
only activated invasive CyaA was protective and that the recombinant CyaA 
was as effective as CyaA from B. pertussis. The capability now exists to 
overproduce the CyaA toxin for possible inclusion in an acellular vaccine. 
Development of acellular vaccines for pertussis has emphasised the inclusion 
of PT, FHA and other adhesins such as PRN. CyaA has been overlooked, 
mainly because of difficulty in obtaining sufficient purified material. The 
ability to produce the toxin in E. coli should overcome this problem. It will be 
of interest to investigate fully the type of protective response promoted by 
active CyaA. As an invasive protein which is degraded intracellularly it may be 
processed via the MHC class I-restricted pathway to activate the cell mediated 
arm of the immune system. Some evidence for this was provided by the 
synthesis of small amounts of IL-2 and INFy, both of which promote this 
response. It will be important to try and separate Thl and Th2 specific CD4^ 
T cell clones from the spleens of vaccinated mice and to compare the cytokine 
profiles created by other protective antigens (such as PT and FHA) and WCV 
with that of CyaA.
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CyaA was shown to act as an adjuvant and increase the antibody response 
to itself and to the co-adminstrated antigen Oa. It will be important to assess if 
CyaA can act as an adjuvant for other protective antigens such as FHA and 
PRN and perhaps even PT itself. Further work will also need to investigate 
whether or not the AC enzymic activity of CyaA is required for the protective 
and adjuvant effect of the toxin.
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APPENDIX I: MEDIA
A. Bordet-Gengou Agar (BG) (pH 7.4)
BG-Agar base (Gibco-BRL) 7.2 g
Glycerol 1% (v/v)
Distilled water 160 ml
Dissolved and autoclaved at 121°C for 15 min. 20% (v/v) sterile 
defibrinated horse blood and lOpg/ml tetracycline was added to the 
autoclaved BG agar cooled previously to 45 °C.
B. Cyclodextrin liquid medium (CDL) ( pH 7.4)
L-Proline 0.24 g
NaCl 2.5 g
KH2PO4  0.5 g
KCl 0.2 g
Mg Cl2f 6  H2 0  0.1 g
CaCl2 0.02 g
Tris 6.1 g
Casamino acids 10 g
Methyl p cyclodextrin 1 g
Distilled water 990 ml
Dissolved and autoclaved at 121 °C for 15 min
C. Supplement for 1 litre of CDL medium
L-cysteine 0.04 g
FeS04p7H 20 0.01 g
Nicotinic acid (Niacin) 0.004 g
Glutathione 0.15 g
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Ascorbic acid 0.4 g
Distilled water 10 ml
Dissolved and sterilized by syringe filter (0.45 pm pore size, Gelman)
D. 2 xYT broth
Tryptone 16 g
Yeast extract 10 g
NaCl 5 g
Distilled water 1 1
Dissolved and autoclaved at 121°C for 15 min.
E. 2 xYT agar
Tryptone 16 g
Yeast extract 10 g
NaCl 5 g
Agar technical 12 g
Distilled water 1 1
Dissolved and autoclaved at 121°C for 15 min.
F. Brain heart infusion broth (BHIB) (pH 7.4)
Brain heart infusion dehydrated (Oxoid) 37 g
Distilled water 1 \
Dissolved and autoclaved at 121° C for 15 min.
G. Brain heart infusion agar (BHIA) (pH 7.4)
Brain heart infusion dehydrated (Oxoid) 37 g
Agar technical 12 g
Distilled water 1 J
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Dissolved and autoclaved at 121° C for 15 min.
H. Tissue culture medium for BHK21 cells
MEM (Gibco-BRL)
HEPES pH 7.4 
Fetal calf serum
I. Tissue culture medium for J774.2 cells
R PM I1640 (Gibco-BRL)
L-Glutamine 
Penicillin/Streptomycin 
Amphotericin B (Fungizone)
Fetal calf serum 
HEPES (pH 7.4)
J. Tissue culture medium for BL3 cells
RPMI 1640 (Gibco-BRL)
L-Glutamine
0I^tal calf serum 
HEPES (pH 7.4)
APPENDIX II Buffers and reagents
A. SDS-PAGE
a. Acrylamide/Bisacrylamide
100 ml
22 mM
2% (v/v)
100 ml 
200 mM
10 mg/ml 
250 pg/ml 
10% (v/v) 
20 mM
100 ml 
200 mM
10% (v/v) 
20 mM
Acrylamide 29.2 g
N, N-methylene bis acrylamide 0.8 g
Distilled water 100 ml
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b. Lower gel buffer (pH 8.8)
Tris (1.5M) 18.2 g
SDS 0.4 g
Distilled water 100 ml
The pH was adjusted to 8.8 with 2N HCl and the final volume made 
up to 100 ml with distilled water and the buffer filtered through 
Whatman No. 1 filter paper and stored at 4°C.
e. Upper gel buffer (pH 6.8)
Tris 6.2 g
SDS 0.4 g
Distilled water 100 ml
The pH was adjusted to 6.8 with 2N HCl and the final volume made 
up to 100 ml with distilled water and the buffer filtered through the 
Whatman No. 1 filter paper and stored at 4°C.
d. TEMED (Sigma)
Undiluted stock, stored in dark.
e. Ammonium persulphate (APS)
A 10% solution (100 mg/ml in distilled water) made up freshly 
before use
f. Solubilising buffer
Glycerol 10 ml
2-mercaptoethanol 5 ml
SDS 4 g
Bromophenol blue 0.01 g
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Upper gel buffer (pH 6.8) (1/4 dilution)
g. Running buffer (8.3)
Tris
Glycine
SDS
Distilled water
100 ml
3.03 g 
14.4 g 
1 g
1 1
h. Staining solution 
Coomasie Blue R250 
50% (v/v) methanol 
Glacial acetic acid
i. Destaining solution 
Methanol 
Glacial acetic acid 
Distilled water
j. Slab gel preparation
1. Lower (separating) gel
1.525 g 
454 ml 
46 ml
50 ml 
75 ml
875 ml
Percent acrylamide
7.7% 10% 12%
Acrylamide/Bis (30%) 5 10 15 ml
Lower gel buffer (pH 8.8) 10 10 10 ml
Distilled water 25 20 15 ml
APS (10%) 200 200 200 Ml
TEMED 20 20 20 Ml
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2. Upper (stacking) gel
Acrylamide/Bis (30%) 
upper gel buffer (pH 6.8)
Distilled water 
APS (10%)
TEMED
B. Phosphate-buffered saline (PBS, pH 7.38)
a. Solution A 
K2HPO4
Deionized water
b. Solution B 
N a2H P04  
Deionized water
c. Solution C 
KCl 
NaCl
Deionized water
4% acrylamide 
2.6 ml
5 ml
9 ml
30 pi
20 pi
2.7 g 
100 ml
2.8 g
100 ml
0.199 g 
7.99 g 
100 ml
38 ml of solution B was added to solution C and pH was adjusted with 
solution A
C. Hanks HEPES (pH 7,4) 
Sodium chloride 
Potassium chloride 
Calcium chloride
150 mM 
5 mM
3 mM
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Magnesium chloride 1 mM
D-Glucose 5 mM
HEPES 10 mM
adjusted to pH 7.4 with 5 M NaOH.
D. Western blotting/Immunoblotting
a. Electroeluting buffer 
Tris 
Glycine
Methanol 20% (v/v) in distilled water
b. Blot developing substrate solution 
3,3'-diaminobenzidine (DAB)*
Cobalt chloride 1 % (w/v) in distilled water 
PBS (pH 3.38)
Hydrogen peroxide (30%)
*DAB is a carcinogen, so was handled with care.
c. Ponceau-S solution
Ponceau-S 0.5 g
Glacial acetic acid 1 ml
Distilled water 100 ml
d. Blocking buffer
Skim milk (3%) 3 g
Tween 20 (0.2%) 0.2 ml
Distilled water 100 ml
3.03 g 
14.4 g 
1 I
0,05 g 
2.00 ,^ | 
98,0 H'jf 
0.10 ml
APPENDICES 204 PART V
e. Horseradish peroxidase-anti-Ig conjugate
A variety of species-specific anti-Ig-conjugates were obtained from  
Scottish Antibody Production Unit (SAPU) and Serotec (Oxford). 
These were diluted as indicated by the manufacturers and stored 
frozen in 20 pi aliquots.
E. Protein reagent for protein estimation
Brilliant Blue G-250 100 mg
ethanol 95% (v/v) 50 ml
phosphoric acid 85% (v/v) 100 ml
F. Purification
a. Equilibrating buffer (DEQ buffer)
Tris-HCl (pH 8.0) 50 mM
CaCl2 0.2 mM
Urea 8 M
NaCl 150 mM
b. Eluting buffer (DEL buffer)
Tris-HCl (pH 8.0) 50 mM
CaCl2 0.2 mM
Urea 8 M
NaCl 2 mM
c. Calmodulin agarose affinity chromatography
1. Buffer A
Tris-HCl (pH 8.0) 10 mM
APPENDICES 205 PART V
mM
mM
mM
EGTA 2 mM
EDTA 0.5 mM
NaCl 1 M
2. Buffer B 
Tris-HCl (pH 8.0)
EDTA
Mg Cl2,6H20
3. Buffer C 
Tris-HCl (pH 8.0)
C aC l2#6H 20  
NaCl
4. UE buffer (Urea extract buffer)
Buffer A (pH 8.0) for 1 g wet weight cell pellets 
Urea
d. Equilibrating buffer for gel filtration
Tris-HCl (pH 7.5) 50 mM
e. Eluting buffer for Gel filtration
Tris-HCl (pH 7.5) 50 mM
NaCl 100 mM
f. Electroeluting buffer for electroelution
Tris-HCl (pH 7.4) 200 mM
SDS 1 % (w/v)
Dithiothreitol 100 mM
10
2
3
10
1
0.5
8
8
mM
mM
M
ml
M
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g. Running buffer for electroelution 
Tris-HCl (pH 7.4)
SDS
Sodium thioglycolate
G. Reagent for Salomon assay
a. Reaction mix (RM)
1. Solution A 
Tris-HCl 
MgCl2 
CaCl2 
BSA
Calmodulin (CaM)
cAMP
H 20
2. Solution B
3h  cAMP (1 mCi/ml)
H2O
50 mM 
0.1% (w/v) 
0.5 mM
1 M
100 mM
10 mM
100 mg/ml 
0.1 mM
10 mM
4 ml
2
4
p i
ml
Mix 4 ml solution A with 1 ml solution B. store at -20 °C.
b. Substrate mix (SM) 
ATP (100 mM) 
a-32p ATP (10 mCi/ml) 
H2O
2 0 0  p i  
2  p i
798 pi
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H. ELISA
a. Coating buffer (carbonate buffer, pH 9.8)
Sodium carbonate 1.59 g
Sodium bicarbonate 2.93 g
Distilled water 1 1
b. Washing buffer
PBS 1 1
Tween-20 50 pi
c. Blocking buffer
PBS 100 ml
Tween-20 50 pi
BSA 2 g
d. Citrate-phosphate buffer (pH 5.0)
1. Solution A: 0.1 M citric acid 21.01 g
2. Solution B; 2 M Na2H P04 28.31 g
To prepare 0.15 M citrate-phosphate(pH 5.0), solution A (49 ml) was 
mixed with solution B (51 ml) just before use.
e. Developing solution
OPD (O-phenylenediamine, Sigma) 17 mg
Citrate phosphate buffer (pH 5.0) 50 ml
Hydrogen peroxide 10 pi
f. Stop solution
12.5% (v/v) sulphuric acid in distilled water.
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L TEN buffer
Tris-HCl (pH 8.0) 50 mM
NaCl 150 mM
EDTA 100 mM
J. TC buffer
Tris-HCl (pH 8.0) 50 mM
CaCl2 0.2 mM
6K. TSB (Tranformation and storage buffer)
PTSB is 2xYT broth suplemented with:
PEG 10% v/v
DMSO 5% v/v
MgCl2 10 mM
M gS04 10 mM
L. GTE buffer (Glucose, Tris and EDTA)
Glucose 50 mM
Tris-HCl (pH 8.0) 25 mM
EDTA (pH 8.0) 10 mM
Solution autoclaved for 15 min at 10 Ib/sq inch and stored at 4 °C.
M. NSD buffer (NaOH, SDS)
Sodium hydroxide (0.2 N) 10 ml
Sodium dodecyl sulphate (SDS) 1% (w/v)
Freshly prepared solution inverted five times and stored on ice for 5 
min.
APPENDICES 209 PART V
N. KAC buffer
Glacial acetic acid 60 ml
Potassium acetate (5M) 11.5 ml
Distilled w ater 28.5 ml
Freshly prepared  solution vortexed gently and stored on ice for 5 min.
O. Dialysis buffer
Tris-HCl (pH 7.5) 10 mM
NaCl 100 mM
CaCl2 1 mM
P. Acylation reaction mix for enzymatic synthesis of acyl-ACP
Adenosine triphosphate (ATP) 5 iiiM
Dithiothreitol (DTT) 2 mM
Triton X-100 2% v/v
Tris-HCl (pH 8.0) 100 mM
LiCl 400 mM
MgCl2 10 mM
fatty acid (sodium salt) 160 pM
Commercial ACP-SH 155 pM
Commercial ACP synthetase 3 units
Freshly p repared  reaction mix incubated a t 37 °C for 3 h and then 
incubated for another 16 h a t 30 ”C.
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